{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 8167, "items": [{"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T20:11:13Z", "timestamp": 1574799073384}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2016, 2, 15]]}, "DOI": "10.1158/1538-7445.sabcs15-ot1-01-03", "type": "proceedings-article", "created": {"date-parts": [[2016, 5, 20]], "date-time": "2016-05-20T08:47:55Z", "timestamp": 1463734075000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Abstract OT1-01-03: Adoptive cell transfer (ACT) using tumor infiltrating lymphocytes to target neoantigens in patients with metastatic breast cancer"], "prefix": "10.1158", "author": [{"given": "SL", "family": "Goff", "sequence": "first", "affiliation": []}, {"given": "SA", "family": "Feldman", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Somerville", "sequence": "additional", "affiliation": []}, {"given": "SA", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2016, 2, 18]]}, "event": {"name": "Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX"}, "container-title": ["Ongoing Clinical Trials"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.SABCS15-OT1-01-03", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T16:54:50Z", "timestamp": 1558198490000}, "score": 41.869537, "issued": {"date-parts": [[2016, 2, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.SABCS15-OT1-01-03"], "URL": "http://dx.doi.org/10.1158/1538-7445.sabcs15-ot1-01-03"}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T17:51:37Z", "timestamp": 1574358697760}, "reference-count": 79, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2008, 4, 1]], "date-time": "2008-04-01T00:00:00Z", "timestamp": 1207008000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Cancer"], "published-print": {"date-parts": [[2008, 4]]}, "DOI": "10.1038/nrc2355", "type": "journal-article", "created": {"date-parts": [[2008, 3, 20]], "date-time": "2008-03-20T08:23:34Z", "timestamp": 1206001414000}, "page": "299-308", "source": "Crossref", "is-referenced-by-count": 810, "title": ["Adoptive cell transfer: a clinical path to effective cancer immunotherapy"], "prefix": "10.1038", "volume": "8", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}, {"given": "Nicholas P.", "family": "Restifo", "sequence": "additional", "affiliation": []}, {"given": "James C.", "family": "Yang", "sequence": "additional", "affiliation": []}, {"given": "Richard A.", "family": "Morgan", "sequence": "additional", "affiliation": []}, {"given": "Mark E.", "family": "Dudley", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "BFnrc2355_CR1", "doi-asserted-by": "crossref", "first-page": "1676", "DOI": "10.1056/NEJM198812223192527", "volume": "319", "author": "SA Rosenberg", "year": "1988", "unstructured": "Rosenberg, S. A. et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319, 1676\u20131680 (1988). The first paper to demonstrate the regression of cancer using TIL for the immunotherapy of patients with metastatic melanoma.", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc2355_CR2", "doi-asserted-by": "crossref", "first-page": "850", "DOI": "10.1126/science.1076514", "volume": "298", "author": "ME Dudley", "year": "2002", "unstructured": "Dudley, M. E. et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science 298, 850\u2013854 (2002).", "journal-title": "Science"}, {"key": "BFnrc2355_CR3", "doi-asserted-by": "crossref", "first-page": "2346", "DOI": "10.1200/JCO.2005.00.240", "volume": "23", "author": "ME Dudley", "year": "2005", "unstructured": "Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346\u20132357 (2005). References 2 and 3 demonstrate that lymphodepletion prior to ACT can lead to increased cancer regression as well as clonal repopulation of patients with anti-tumour lymphocytes.", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc2355_CR4", "doi-asserted-by": "crossref", "first-page": "126", "DOI": "10.1126/science.1129003", "volume": "314", "author": "RA Morgan", "year": "2006", "unstructured": "Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006). The first paper demonstrating the adoptive cell transfer of lymphocytes transduced with a retrovirus encoding TCRs that recognize a cancer antigen can mediate anti-tumour responses in patients with metastatic melanoma.", "journal-title": "Science"}, {"key": "BFnrc2355_CR5", "doi-asserted-by": "crossref", "first-page": "1485", "DOI": "10.1056/NEJM198512053132327", "volume": "313", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485\u20131492 (1985).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc2355_CR6", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1097/00000658-199809000-00004", "volume": "228", "author": "SA Rosenberg", "year": "1998", "unstructured": "Rosenberg, S. A., Yang, J. C., White, D. E. & Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann. Surg. 228, 307\u2013319 (1998).", "journal-title": "Ann. Surg."}, {"key": "BFnrc2355_CR7", "doi-asserted-by": "crossref", "first-page": "3117", "DOI": "10.1001/jama.1986.03380220083027", "volume": "256", "author": "MT Lotze", "year": "1986", "unstructured": "Lotze, M. T. et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings. J. Am. Med. Assoc. 256, 3117\u20133124 (1986).", "journal-title": "J. Am. Med. Assoc."}, {"key": "BFnrc2355_CR8", "doi-asserted-by": "crossref", "first-page": "797", "DOI": "10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M", "volume": "83", "author": "US Kammula", "year": "1998", "unstructured": "Kammula, U. S., White, D. E. & Rosenberg, S. A. Trends in the safety high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83, 797\u2013805 (1998).", "journal-title": "Cancer"}, {"key": "BFnrc2355_CR9", "doi-asserted-by": "crossref", "first-page": "8372", "DOI": "10.1073/pnas.1533209100", "volume": "100", "author": "GQ Phan", "year": "2003", "unstructured": "Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372\u20138377 (2003).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc2355_CR10", "doi-asserted-by": "crossref", "first-page": "6043", "DOI": "10.1200/JCO.2005.06.205", "volume": "23", "author": "P Attia", "year": "2005", "unstructured": "Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043\u20136053 (2005).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc2355_CR11", "doi-asserted-by": "crossref", "first-page": "1643", "DOI": "10.1126/science.1840703", "volume": "254", "author": "P Van der Bruggen", "year": "1991", "unstructured": "Van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643\u20131647 (1991).", "journal-title": "Science"}, {"key": "BFnrc2355_CR12", "doi-asserted-by": "crossref", "first-page": "281", "DOI": "10.1016/S1074-7613(00)80028-X", "volume": "10", "author": "SA Rosenberg", "year": "1999", "unstructured": "Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281\u2013287 (1999).", "journal-title": "Immunity"}, {"key": "BFnrc2355_CR13", "doi-asserted-by": "crossref", "first-page": "909", "DOI": "10.1038/nm1100", "volume": "10", "author": "SA Rosenberg", "year": "2004", "unstructured": "Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909\u2013915 (2004).", "journal-title": "Nature Med."}, {"key": "BFnrc2355_CR14", "doi-asserted-by": "crossref", "first-page": "6169", "DOI": "10.4049/jimmunol.175.9.6169", "volume": "175", "author": "SA Rosenberg", "year": "2005", "unstructured": "Rosenberg, S. A. et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169\u20136176 (2005). The demonstration that peptide vaccines are capable of generating large numbers of anti-tumour lymphocytes  in vivo , but these lymphocytes do not appear to have any  in vivo  ability to prevent recurrence.", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR15", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1084/jem.102.2.157", "volume": "102", "author": "NA Mitchison", "year": "1955", "unstructured": "Mitchison, N. A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102, 157\u2013177 (1955). A seminal paper demonstrating the role of the cellular immune response in the rejection of tumour transplants.", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR16", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1016/S0140-6736(64)90126-6", "volume": "2", "author": "EJ Delorme", "year": "1964", "unstructured": "Delorme, E. J. & Alexander, P. Treatment of primary fibrosarcoma in the rat with immune lymphocytes. Lancet 2, 117\u2013120 (1964).", "journal-title": "Lancet"}, {"key": "BFnrc2355_CR17", "first-page": "2177", "volume": "29", "author": "A Fefer", "year": "1969", "unstructured": "Fefer, A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 29, 2177\u20132183 (1969).", "journal-title": "Cancer Res."}, {"key": "BFnrc2355_CR18", "first-page": "714", "volume": "119", "author": "MA Cheever", "year": "1977", "unstructured": "Cheever, M. A., Kempf, R. A. & Fefer, A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J. Immunol. 119, 714\u2013718 (1977).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR19", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1084/jem.156.2.385", "volume": "156", "author": "TJ Eberlein", "year": "1982", "unstructured": "Eberlein, T. J., Rosenstein, M. & Rosenberg, S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J. Exp. Med. 156, 385\u2013397 (1982). Demonstration that the intravenous administration of anti-tumour lymphocytes expanded in IL2 could mediate the regression of established disseminated syngeneic tumours in mice.", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR20", "first-page": "2123", "volume": "132", "author": "JH Donohue", "year": "1984", "unstructured": "Donohue, J. H. et al. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocyte to cure a disseminated syngeneic lymphoma. J. Immunol. 132, 2123\u20132128 (1984).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR21", "doi-asserted-by": "crossref", "first-page": "1318", "DOI": "10.1126/science.3489291", "volume": "233", "author": "SA Rosenberg", "year": "1986", "unstructured": "Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986). The first demonstration in murine models that the adoptive transfer of TIL could mediate the regression of established murine tumours.", "journal-title": "Science"}, {"key": "BFnrc2355_CR22", "doi-asserted-by": "crossref", "first-page": "569", "DOI": "10.1084/jem.20030590", "volume": "198", "author": "WW Overwijk", "year": "2003", "unstructured": "Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003). This paper demonstrated that adoptive cell transfer, vaccine and IL2 administration could mediate the rejection of large established transgenic B16 melanomas in mice.", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR23", "doi-asserted-by": "crossref", "first-page": "2591", "DOI": "10.4049/jimmunol.174.5.2591", "volume": "174", "author": "PA Antony", "year": "2005", "unstructured": "Antony, P. A. et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591\u20132601 (2005).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR24", "doi-asserted-by": "crossref", "first-page": "907", "DOI": "10.1084/jem.20050732", "volume": "202", "author": "L Gattinoni", "year": "2005", "unstructured": "Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR25", "doi-asserted-by": "crossref", "first-page": "492", "DOI": "10.1172/JCI30414", "volume": "117", "author": "C Wrzesiniski", "year": "2007", "unstructured": "Wrzesiniski, C. et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117, 492\u2013501 (2007).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrc2355_CR26", "doi-asserted-by": "crossref", "first-page": "1616", "DOI": "10.1172/JCI24480", "volume": "115", "author": "L Gattinoni", "year": "2005", "unstructured": "Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrc2355_CR27", "doi-asserted-by": "crossref", "first-page": "2197", "DOI": "10.1172/JCI32205", "volume": "117", "author": "CM Paulos", "year": "2007", "unstructured": "Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197\u20132204 (2007).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrc2355_CR28", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1097/CJI.0b013e31815c193f", "volume": "31", "author": "JD Abad", "year": "2008", "unstructured": "Abad, J. D. et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31, 1\u20136 (2008).", "journal-title": "J. Immunother."}, {"key": "BFnrc2355_CR29", "first-page": "989", "volume": "138", "author": "LM Muul", "year": "1987", "unstructured": "Muul, L. M., Spiess, P. J., Director, E. P. & Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989\u2013995 (1987). The first description of the ability of TIL in the human to recognize human tumour antigens presented on cancer cells.", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR30", "doi-asserted-by": "crossref", "first-page": "332", "DOI": "10.1097/00002371-200307000-00005", "volume": "26", "author": "ME Dudley", "year": "2003", "unstructured": "Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332\u2013342 (2003).", "journal-title": "J. Immunother."}, {"key": "BFnrc2355_CR31", "doi-asserted-by": "crossref", "first-page": "1159", "DOI": "10.1093/jnci/86.15.1159", "volume": "86", "author": "SA Rosenberg", "year": "1994", "unstructured": "Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 86, 1159\u20131166 (1994).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnrc2355_CR32", "doi-asserted-by": "crossref", "first-page": "932", "DOI": "10.1093/jnci/83.13.932", "volume": "13", "author": "P Aebersold", "year": "1991", "unstructured": "Aebersold, P. et al. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J. Natl Cancer Inst. 13, 932\u2013937 (1991).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnrc2355_CR33", "doi-asserted-by": "crossref", "first-page": "1475", "DOI": "10.1200/JCO.1994.12.7.1475", "volume": "12", "author": "DJ Schwartzentruber", "year": "1994", "unstructured": "Schwartzentruber, D. J. et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12, 1475\u20131483 (1994).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc2355_CR34", "doi-asserted-by": "crossref", "first-page": "570", "DOI": "10.1056/NEJM199008303230904", "volume": "323", "author": "SA Rosenberg", "year": "1990", "unstructured": "Rosenberg, S. A. et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570\u2013578 (1990).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc2355_CR35", "doi-asserted-by": "crossref", "first-page": "185", "DOI": "10.1172/JCI0215175", "volume": "110", "author": "W Dummer", "year": "2002", "unstructured": "Dummer, W. et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185\u2013192 (2002).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrc2355_CR36", "doi-asserted-by": "crossref", "first-page": "16168", "DOI": "10.1073/pnas.242600099", "volume": "99", "author": "C Yee", "year": "2002", "unstructured": "Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168\u201316173 (2002).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc2355_CR37", "doi-asserted-by": "crossref", "first-page": "7125", "DOI": "10.4049/jimmunol.173.12.7125", "volume": "173", "author": "PF Robbins", "year": "2004", "unstructured": "Robbins, P. F. et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125\u20137130 (2004). This paper demonstrated that persistence of adoptively transferred cells correlated directly with the likelihood of cancer regression.", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR38", "doi-asserted-by": "crossref", "first-page": "7046", "DOI": "10.4049/jimmunol.175.10.7046", "volume": "175", "author": "J Zhou", "year": "2005", "unstructured": "Zhou, J., Shen, X., Hodes, R. J., Rosenberg, S. A. & Robbins, P. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046\u20137052 (2005). The paper shows that the telomere length of the transferred lymphocytes correlated both with  in vivo  persistence of the transferred cells as well as with tumour regression.", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR39", "first-page": "241", "volume": "101", "author": "DJ Powell", "year": "2004", "unstructured": "Powell, D. J., Dudley, M. E., Robbins, P. F. & Rosenberg, S. A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 101, 241\u2013250 (2004).", "journal-title": "Blood"}, {"key": "BFnrc2355_CR40", "doi-asserted-by": "crossref", "first-page": "1407", "DOI": "10.1084/jem.20040717", "volume": "200", "author": "AF Ochsenbein", "year": "2004", "unstructured": "Ochsenbein, A. F. et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200, 1407\u20131417 (2004).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR41", "doi-asserted-by": "crossref", "first-page": "2742", "DOI": "10.1073/pnas.0530192100", "volume": "100", "author": "WAE Marijt", "year": "2003", "unstructured": "Marijt, W. A. E. et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA 100, 2742\u20132747 (2003).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc2355_CR42", "first-page": "2462", "volume": "76", "author": "HJ Kolb", "year": "1990", "unstructured": "Kolb, H. J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462\u20132465 (1990). This paper was the first to show that treatment with donor lymphocytes could mediate cytogenetic remissions in patients with chronic myeloid leukaemia.", "journal-title": "Blood"}, {"key": "BFnrc2355_CR43", "first-page": "1261", "volume": "86", "author": "S Mackinnon", "year": "1995", "unstructured": "Mackinnon, S. et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86, 1261\u20131268 (1995).", "journal-title": "Blood"}, {"key": "BFnrc2355_CR44", "doi-asserted-by": "crossref", "first-page": "9", "DOI": "10.1016/j.bbmt.2005.10.025", "volume": "12", "author": "SR Riddell", "year": "2006", "unstructured": "Riddell, S. R., Bleakley, M., Nishida, T., Berger, C. & Warren, E. H. Adoptive transfer of allogeneic antigen-specific T cells. Biol. Blood Marrow Transplant. 12, 9\u201312 (2006).", "journal-title": "Biol. Blood Marrow Transplant."}, {"key": "BFnrc2355_CR45", "doi-asserted-by": "crossref", "first-page": "1185", "DOI": "10.1056/NEJM199404283301703", "volume": "330", "author": "EB Papadopoulos", "year": "1994", "unstructured": "Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein\u2013Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185\u20131191 (1994). This paper showed that the infusion of normal donor lymphocytes could achieve complete responses in patients with lymphomas that occurred following the treatment of leukaemia with chemotherapy and T-cell-depleted allogeneic stem cell grafts.", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc2355_CR46", "doi-asserted-by": "crossref", "first-page": "9", "DOI": "10.1016/S0140-6736(95)91150-2", "volume": "345", "author": "CM Rooney", "year": "1995", "unstructured": "Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein\u2013Barr-virus-related lymphoproliferation. Lancet 345, 9\u201313 (1995).", "journal-title": "Lancet"}, {"key": "BFnrc2355_CR47", "first-page": "1549", "volume": "92", "author": "CM Rooney", "year": "1998", "unstructured": "Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein\u2013Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549\u20131555 (1998). References 46 and 47 showed that tumour regression could be obtained by the infusion of long-term cultured EBV-specific T-cell lines.", "journal-title": "Blood"}, {"key": "BFnrc2355_CR48", "doi-asserted-by": "crossref", "first-page": "10391", "DOI": "10.1073/pnas.96.18.10391", "volume": "96", "author": "R Khanna", "year": "1999", "unstructured": "Khanna, R. et al. Activation and adoptive transfer of Epstein\u2013Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10391\u201310396 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc2355_CR49", "doi-asserted-by": "crossref", "first-page": "1399", "DOI": "10.1097/00007890-200110270-00012", "volume": "72", "author": "T Haque", "year": "2001", "unstructured": "Haque, T. et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein\u2013Barr virus-specific cytotoxic T cells. Transplantation 72, 1399\u20131402 (2001).", "journal-title": "Transplantation"}, {"key": "BFnrc2355_CR50", "doi-asserted-by": "crossref", "first-page": "1123", "DOI": "10.1182/blood-2006-12-063008", "volume": "110", "author": "T Haque", "year": "2007", "unstructured": "Haque, T. et al. Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lymphoproliferative disease: results of a phase 2 multicentre clinical trial. Blood 110, 1123\u20131131 (2007).", "journal-title": "Blood"}, {"key": "BFnrc2355_CR51", "doi-asserted-by": "crossref", "first-page": "1898", "DOI": "10.1182/blood-2004-07-2975", "volume": "105", "author": "K Straathof", "year": "2005", "unstructured": "Straathof, K. et al. Treatment of nasopharyngeal carcinoma with Epstein\u2013Barr virus-specific T lymphocytes. Blood 105, 1898\u20131904 (2005).", "journal-title": "Blood"}, {"key": "BFnrc2355_CR52", "doi-asserted-by": "crossref", "first-page": "8942", "DOI": "10.1200/JCO.2005.02.6195", "volume": "23", "author": "P Comoli", "year": "2005", "unstructured": "Comoli, P. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein\u2013Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23, 8942\u20138949 (2005).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc2355_CR53", "doi-asserted-by": "crossref", "first-page": "1623", "DOI": "10.1084/jem.20040890", "volume": "200", "author": "C Bollard", "year": "2004", "unstructured": "Bollard, C. et al. Cytotoxic T lymphocyte therapy for Epstein\u2013Barr virus Hodgkin's disease. J. Exp. Med. 200, 1623\u20131633 (2004).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR54", "doi-asserted-by": "crossref", "first-page": "238", "DOI": "10.1126/science.1352912", "volume": "257", "author": "SR Riddell", "year": "1992", "unstructured": "Riddell, S. R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238\u2013241 (1992).", "journal-title": "Science"}, {"key": "BFnrc2355_CR55", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1038/nrc971", "volume": "3", "author": "M Sadelain", "year": "2003", "unstructured": "Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nature Rev. Cancer 3, 35\u201345 (2003).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnrc2355_CR56", "doi-asserted-by": "crossref", "first-page": "403", "DOI": "10.1016/j.immuni.2005.03.007", "volume": "22", "author": "A Murphy", "year": "2005", "unstructured": "Murphy, A. et al. Gene modification strategies to induce tumor immunity. Immunity 22, 403\u2013414 (2005).", "journal-title": "Immunity"}, {"key": "BFnrc2355_CR57", "first-page": "748", "volume": "55", "author": "DJ Cole", "year": "1995", "unstructured": "Cole, D. J. et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55, 748\u2013752 (1995).", "journal-title": "Cancer Res."}, {"key": "BFnrc2355_CR58", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.1089/hum.2005.16.457", "volume": "16", "author": "MS Hughes", "year": "2005", "unstructured": "Hughes, M. S. et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene. Ther. 16, 457\u2013472 (2005).", "journal-title": "Hum. Gene. Ther."}, {"key": "BFnrc2355_CR59", "doi-asserted-by": "crossref", "first-page": "3287", "DOI": "10.4049/jimmunol.171.6.3287", "volume": "171", "author": "RA Morgan", "year": "2003", "unstructured": "Morgan, R. A. et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171, 3287\u20133295 (2003).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR60", "doi-asserted-by": "crossref", "first-page": "4415", "DOI": "10.4049/jimmunol.174.7.4415", "volume": "174", "author": "Y Zhao", "year": "2005", "unstructured": "Zhao, Y. et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415\u20134423 (2005).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR61", "doi-asserted-by": "crossref", "first-page": "8878", "DOI": "10.1158/0008-5472.CAN-06-1450", "volume": "66", "author": "CJ Cohen", "year": "2006", "unstructured": "Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878\u20138886 (2006).", "journal-title": "Cancer Res."}, {"key": "BFnrc2355_CR62", "doi-asserted-by": "crossref", "first-page": "3898", "DOI": "10.1158/0008-5472.CAN-06-3986", "volume": "67", "author": "CJ Cohen", "year": "2007", "unstructured": "Cohen, C. J. et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898\u20133903 (2007).", "journal-title": "Cancer Res."}, {"key": "BFnrc2355_CR63", "doi-asserted-by": "crossref", "first-page": "11993", "DOI": "10.1073/pnas.92.26.11993", "volume": "92", "author": "MBJ Theobald", "year": "1995", "unstructured": "Theobald, M. B. J., Dittmer, D., Levine, A. J. & Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA 92, 11993\u201311997 (1995).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc2355_CR64", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1016/j.immuni.2004.12.005", "volume": "22", "author": "J Kuball", "year": "2005", "unstructured": "Kuball, J., Schmitz, F. W. & Voss, R. H. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22, 117\u2013129 (2005).", "journal-title": "Immunity"}, {"key": "BFnrc2355_CR65", "doi-asserted-by": "crossref", "first-page": "5799", "DOI": "10.4049/jimmunol.175.9.5799", "volume": "175", "author": "CJ Cohen", "year": "2005", "unstructured": "Cohen, C. J. et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175, 5799\u20135808 (2005). References 58\u201365 demonstrate that TCRs can be identified that recognize cancer antigens and that transduction of these TCRs into normal human cells can transfer this antigen recognition.", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR66", "doi-asserted-by": "crossref", "first-page": "349", "DOI": "10.1038/nbt1070", "volume": "23", "author": "Y Li", "year": "2005", "unstructured": "Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nature Biotech. 23, 349\u2013354 (2005).", "journal-title": "Nature Biotech."}, {"key": "BFnrc2355_CR67", "doi-asserted-by": "crossref", "first-page": "10024", "DOI": "10.1073/pnas.86.24.10024", "volume": "86", "author": "G Gross", "year": "1989", "unstructured": "Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024\u201310028 (1989).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc2355_CR68", "doi-asserted-by": "crossref", "first-page": "6106", "DOI": "10.1158/1078-0432.CCR-06-1183", "volume": "12", "author": "MH Kershaw", "year": "2006", "unstructured": "Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrc2355_CR69", "doi-asserted-by": "crossref", "first-page": "e20", "DOI": "10.1200/JCO.2006.05.9964", "volume": "24", "author": "CHJ Lamers", "year": "2006", "unstructured": "Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc2355_CR70", "doi-asserted-by": "crossref", "first-page": "825", "DOI": "10.1038/sj.mt.6300104", "volume": "15", "author": "JR Park", "year": "2007", "unstructured": "Park, J. R. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825\u2013833 (2007).", "journal-title": "Mol. Ther."}, {"key": "BFnrc2355_CR71", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1038/nm827", "volume": "9", "author": "RJ Brentjens", "year": "2003", "unstructured": "Brentjens R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med. 9, 279\u2013286 (2003).", "journal-title": "Nature Med."}, {"key": "BFnrc2355_CR72", "doi-asserted-by": "crossref", "first-page": "6548", "DOI": "10.4049/jimmunol.177.9.6548", "volume": "177", "author": "LA Johnson", "year": "2006", "unstructured": "Johnson, L. A. et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating. J. Immunol. 177, 6548\u20136559 (2006).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR73", "doi-asserted-by": "crossref", "first-page": "823", "DOI": "10.1084/jem.152.4.823", "volume": "152", "author": "E Fernandez-Cruz", "year": "1980", "unstructured": "Fernandez-Cruz, E., Woda, B. A. & Feldman, J. D. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J. Exp. Med. 152, 823\u2013841 (1980).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR74", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1084/jem.151.1.69", "volume": "151", "author": "MJ Berendt", "year": "1980", "unstructured": "Berendt, M. J. & North, R. J. T-cell-mediated suppression of anti-tumor immunity: an explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151, 69\u201380 (1980).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc2355_CR75", "doi-asserted-by": "crossref", "first-page": "1487", "DOI": "10.1126/science.6332379", "volume": "225", "author": "JJ Mule", "year": "1984", "unstructured": "Mule, J. J., Shu, S., Schwarz, S. L. & Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487\u20131489 (1984).", "journal-title": "Science"}, {"key": "BFnrc2355_CR76", "doi-asserted-by": "crossref", "first-page": "6356", "DOI": "10.4049/jimmunol.167.11.6356", "volume": "167", "author": "K Liu", "year": "2001", "unstructured": "Liu, K. & Rosenberg, S. A. Transduction of an interleukin-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356\u20136365 (2001).", "journal-title": "J. Immunol."}, {"key": "BFnrc2355_CR77", "doi-asserted-by": "crossref", "first-page": "595", "DOI": "10.1038/nri1901", "volume": "6", "author": "TA Waldmann", "year": "2007", "unstructured": "Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Rev. Immunol. 6, 595\u2013601 (2007).", "journal-title": "Nature Rev. Immunol."}, {"key": "BFnrc2355_CR78", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1016/j.coi.2005.01.007", "volume": "17", "author": "L Ruggeri", "year": "2005", "unstructured": "Ruggeri, L., Mancusi, A., Capanni, M., Martelli, M. F. & Velardi, A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol. 17, 211\u2013217 (2005).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnrc2355_CR79", "unstructured": "Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. (in the press)."}], "container-title": ["Nature Reviews Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrc2355.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrc2355", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrc2355.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T10:41:53Z", "timestamp": 1557398513000}, "score": 41.75698, "issued": {"date-parts": [[2008, 4]]}, "references-count": 79, "journal-issue": {"published-print": {"date-parts": [[2008, 4]]}, "issue": "4"}, "alternative-id": ["BFnrc2355"], "URL": "http://dx.doi.org/10.1038/nrc2355", "relation": {"cites": []}, "ISSN": ["1474-175X", "1474-1768"], "issn-type": [{"value": "1474-175X", "type": "print"}, {"value": "1474-1768", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T02:46:10Z", "timestamp": 1574736370014}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2015, 10]]}, "DOI": "10.1158/2326-6074.tumimm14-ia19", "type": "proceedings-article", "created": {"date-parts": [[2015, 10, 16]], "date-time": "2015-10-16T23:47:41Z", "timestamp": 1445039261000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract IA19: Curative potential of T-cell immunotherapy for cancer"], "prefix": "10.1158", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2015, 10, 9]]}, "event": {"name": "Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL"}, "container-title": ["Adoptive T-Cell Therapy"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/2326-6074.TUMIMM14-IA19", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T17:41:36Z", "timestamp": 1557423696000}, "score": 41.14235, "issued": {"date-parts": [[2015, 10]]}, "references-count": 0, "alternative-id": ["10.1158/2326-6074.TUMIMM14-IA19"], "URL": "http://dx.doi.org/10.1158/2326-6074.tumimm14-ia19"}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T15:27:03Z", "timestamp": 1576855623914}, "reference-count": 94, "publisher": "American Association for the Advancement of Science (AAAS)", "issue": "6230", "license": [{"URL": "http://www.sciencemag.org/about/science-licenses-journal-article-reuse", "start": {"date-parts": [[2016, 4, 3]], "date-time": "2016-04-03T00:00:00Z", "timestamp": 1459641600000}, "delay-in-days": 367, "content-version": "vor"}], "funder": [{"DOI": "10.13039/100000002", "name": "National Institutes of Health", "doi-asserted-by": "publisher", "award": []}, {"DOI": "10.13039/100000054", "name": "National Cancer Institute", "doi-asserted-by": "publisher", "award": []}, {"name": "Center for Cancer Research", "award": []}, {"name": "Milstein Family Foundation", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Science"], "published-print": {"date-parts": [[2015, 4, 3]]}, "abstract": "<jats:p>Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally occurring tumor-reactive lymphocytes has mediated durable, complete regressions in patients with melanoma, probably by targeting somatic mutations exclusive to each cancer. These results have expanded the reach of ACT to the treatment of common epithelial cancers. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.</jats:p>", "DOI": "10.1126/science.aaa4967", "type": "journal-article", "created": {"date-parts": [[2015, 4, 2]], "date-time": "2015-04-02T19:33:46Z", "timestamp": 1428003226000}, "page": "62-68", "source": "Crossref", "is-referenced-by-count": 764, "title": ["Adoptive cell transfer as personalized immunotherapy for human cancer"], "prefix": "10.1126", "volume": "348", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}, {"given": "Nicholas P.", "family": "Restifo", "sequence": "additional", "affiliation": []}], "member": "221", "published-online": {"date-parts": [[2015, 4, 2]]}, "reference": [{"key": "2019031311450946000_348.6230.62.1", "DOI": "10.1016/S0140-6736(64)90126-6", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.2", "first-page": "2177", "article-title": "Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice", "volume": "29", "author": "Fefer", "year": "1969", "journal-title": "Cancer Res."}, {"key": "2019031311450946000_348.6230.62.3", "DOI": "10.1084/jem.152.4.823", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.4", "DOI": "10.1084/jem.151.1.69", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.5", "DOI": "10.1126/science.181845", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.6", "DOI": "10.1084/jem.161.5.1169", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.7", "DOI": "10.1084/jem.156.2.385", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.8", "first-page": "2123", "article-title": "The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma", "volume": "132", "author": "Donohue", "year": "1984", "journal-title": "J. Immunol."}, {"key": "2019031311450946000_348.6230.62.9", "DOI": "10.1056/NEJM198512053132327", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.10", "DOI": "10.1126/science.3489291", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.11", "first-page": "989", "article-title": "Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma", "volume": "138", "author": "Muul", "year": "1987", "journal-title": "J. Immunol."}, {"key": "2019031311450946000_348.6230.62.12", "DOI": "10.1056/NEJM198812223192527", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.13", "DOI": "10.1126/science.1076514", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.14", "DOI": "10.1038/ni1001-957", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.15", "DOI": "10.1126/science.1129003", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.16", "DOI": "10.1182/blood-2010-04-281931", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.17", "DOI": "10.1158/1078-0432.CCR-11-0116", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.18", "DOI": "10.1097/CJI.0b013e31826e8f5f", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.19", "DOI": "10.1158/1078-0432.CCR-12-1177", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.20", "DOI": "10.1158/1078-0432.CCR-13-0380", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.21", "DOI": "10.1158/1078-0432.CCR-10-1507", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.22", "DOI": "10.1056/NEJM199008303230904", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.23", "first-page": "5313", "article-title": "Apoptotic death of CD8+ T lymphocytes after immunization: Induction of a suppressive population of Mac-1+/Gr-1+ cells", "volume": "161", "author": "Bronte", "year": "1998", "journal-title": "J. Immunol."}, {"key": "2019031311450946000_348.6230.62.24", "DOI": "10.1182/blood-2011-10-386482", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.25", "DOI": "10.1084/jem.20050732", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.26", "DOI": "10.1200/JCO.2008.16.5449", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.27", "DOI": "10.1172/JCI32205", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.28", "DOI": "10.1038/nri3191", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.29", "DOI": "10.1038/nm.2446", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.30", "DOI": "10.1073/pnas.91.14.6458", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.31", "DOI": "10.1073/pnas.91.9.3515", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.32", "DOI": "10.1182/blood-2009-03-211714", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.33", "DOI": "10.1038/nature12213", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.34", "DOI": "10.1126/science.7652577", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.35", "DOI": "10.1038/nature13988", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.36", "DOI": "10.1056/NEJMoa1200690", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.37", "DOI": "10.1200/JCO.2012.47.7521", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.38", "DOI": "10.1101/gr.165985.113", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.39", "DOI": "10.1038/nm.3161", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.40", "DOI": "10.1158/1078-0432.CCR-14-0433", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.41", "DOI": "10.1038/nm1100", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.42", "DOI": "10.1111/j.1600-065X.2010.00979.x", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.43", "DOI": "10.1126/science.aaa4971", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.44", "DOI": "10.1126/science.1251102", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.45", "DOI": "10.1073/pnas.86.24.10024", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.46", "DOI": "10.1038/nbt0102-70", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.47", "DOI": "10.1038/sj.leu.2403302", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.48", "DOI": "10.1158/0008-5472.CAN-11-0422", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.49", "DOI": "10.1073/pnas.0503726102", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.50", "DOI": "10.1172/JCI32103", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.51", "DOI": "10.1038/nri1842", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.52", "DOI": "10.1172/JCI24480", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.53", "DOI": "10.1126/science.1235454", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.54", "DOI": "10.1126/science.1235487", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.55", "DOI": "10.1016/j.immuni.2011.09.019", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.56", "DOI": "10.1073/pnas.0710929105", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.57", "DOI": "10.1038/mt.2013.17", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.58", "DOI": "10.1038/mt.2010.272", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.59", "DOI": "10.1097/CJI.0b013e3182829903", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.60", "DOI": "10.1038/mt.2010.24", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.61", "DOI": "10.1038/nbt1070", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.62", "DOI": "10.4049/jimmunol.180.9.6116", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.63", "DOI": "10.1182/blood-2013-03-490565", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.64", "DOI": "10.1097/PPO.0000000000000030", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.65", "DOI": "10.1111/imr.12243", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.66", "DOI": "10.1158/2159-8290.CD-12-0548", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.67", "DOI": "10.1038/nrclinonc.2013.46", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.68", "DOI": "10.1126/scitranslmed.3002842", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.69", "DOI": "10.1056/NEJMoa1215134", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.70", "DOI": "10.1126/scitranslmed.3005930", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.71", "DOI": "10.1200/JCO.2014.56.2025", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.72", "DOI": "10.1182/blood-2014-05-552729", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.73", "DOI": "10.1111/imr.12137", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.74", "DOI": "10.1126/science.1258096", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.75", "DOI": "10.1038/leu.2014.62", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.76", "DOI": "10.1182/blood-2006-11-059139", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.77", "DOI": "10.1182/blood-2014-08-595801", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.78", "DOI": "10.1182/blood-2011-05-354449", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.79", "DOI": "10.1158/0008-5472.CAN-10-2880", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.80", "DOI": "10.1034/j.1600-065X.2002.18803.x", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.81", "DOI": "10.1200/JCO.2010.32.2537", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.82", "DOI": "10.1089/hum.2012.041", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.83", "DOI": "10.1172/JCI73639", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.84", "DOI": "10.4049/jimmunol.175.4.2261", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.85", "DOI": "10.1158/0008-5472.CAN-14-2277", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.86", "DOI": "10.1172/JCI58814", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.87", "DOI": "10.1056/NEJMoa1106152", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.88", "DOI": "10.1093/jnci/86.15.1159", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.89", "unstructured": "C. S. Hinrichs, S. Stevanovic, L. Draper, R. Somerville, J. Wunderlich, N. P. Restifo, R. Sherry, P. Q. Giao, U. S. Kammula, J. C. Yang, S. A. Rosenberg, \u201cHPV-targeted tumor-infiltrating lymphocytes for cervical cancer,\u201d 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 30 May to 3 June 1014 (ASCO, Alexandria, VA, 2014), abstract LBA3008; http://meetinglibrary.asco.org/content/129263-144."}, {"key": "2019031311450946000_348.6230.62.90", "DOI": "10.1056/NEJMoa0800251", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.91", "DOI": "10.1126/scitranslmed.3004916", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.92", "DOI": "10.1056/NEJMoa1407222", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.93", "DOI": "10.1126/scitranslmed.3008226", "doi-asserted-by": "publisher"}, {"key": "2019031311450946000_348.6230.62.94", "DOI": "10.1016/S0140-6736(14)61403-3", "doi-asserted-by": "publisher"}], "container-title": ["Science"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1126/science.aaa4967", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 13]], "date-time": "2019-03-13T18:47:48Z", "timestamp": 1552502868000}, "score": 40.627724, "issued": {"date-parts": [[2015, 4, 2]]}, "references-count": 94, "journal-issue": {"published-online": {"date-parts": [[2015, 4, 2]]}, "published-print": {"date-parts": [[2015, 4, 3]]}, "issue": "6230"}, "alternative-id": ["10.1126/science.aaa4967"], "URL": "http://dx.doi.org/10.1126/science.aaa4967", "relation": {"cites": []}, "ISSN": ["0036-8075", "1095-9203"], "issn-type": [{"value": "0036-8075", "type": "print"}, {"value": "1095-9203", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T04:12:28Z", "timestamp": 1574827948874}, "reference-count": 66, "publisher": "SAGE Publications", "issue": "4", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[2013, 10, 1]], "date-time": "2013-10-01T00:00:00Z", "timestamp": 1380585600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["journals.sagepub.com"], "crossmark-restriction": true}, "short-container-title": ["Cancer Control"], "published-print": {"date-parts": [[2013, 10]]}, "DOI": "10.1177/107327481302000406", "type": "journal-article", "created": {"date-parts": [[2017, 8, 30]], "date-time": "2017-08-30T10:52:15Z", "timestamp": 1504090335000}, "page": "289-297", "update-policy": "http://dx.doi.org/10.1177/sage-journals-update-policy", "source": "Crossref", "is-referenced-by-count": 48, "title": ["Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy"], "prefix": "10.1177", "volume": "20", "author": [{"given": "Giao Q.", "family": "Phan", "sequence": "first", "affiliation": [{"name": "Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}]}, {"given": "Steven A.", "family": "Rosenberg", "sequence": "additional", "affiliation": [{"name": "Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}]}], "member": "179", "published-online": {"date-parts": [[2013, 10]]}, "reference": [{"issue": "8", "key": "bibr1-107327481302000406", "doi-asserted-by": "crossref", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "Hodi F.S.", "year": "2010", "journal-title": "N Engl J Med."}, {"issue": "7", "key": "bibr2-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2337s", "DOI": "10.1158/1078-0432.CCR-05-2555", "volume": "12", "author": "Sondak V.K.", "year": "2006", "journal-title": "Clin Cancer Res."}, {"issue": "5", "key": "bibr3-107327481302000406", "doi-asserted-by": "crossref", "first-page": "379", "DOI": "10.1097/PPO.0b013e3182346320", "volume": "17", "author": "Chur ch S.E.", "year": "2011", "journal-title": "Cancer J."}, {"issue": "9", "key": "bibr4-107327481302000406", "doi-asserted-by": "crossref", "first-page": "909", "DOI": "10.1038/nm1100", "volume": "10", "author": "Rosenberg S.A.", "year": "2004", "journal-title": "Nat Med."}, {"issue": "9", "key": "bibr5-107327481302000406", "doi-asserted-by": "crossref", "first-page": "6169", "DOI": "10.4049/jimmunol.175.9.6169", "volume": "175", "author": "Rosenberg S.A.", "year": "2005", "journal-title": "J Immunol."}, {"issue": "7", "key": "bibr6-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2105", "DOI": "10.1200/JCO.1999.17.7.2105", "volume": "17", "author": "Atkins M.B.", "year": "1999", "journal-title": "J Clin Oncol."}, {"issue": "1", "key": "bibr7-107327481302000406", "first-page": "S11", "volume": "6", "author": "Atkins M.B.", "year": "2000", "journal-title": "Cancer J Sci Am."}, {"issue": "7", "key": "bibr8-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2039", "DOI": "10.1158/1078-0432.CCR-11-1823", "volume": "18", "author": "Prieto P.A.", "year": "2012", "journal-title": "Clin Cancer Res."}, {"issue": "26", "key": "bibr9-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2443", "DOI": "10.1056/NEJMoa1200690", "volume": "366", "author": "Topalian S.L.", "year": "2012", "journal-title": "N Engl J Med."}, {"issue": "2", "key": "bibr10-107327481302000406", "doi-asserted-by": "crossref", "first-page": "134", "DOI": "10.1056/NEJMoa1305133", "volume": "369", "author": "Hamid O.", "year": "2013", "journal-title": "N Engl J Med."}, {"issue": "26", "key": "bibr11-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2455", "DOI": "10.1056/NEJMoa1200694", "volume": "366", "author": "Brahmer J.R.", "year": "2012", "journal-title": "N Engl J Med."}, {"issue": "2", "key": "bibr12-107327481302000406", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1056/NEJMoa1302369", "volume": "369", "author": "Wolchok J.D.", "year": "2013", "journal-title": "N Engl J Med."}, {"issue": "13", "key": "bibr13-107327481302000406", "doi-asserted-by": "crossref", "first-page": "4550", "DOI": "10.1158/1078-0432.CCR-11-0116", "volume": "17", "author": "Rosenberg S.A.", "year": "2011", "journal-title": "Clin Cancer Res."}, {"issue": "1", "key": "bibr14-107327481302000406", "first-page": "9", "volume": "76", "author": "Maccarty W.C.", "year": "1922", "journal-title": "Ann Surg."}, {"issue": "910", "key": "bibr15-107327481302000406", "doi-asserted-by": "crossref", "first-page": "58", "DOI": "10.1098/rspb.1954.0054", "volume": "143", "author": "Billingham R.E.", "year": "1954", "journal-title": "Proc R Soc Lond B Biol Sci."}, {"issue": "4257", "key": "bibr16-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1007", "DOI": "10.1126/science.181845", "volume": "193", "author": "Morgan D.A.", "year": "1976", "journal-title": "Science."}, {"issue": "6", "key": "bibr17-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1551", "DOI": "10.1084/jem.151.6.1551", "volume": "151", "author": "Smith K.A.", "year": "1980", "journal-title": "J Exp Med."}, {"issue": "5785", "key": "bibr18-107327481302000406", "doi-asserted-by": "crossref", "first-page": "853", "DOI": "10.1038/287853a0", "volume": "287", "author": "Smith K.A.", "year": "1980", "journal-title": "Nature."}, {"issue": "4643", "key": "bibr19-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1412", "DOI": "10.1126/science.6367046", "volume": "223", "author": "Rosenberg S.A.", "year": "1984", "journal-title": "Science."}, {"issue": "23", "key": "bibr20-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1485", "DOI": "10.1056/NEJM198512053132327", "volume": "313", "author": "Rosenberg S.A.", "year": "1985", "journal-title": "N Engl J Med."}, {"issue": "8", "key": "bibr21-107327481302000406", "doi-asserted-by": "crossref", "first-page": "622", "DOI": "10.1093/jnci/85.8.622", "volume": "85", "author": "Rosenberg S.A.", "year": "1993", "journal-title": "J Natl Cancer Inst."}, {"issue": "4770", "key": "bibr22-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1318", "DOI": "10.1126/science.3489291", "volume": "233", "author": "Rosenberg S.A.", "year": "1986", "journal-title": "Science."}, {"issue": "3", "key": "bibr23-107327481302000406", "first-page": "989", "volume": "138", "author": "Muul L.M.", "year": "1987", "journal-title": "J Immunol."}, {"issue": "5", "key": "bibr24-107327481302000406", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1200/JCO.1988.6.5.839", "volume": "6", "author": "Topalian S.L.", "year": "1988", "journal-title": "J Clin Oncol."}, {"issue": "8", "key": "bibr25-107327481302000406", "doi-asserted-by": "crossref", "first-page": "840", "DOI": "10.1097/CJI.0b013e3181f05b91", "volume": "33", "author": "Goff S.L.", "year": "2010", "journal-title": "J Immunother."}, {"issue": "25", "key": "bibr26-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1676", "DOI": "10.1056/NEJM198812223192527", "volume": "319", "author": "Rosenberg S.A.", "year": "1988", "journal-title": "N Engl J Med."}, {"issue": "15", "key": "bibr27-107327481302000406", "doi-asserted-by": "crossref", "first-page": "3477", "DOI": "10.1200/JCO.2001.19.15.3477", "volume": "19", "author": "Phan G.Q.", "year": "2001", "journal-title": "J Clin Oncol."}, {"issue": "4", "key": "bibr28-107327481302000406", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1097/00002371-200107000-00004", "volume": "24", "author": "Schwartzentruber D.J.", "year": "2001", "journal-title": "J Immunother."}, {"issue": "15", "key": "bibr29-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1159", "DOI": "10.1093/jnci/86.15.1159", "volume": "86", "author": "Rosenberg S.A.", "year": "1994", "journal-title": "J Natl Cancer Inst."}, {"issue": "7", "key": "bibr30-107327481302000406", "doi-asserted-by": "crossref", "first-page": "907", "DOI": "10.1084/jem.20050732", "volume": "202", "author": "Gattinoni L.", "year": "2005", "journal-title": "J Exp Med."}, {"issue": "2", "key": "bibr31-107327481302000406", "doi-asserted-by": "crossref", "first-page": "195", "DOI": "10.1016/j.coi.2005.02.002", "volume": "17", "author": "Wrzesinski C.", "year": "2005", "journal-title": "Curr Opin Immunol."}, {"issue": "32", "key": "bibr32-107327481302000406", "doi-asserted-by": "crossref", "first-page": "5233", "DOI": "10.1200/JCO.2008.16.5449", "volume": "26", "author": "Dudley M.E.", "year": "2008", "journal-title": "J Clin Oncol."}, {"issue": "11", "key": "bibr33-107327481302000406", "doi-asserted-by": "crossref", "first-page": "750", "DOI": "10.1056/NEJM200009143431101", "volume": "343", "author": "Childs R.", "year": "2000", "journal-title": "N Engl J Med."}, {"issue": "3", "key": "bibr34-107327481302000406", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1093/jnci/92.3.205", "volume": "92", "author": "Therasse P.", "year": "2000", "journal-title": "J Natl Cancer Inst."}, {"issue": "10", "key": "bibr35-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2346", "DOI": "10.1200/JCO.2005.00.240", "volume": "23", "author": "Dudley M.E.", "year": "2005", "journal-title": "J Clin Oncol."}, {"issue": "19", "key": "bibr36-107327481302000406", "doi-asserted-by": "crossref", "first-page": "4892", "DOI": "10.1158/1078-0432.CCR-10-1507", "volume": "16", "author": "Hong J.J.", "year": "2010", "journal-title": "Clin Cancer Res."}, {"issue": "10", "key": "bibr37-107327481302000406", "doi-asserted-by": "crossref", "first-page": "7046", "DOI": "10.4049/jimmunol.175.10.7046", "volume": "175", "author": "Zhou J.", "year": "2005", "journal-title": "J Immunol."}, {"issue": "3", "key": "bibr38-107327481302000406", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1097/01.cji.0000158855.92792.7a", "volume": "28", "author": "Huang J.", "year": "2005", "journal-title": "J Immunother."}, {"issue": "12", "key": "bibr39-107327481302000406", "doi-asserted-by": "crossref", "first-page": "7726", "DOI": "10.4049/jimmunol.176.12.7726", "volume": "176", "author": "Huang J.", "year": "2006", "journal-title": "J Immunol."}, {"issue": "8", "key": "bibr40-107327481302000406", "doi-asserted-by": "crossref", "first-page": "742", "DOI": "10.1097/CJI.0b013e31818403d5", "volume": "31", "author": "Tran K.Q.", "year": "2008", "journal-title": "J Immunother."}, {"issue": "24", "key": "bibr41-107327481302000406", "doi-asserted-by": "crossref", "first-page": "6122", "DOI": "10.1158/1078-0432.CCR-10-1297", "volume": "16", "author": "Dudley M.E.", "year": "2010", "journal-title": "Clin Cancer Res."}, {"issue": "9", "key": "bibr42-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2646", "DOI": "10.1158/1078-0432.CCR-10-0041", "volume": "16", "author": "Besser M.J.", "year": "2010", "journal-title": "Clin Cancer Res."}, {"issue": "2", "key": "bibr43-107327481302000406", "doi-asserted-by": "crossref", "first-page": "212", "DOI": "10.1097/CJI.0b013e318209c94c", "volume": "34", "author": "Itzhaki O.", "year": "2011", "journal-title": "J Immunother."}, {"issue": "8", "key": "bibr44-107327481302000406", "doi-asserted-by": "crossref", "first-page": "615", "DOI": "10.1097/CJI.0b013e31826e8f5f", "volume": "35", "author": "Pilon-Thomas S.", "year": "2012", "journal-title": "J Immunother."}, {"issue": "5", "key": "bibr45-107327481302000406", "doi-asserted-by": "crossref", "first-page": "725", "DOI": "10.1007/s00262-011-1182-4", "volume": "61", "author": "Ullenhag G.J.", "year": "2012", "journal-title": "Cancer Immunol Immunother."}, {"issue": "14", "key": "bibr46-107327481302000406", "doi-asserted-by": "crossref", "first-page": "4882", "DOI": "10.1158/1078-0432.CCR-10-2769", "volume": "17", "author": "Joseph R.W.", "year": "2011", "journal-title": "Clin Cancer Res."}, {"key": "bibr47-107327481302000406", "author": "Ellebaek E.", "volume": "10", "first-page": "169", "year": "2012", "journal-title": "J Transl Med.", "DOI": "10.1186/1479-5876-10-169", "doi-asserted-by": "crossref"}, {"issue": "1", "key": "bibr48-107327481302000406", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1038/nrc971", "volume": "3", "author": "Sadelain M.", "year": "2003", "journal-title": "Nat Rev Cancer."}, {"issue": "11", "key": "bibr49-107327481302000406", "doi-asserted-by": "crossref", "first-page": "550", "DOI": "10.1016/j.tibtech.2011.04.009", "volume": "29", "author": "Park T.S.", "year": "2011", "journal-title": "Trends Biotechnol."}, {"issue": "5796", "key": "bibr50-107327481302000406", "doi-asserted-by": "crossref", "first-page": "126", "DOI": "10.1126/science.1129003", "volume": "314", "author": "Morgan R.A.", "year": "2006", "journal-title": "Science."}, {"issue": "3", "key": "bibr51-107327481302000406", "doi-asserted-by": "crossref", "first-page": "535", "DOI": "10.1182/blood-2009-03-211714", "volume": "114", "author": "Johnson L.A.", "year": "2009", "journal-title": "Blood."}, {"issue": "3", "key": "bibr52-107327481302000406", "doi-asserted-by": "crossref", "first-page": "620", "DOI": "10.1038/mt.2010.272", "volume": "19", "author": "Parkhurst M.R.", "year": "2011", "journal-title": "Mol Ther."}, {"issue": "7", "key": "bibr53-107327481302000406", "doi-asserted-by": "crossref", "first-page": "917", "DOI": "10.1200/JCO.2010.32.2537", "volume": "29", "author": "Robbins P.F.", "year": "2011", "journal-title": "J Clin Oncol."}, {"issue": "10", "key": "bibr54-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2769", "DOI": "10.1158/1078-0432.CCR-10-0043", "volume": "16", "author": "Lo A.S.", "year": "2010", "journal-title": "Clin Cancer Res."}, {"issue": "18", "key": "bibr55-107327481302000406", "doi-asserted-by": "crossref", "first-page": "5852", "DOI": "10.1158/1078-0432.CCR-08-3163", "volume": "15", "author": "Yvon E.", "year": "2009", "journal-title": "Clin Cancer Res."}, {"issue": "8", "key": "bibr56-107327481302000406", "doi-asserted-by": "crossref", "first-page": "3027", "DOI": "10.1158/0008-5472.CAN-09-2824", "volume": "70", "author": "Burns W.R.", "year": "2010", "journal-title": "Cancer Res."}, {"issue": "11", "key": "bibr57-107327481302000406", "doi-asserted-by": "crossref", "first-page": "1264", "DOI": "10.1038/nm.1882", "volume": "14", "author": "Pule M.A.", "year": "2008", "journal-title": "Nat Med."}, {"issue": "1", "key": "bibr58-107327481302000406", "first-page": "13", "volume": "71", "author": "Uckun F.M.", "year": "1988", "journal-title": "Blood."}, {"issue": "20", "key": "bibr59-107327481302000406", "doi-asserted-by": "crossref", "first-page": "4099", "DOI": "10.1182/blood-2010-04-281931", "volume": "116", "author": "Kochenderfer J.N.", "year": "2010", "journal-title": "Blood."}, {"issue": "12", "key": "bibr60-107327481302000406", "doi-asserted-by": "crossref", "first-page": "2709", "DOI": "10.1182/blood-2011-10-384388", "volume": "119", "author": "Kochenderfer J.N.", "year": "2012", "journal-title": "Blood."}, {"issue": "8", "key": "bibr61-107327481302000406", "doi-asserted-by": "crossref", "first-page": "725", "DOI": "10.1056/NEJMoa1103849", "volume": "365", "author": "Porter D.L.", "year": "2011", "journal-title": "N Engl J Med."}, {"issue": "4", "key": "bibr62-107327481302000406", "doi-asserted-by": "crossref", "first-page": "666", "DOI": "10.1038/mt.2010.31", "volume": "18", "author": "Brentjens R.", "year": "2010", "journal-title": "Mol Ther."}, {"issue": "4", "key": "bibr63-107327481302000406", "doi-asserted-by": "crossref", "first-page": "843", "DOI": "10.1038/mt.2010.24", "volume": "18", "author": "Morgan R.A.", "year": "2010", "journal-title": "Mol Ther."}, {"issue": "36", "key": "bibr64-107327481302000406", "doi-asserted-by": "crossref", "first-page": "6199", "DOI": "10.1200/JCO.2009.23.4799", "volume": "27", "author": "Balch C.M.", "year": "2009", "journal-title": "J Clin Oncol."}, {"issue": "17", "key": "bibr65-107327481302000406", "doi-asserted-by": "crossref", "first-page": "6725", "DOI": "10.1158/0008-5472.CAN-10-0735", "volume": "70", "author": "Kerkar S.P.", "year": "2010", "journal-title": "Cancer Res."}, {"issue": "4", "key": "bibr66-107327481302000406", "doi-asserted-by": "crossref", "first-page": "751", "DOI": "10.1038/mt.2010.313", "volume": "19", "author": "Zhang L.", "year": "2011", "journal-title": "Mol Ther."}], "container-title": ["Cancer Control"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1177/107327481302000406", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1177/107327481302000406", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 12, 18]], "date-time": "2017-12-18T10:23:57Z", "timestamp": 1513592637000}, "score": 38.375874, "issued": {"date-parts": [[2013, 10]]}, "references-count": 66, "journal-issue": {"published-online": {"date-parts": [[2013, 10]]}, "published-print": {"date-parts": [[2013, 10]]}, "issue": "4"}, "alternative-id": ["10.1177/107327481302000406"], "URL": "http://dx.doi.org/10.1177/107327481302000406", "relation": {"cites": []}, "ISSN": ["1073-2748", "1073-2748"], "issn-type": [{"value": "1073-2748", "type": "print"}, {"value": "1073-2748", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T16:31:58Z", "timestamp": 1575390718786}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://creativecommons.org/licenses/by/2.0", "start": {"date-parts": [[2013, 11, 1]], "date-time": "2013-11-01T00:00:00Z", "timestamp": 1383264000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["j. immunotherapy cancer"], "published-print": {"date-parts": [[2013, 11]]}, "DOI": "10.1186/2051-1426-1-s1-p15", "type": "journal-article", "created": {"date-parts": [[2013, 11, 7]], "date-time": "2013-11-07T10:03:44Z", "timestamp": 1383818624000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Adoptive transfer of tumor infiltrating lymphocytes for metastatic cervical cancer"], "prefix": "10.1186", "volume": "1", "author": [{"given": "Christian S", "family": "Hinrichs", "sequence": "first", "affiliation": []}, {"given": "Sanja", "family": "Stevanovic", "sequence": "additional", "affiliation": []}, {"given": "Lindsey", "family": "Draper", "sequence": "additional", "affiliation": []}, {"given": "Michelle", "family": "Langhan", "sequence": "additional", "affiliation": []}, {"given": "Mark", "family": "Dudley", "sequence": "additional", "affiliation": []}, {"given": "John", "family": "Wunderlich", "sequence": "additional", "affiliation": []}, {"given": "Steven A", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2013, 11, 7]]}, "container-title": ["Journal for ImmunoTherapy of Cancer"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/2051-1426-1-S1-P15.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/2051-1426-1-S1-P15/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/2051-1426-1-S1-P15.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T13:40:36Z", "timestamp": 1548164436000}, "score": 35.02315, "issued": {"date-parts": [[2013, 11]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2013, 11]]}, "issue": "S1"}, "alternative-id": ["57"], "URL": "http://dx.doi.org/10.1186/2051-1426-1-s1-p15", "ISSN": ["2051-1426"], "issn-type": [{"value": "2051-1426", "type": "electronic"}], "subject": ["Immunology", "Immunology and Allergy", "Molecular Medicine", "Cancer Research", "Oncology", "Pharmacology"], "article-number": "P15"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:22:05Z", "timestamp": 1574414525289}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Sci Am"], "published-print": {"date-parts": [[1990, 5]]}, "DOI": "10.1038/scientificamerican0590-62", "type": "journal-article", "created": {"date-parts": [[2010, 2, 24]], "date-time": "2010-02-24T16:16:03Z", "timestamp": 1267028163000}, "page": "62-69", "source": "Crossref", "is-referenced-by-count": 50, "title": ["Adoptive Immunotherapy for Cancer"], "prefix": "10.1038", "volume": "262", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Scientific American"], "deposited": {"date-parts": [[2011, 8, 12]], "date-time": "2011-08-12T13:17:02Z", "timestamp": 1313155022000}, "score": 34.910736, "issued": {"date-parts": [[1990, 5]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1990, 5]]}, "issue": "5"}, "alternative-id": ["scientificamerican0590-62"], "URL": "http://dx.doi.org/10.1038/scientificamerican0590-62", "ISSN": ["0036-8733"], "issn-type": [{"value": "0036-8733", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T17:48:10Z", "timestamp": 1575395290498}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2019, 2]]}, "DOI": "10.1158/2326-6074.cricimteatiaacr18-ia14", "type": "proceedings-article", "created": {"date-parts": [[2019, 2, 4]], "date-time": "2019-02-04T20:19:41Z", "timestamp": 1549311581000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Abstract IA14: Cell transfer immunotherapy targeting unique somatic mutations in cancer"], "prefix": "10.1158", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}], "member": "1086", "event": {"name": "Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY"}, "container-title": ["Genetically Engineered T-cells"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/2326-6074.CRICIMTEATIAACR18-IA14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 2, 4]], "date-time": "2019-02-04T20:20:46Z", "timestamp": 1549311646000}, "score": 34.4705, "issued": {"date-parts": [[2019, 2]]}, "references-count": 0, "alternative-id": ["10.1158/2326-6074.CRICIMTEATIAACR18-IA14"], "URL": "http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-ia14"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:30:24Z", "timestamp": 1574415024429}, "reference-count": 30, "publisher": "Elsevier BV", "issue": "3-5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1986, 9, 1]], "date-time": "1986-09-01T00:00:00Z", "timestamp": 525916800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Immunobiology"], "published-print": {"date-parts": [[1986, 9]]}, "DOI": "10.1016/s0171-2985(86)80122-x", "type": "journal-article", "created": {"date-parts": [[2011, 11, 3]], "date-time": "2011-11-03T19:12:39Z", "timestamp": 1320347559000}, "page": "420-437", "source": "Crossref", "is-referenced-by-count": 39, "title": ["Results of Clinical Trials with the Administration of Interleukin 2 and Adoptive Immunotherapy with Activated Cells in Patients with Cancer"], "prefix": "10.1016", "volume": "172", "author": [{"given": "M.T.", "family": "Lotze", "sequence": "first", "affiliation": []}, {"given": "S.A.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Immunobiology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S017129858680122X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S017129858680122X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 19]], "date-time": "2019-06-19T02:02:58Z", "timestamp": 1560909778000}, "score": 32.460613, "issued": {"date-parts": [[1986, 9]]}, "references-count": 30, "journal-issue": {"published-print": {"date-parts": [[1986, 9]]}, "issue": "3-5"}, "alternative-id": ["S017129858680122X"], "URL": "http://dx.doi.org/10.1016/s0171-2985(86)80122-x", "ISSN": ["0171-2985"], "issn-type": [{"value": "0171-2985", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T17:50:43Z", "timestamp": 1574531443011}, "reference-count": 61, "publisher": "Springer Science and Business Media LLC", "issue": "10", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2011, 8, 2]], "date-time": "2011-08-02T00:00:00Z", "timestamp": 1312243200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Clin Oncol"], "published-print": {"date-parts": [[2011, 10]]}, "DOI": "10.1038/nrclinonc.2011.116", "type": "journal-article", "created": {"date-parts": [[2011, 8, 2]], "date-time": "2011-08-02T09:58:54Z", "timestamp": 1312279134000}, "page": "577-585", "source": "Crossref", "is-referenced-by-count": 186, "title": ["Cell transfer immunotherapy for metastatic solid cancer\u2014what clinicians need to know"], "prefix": "10.1038", "volume": "8", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2011, 8, 2]]}, "reference": [{"key": "BFnrclinonc2011116_CR1", "unstructured": "Rosenberg, S. A., Robbins, P. F. & Restifo, N. P. Cancer immunotherapy in Cancer: Principles & Practice of Oncology (Eds DeVita, V. T., Lawrence, T. S. & Rosenberg, S. A.) 332\u2013344 (Lippincott Williams & Wilkins, Philadelphia, 2011)."}, {"key": "BFnrclinonc2011116_CR2", "unstructured": "Slingluff, C. L., Flaherty, K., Rosenberg, S. A. & Read, P. W. Cutaneous Melanoma in Cancer: Principles & Practice of Oncology (Eds DeVita, V. T., Lawrence, T. S. & Rosenberg, S. A.) 1643\u20131691 (Lippincott Williams & Wilkins, Philadelphia, 2011)."}, {"key": "BFnrclinonc2011116_CR3", "doi-asserted-by": "publisher", "first-page": "4550", "DOI": "10.1158/1078-0432.CCR-11-0116", "volume": "17", "author": "SA Rosenberg", "year": "2011", "unstructured": "Rosenberg, S. A.  et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrclinonc2011116_CR4", "doi-asserted-by": "publisher", "first-page": "688", "DOI": "10.3181/00379727-49-13670", "volume": "49", "author": "K Landsteiner", "year": "1942", "unstructured": "Landsteiner, K. & Chase, M. W. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc. Soc. Exp. Biol. Med. 49, 688\u2013690 (1942).", "journal-title": "Proc. Soc. Exp. Biol. Med."}, {"key": "BFnrclinonc2011116_CR5", "first-page": "326", "volume": "3", "author": "L Gross", "year": "1943", "unstructured": "Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326\u2013333 (1943).", "journal-title": "Cancer Res."}, {"key": "BFnrclinonc2011116_CR6", "doi-asserted-by": "publisher", "first-page": "1007", "DOI": "10.1126/science.181845", "volume": "193", "author": "DA Morgan", "year": "1976", "unstructured": "Morgan, D. A., Ruscetti, F. W. & Gallo, R. G. Selective in vitro growth of T-lymphocytes from normal bone marrow. Science 193, 1007\u20131008 (1976).", "journal-title": "Science"}, {"key": "BFnrclinonc2011116_CR7", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1038/302305a0", "volume": "302", "author": "T Taniguchi", "year": "1983", "unstructured": "Taniguchi, T., Matsui, H. & Fujita, T. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305\u2013307 (1983).", "journal-title": "Nature"}, {"key": "BFnrclinonc2011116_CR8", "doi-asserted-by": "publisher", "first-page": "1412", "DOI": "10.1126/science.6367046", "volume": "223", "author": "SA Rosenberg", "year": "1984", "unstructured": "Rosenberg, S. A.  et al. Biological activity of recombinant human interleukin-2 produced in E. coli Science 223, 1412\u20131414 (1984).", "journal-title": "Science"}, {"key": "BFnrclinonc2011116_CR9", "doi-asserted-by": "publisher", "first-page": "1485", "DOI": "10.1056/NEJM198512053132327", "volume": "313", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg, S. A.  et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485\u20131492 (1985).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrclinonc2011116_CR10", "doi-asserted-by": "publisher", "first-page": "5610", "DOI": "10.1158/1078-0432.CCR-08-0116", "volume": "14", "author": "FO Smith", "year": "2008", "unstructured": "Smith, F. O.  et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14, 5610\u20135618 (2008).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrclinonc2011116_CR11", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "FS Hodi", "year": "2010", "unstructured": "Hodi, F. S.  et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrclinonc2011116_CR12", "doi-asserted-by": "publisher", "first-page": "1643", "DOI": "10.1126/science.1840703", "volume": "254", "author": "P van der Bruggen", "year": "1991", "unstructured": "van der Bruggen, P.  et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643\u20131647 (1991).", "journal-title": "Science"}, {"key": "BFnrclinonc2011116_CR13", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.1016/S1074-7613(00)80028-X", "volume": "10", "author": "SA Rosenberg", "year": "1999", "unstructured": "Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281\u2013287 (1999).", "journal-title": "Immunity"}, {"key": "BFnrclinonc2011116_CR14", "unstructured": "Robbins, P. F., Wang, R.-F. & Rosenberg, S. A. Tumor antigens recognized by cytotoxic lymphocytes in Cytotoxic Cells: Basic Mechanisms and Medical Applications (Eds Sitkovsky, M. V. & Henkart, P. A.) 363\u2013383 (J. B. Lippincott, Philadelphia, 2000)."}, {"key": "BFnrclinonc2011116_CR15", "doi-asserted-by": "publisher", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "volume": "363", "author": "PW Kantoff", "year": "2010", "unstructured": "Kantoff, P. W.  et al. Sipuleucel-T immunotherapy for castration-resistant prostrate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrclinonc2011116_CR16", "doi-asserted-by": "publisher", "first-page": "6169", "DOI": "10.4049/jimmunol.175.9.6169", "volume": "175", "author": "SA Rosenberg", "year": "2005", "unstructured": "Rosenberg, S. A.  et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169\u20136176 (2005).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR17", "doi-asserted-by": "publisher", "first-page": "850", "DOI": "10.1126/science.1076514", "volume": "298", "author": "ME Dudley", "year": "2002", "unstructured": "Dudley, M. E.  et al. Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. Science 298, 850\u2013854 (2002).", "journal-title": "Science"}, {"key": "BFnrclinonc2011116_CR18", "doi-asserted-by": "publisher", "first-page": "5233", "DOI": "10.1200/JCO.2008.16.5449", "volume": "26", "author": "ME Dudley", "year": "2008", "unstructured": "Dudley, M. E.  et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233\u20135239 (2008).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrclinonc2011116_CR19", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1016/j.coi.2009.03.002", "volume": "21", "author": "SA Rosenberg", "year": "2009", "unstructured": "Rosenberg, S. A. & Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233\u2013240 (2009).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnrclinonc2011116_CR20", "doi-asserted-by": "publisher", "first-page": "917", "DOI": "10.1200/JCO.2010.32.2537", "volume": "29", "author": "PF Robbins", "year": "2011", "unstructured": "Robbins, P. F.  et al. Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrclinonc2011116_CR21", "doi-asserted-by": "publisher", "first-page": "4099", "DOI": "10.1182/blood-2010-04-281931", "volume": "116", "author": "JN Kochenderfer", "year": "2010", "unstructured": "Kochenderfer, J. N.  et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).", "journal-title": "Blood"}, {"key": "BFnrclinonc2011116_CR22", "doi-asserted-by": "publisher", "first-page": "620", "DOI": "10.1038/mt.2010.272", "volume": "19", "author": "MR Parkhurst", "year": "2011", "unstructured": "Parkhurst, M. R.  et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).", "journal-title": "Mol. Ther."}, {"key": "BFnrclinonc2011116_CR23", "doi-asserted-by": "publisher", "first-page": "1264", "DOI": "10.1038/nm.1882", "volume": "14", "author": "MA Pule", "year": "2008", "unstructured": "Pule, M. A.  et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264\u20131270 (2008).", "journal-title": "Nat. Med."}, {"key": "BFnrclinonc2011116_CR24", "doi-asserted-by": "publisher", "first-page": "1898", "DOI": "10.1182/blood-2004-07-2975", "volume": "105", "author": "K Straathof", "year": "2005", "unstructured": "Straathof, K.  et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898\u20131904 (2005).", "journal-title": "Blood"}, {"key": "BFnrclinonc2011116_CR25", "first-page": "1549", "volume": "92", "author": "CM Rooney", "year": "1998", "unstructured": "Rooney, C. M.  et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549\u20131555 (1998).", "journal-title": "Blood"}, {"key": "BFnrclinonc2011116_CR26", "doi-asserted-by": "publisher", "first-page": "1318", "DOI": "10.1126/science.3489291", "volume": "233", "author": "SA Rosenberg", "year": "1986", "unstructured": "Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986).", "journal-title": "Science"}, {"key": "BFnrclinonc2011116_CR27", "first-page": "989", "volume": "138", "author": "LM Muul", "year": "1987", "unstructured": "Muul, L. M., Spiess, P. J., Director, E. P. & Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989\u2013995 (1987).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR28", "doi-asserted-by": "publisher", "first-page": "1676", "DOI": "10.1056/NEJM198812223192527", "volume": "319", "author": "SA Rosenberg", "year": "1988", "unstructured": "Rosenberg, S. A.  et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319, 1676\u20131680 (1988).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrclinonc2011116_CR29", "doi-asserted-by": "publisher", "first-page": "1159", "DOI": "10.1093/jnci/86.15.1159", "volume": "86", "author": "SA Rosenberg", "year": "1994", "unstructured": "Rosenberg, S. A.  et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 86, 1159\u20131166 (1994).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnrclinonc2011116_CR30", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1097/CJI.0b013e3181b88ffc", "volume": "33", "author": "C Wrzesiniski", "year": "2010", "unstructured": "Wrzesiniski, C.  et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33, 1\u20137 (2010).", "journal-title": "J. Immunother."}, {"key": "BFnrclinonc2011116_CR31", "doi-asserted-by": "publisher", "first-page": "2507", "DOI": "10.1056/NEJMoa1103782", "volume": "364", "author": "PB Chapman", "year": "2011", "unstructured": "Chapman, P. B.  et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrclinonc2011116_CR32", "first-page": "2973", "volume": "9", "author": "SA Rosenberg", "year": "2003", "unstructured": "Rosenberg, S. A.  et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9, 2973\u20132980 (2003).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrclinonc2011116_CR33", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1038/nri1842", "volume": "6", "author": "L Gattinoni", "year": "2006", "unstructured": "Gattinoni, L., Powell, D. J., Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383\u2013393 (2006).", "journal-title": "Nat. Rev. Immunol."}, {"key": "BFnrclinonc2011116_CR34", "doi-asserted-by": "publisher", "first-page": "2197", "DOI": "10.1172/JCI32205", "volume": "117", "author": "CM Paulos", "year": "2007", "unstructured": "Paulos, C. M.  et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197\u20132204 (2007).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrclinonc2011116_CR35", "doi-asserted-by": "publisher", "first-page": "7046", "DOI": "10.4049/jimmunol.175.10.7046", "volume": "175", "author": "J Zhou", "year": "2005", "unstructured": "Zhou, J., Shen, X., Hodes, R. J., Rosenberg, S. A. & Robbins, P. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046\u20137052 (2005).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR36", "doi-asserted-by": "publisher", "first-page": "7726", "DOI": "10.4049/jimmunol.176.12.7726", "volume": "176", "author": "J Huang", "year": "2006", "unstructured": "Huang, J.  et al. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J. Immunol. 176, 7726\u20137735 (2006).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR37", "doi-asserted-by": "publisher", "first-page": "7125", "DOI": "10.4049/jimmunol.173.12.7125", "volume": "173", "author": "PF Robbins", "year": "2004", "unstructured": "Robbins, P. F.  et al. Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125\u20137130 (2004).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR38", "doi-asserted-by": "publisher", "first-page": "742", "DOI": "10.1097/CJI.0b013e31818403d5", "volume": "31", "author": "KQ Tran", "year": "2008", "unstructured": "Tran, K. Q.  et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 31, 742\u2013751 (2008).", "journal-title": "J. Immunother."}, {"key": "BFnrclinonc2011116_CR39", "doi-asserted-by": "publisher", "first-page": "2646", "DOI": "10.1158/1078-0432.CCR-10-0041", "volume": "16", "author": "MJ Besser", "year": "2010", "unstructured": "Besser, M. J.  et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646\u20132655 (2010).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrclinonc2011116_CR40", "doi-asserted-by": "publisher", "first-page": "6122", "DOI": "10.1158/1078-0432.CCR-10-1297", "volume": "16", "author": "ME Dudley", "year": "2010", "unstructured": "Dudley, M. E.  et al. CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16, 6122\u20136131 (2010).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrclinonc2011116_CR41", "doi-asserted-by": "publisher", "first-page": "6356", "DOI": "10.4049/jimmunol.167.11.6356", "volume": "167", "author": "K Liu", "year": "2001", "unstructured": "Liu, K. & Rosenberg, S. A. Transduction of an interleukin-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356\u20136365 (2001).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR42", "doi-asserted-by": "publisher", "first-page": "5168", "DOI": "10.1182/blood-2006-06-029173", "volume": "109", "author": "C Hsu", "year": "2007", "unstructured": "Hsu, C.  et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109, 5168\u20135177 (2007).", "journal-title": "Blood"}, {"key": "BFnrclinonc2011116_CR43", "doi-asserted-by": "publisher", "first-page": "808", "DOI": "10.1182/blood-2010-05-286286", "volume": "117", "author": "CS Hinrichs", "year": "2011", "unstructured": "Hinrichs, C. S.  et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808\u2013814 (2011).", "journal-title": "Blood"}, {"key": "BFnrclinonc2011116_CR44", "doi-asserted-by": "publisher", "first-page": "336", "DOI": "10.1097/PPO.0b013e3181eb3879", "volume": "16", "author": "RA Morgan", "year": "2010", "unstructured": "Morgan, R. A., Dudley, M. E. & Rosenberg, S. A. Adoptive cell therapy: Genetic modification to redirect effector cell specificity. Cancer J. 16, 336\u2013341 (2010).", "journal-title": "Cancer J."}, {"key": "BFnrclinonc2011116_CR45", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.4049/jimmunol.1001775", "volume": "186", "author": "N Chinnasamy", "year": "2011", "unstructured": "Chinnasamy, N.  et al. A TCR targeting the HLA-A*0201\u2013restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186, 685\u2013696 (2011).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR46", "doi-asserted-by": "publisher", "first-page": "6116", "DOI": "10.4049/jimmunol.180.9.6116", "volume": "180", "author": "PF Robbins", "year": "2008", "unstructured": "Robbins, P. F.  et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116\u20136131 (2008).", "journal-title": "J. Immunol."}, {"key": "BFnrclinonc2011116_CR47", "doi-asserted-by": "publisher", "first-page": "8878", "DOI": "10.1158/0008-5472.CAN-06-1450", "volume": "66", "author": "CJ Cohen", "year": "2006", "unstructured": "Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878\u20138886 (2006).", "journal-title": "Cancer Res."}, {"key": "BFnrclinonc2011116_CR48", "doi-asserted-by": "publisher", "first-page": "3898", "DOI": "10.1158/0008-5472.CAN-06-3986", "volume": "67", "author": "CJ Cohen", "year": "2007", "unstructured": "Cohen, C. J.  et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898\u20133903 (2007).", "journal-title": "Cancer Res."}, {"key": "BFnrclinonc2011116_CR49", "doi-asserted-by": "publisher", "first-page": "126", "DOI": "10.1126/science.1129003", "volume": "314", "author": "RA Morgan", "year": "2006", "unstructured": "Morgan, R. A.  et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).", "journal-title": "Science"}, {"key": "BFnrclinonc2011116_CR50", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1182/blood-2009-03-211714", "volume": "114", "author": "LA Johnson", "year": "2009", "unstructured": "Johnson, L. A.  et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).", "journal-title": "Blood"}, {"key": "BFnrclinonc2011116_CR51", "doi-asserted-by": "publisher", "first-page": "22", "DOI": "10.1034/j.1600-065X.2002.18803.x", "volume": "188", "author": "MJ Scanlan", "year": "2002", "unstructured": "Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22\u201332 (2002).", "journal-title": "Immunol. Rev."}, {"key": "BFnrclinonc2011116_CR52", "doi-asserted-by": "publisher", "first-page": "625", "DOI": "10.1038/nrc1669", "volume": "5", "author": "AJ Simpson", "year": "2005", "unstructured": "Simpson, A. J., Caballero, O. L., Jungbluth, A., Chen, Y. T. & Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 625 (2005).", "journal-title": "Nat. Rev. Cancer"}, {"key": "BFnrclinonc2011116_CR53", "doi-asserted-by": "publisher", "first-page": "10024", "DOI": "10.1073/pnas.86.24.10024", "volume": "86", "author": "G Gross", "year": "1989", "unstructured": "Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024\u201310028 (1989).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrclinonc2011116_CR54", "doi-asserted-by": "publisher", "first-page": "e20", "DOI": "10.1200/JCO.2006.05.9964", "volume": "24", "author": "CHJ Lamers", "year": "2006", "unstructured": "Lamers, C. H. J.  et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrclinonc2011116_CR55", "doi-asserted-by": "publisher", "first-page": "3953", "DOI": "10.1172/JCI43490", "volume": "120", "author": "D Chinnasamy", "year": "2010", "unstructured": "Chinnasamy, D.  et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953\u20133968 (2010).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrclinonc2011116_CR56", "doi-asserted-by": "publisher", "first-page": "666", "DOI": "10.1038/mt.2010.31", "volume": "18", "author": "R Brentjens", "year": "2010", "unstructured": "Brentjens, R., Yeh, R., Bernal, Y., Riviere, I. & Sadelain, M. Treatment of chronic lymphotic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase 1 clinical trial. Mol. Ther. 18, 666\u2013668 (2010).", "journal-title": "Mol. Ther."}, {"key": "BFnrclinonc2011116_CR57", "doi-asserted-by": "publisher", "first-page": "843", "DOI": "10.1038/mt.2010.24", "volume": "18", "author": "RA Morgan", "year": "2010", "unstructured": "Morgan, R. A.  et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).", "journal-title": "Mol. Ther."}, {"key": "BFnrclinonc2011116_CR58", "doi-asserted-by": "publisher", "first-page": "565", "DOI": "10.1038/nm.2128", "volume": "16", "author": "GM Bendle", "year": "2010", "unstructured": "Bendle, G. M.  et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565\u2013570 (2010).", "journal-title": "Nat. Med."}, {"key": "BFnrclinonc2011116_CR59", "doi-asserted-by": "publisher", "first-page": "1744", "DOI": "10.1038/mt.2010.195", "volume": "18", "author": "SA Rosenberg", "year": "2010", "unstructured": "Rosenberg, S. A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 18, 1744\u20131755 (2010).", "journal-title": "Mol. Ther."}, {"key": "BFnrclinonc2011116_CR60", "doi-asserted-by": "publisher", "first-page": "158", "DOI": "10.1200/JCO.2000.18.1.158", "volume": "18", "author": "MR Middleton", "year": "2000", "unstructured": "Middleton, M. R.  et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18, 158\u2013166 (2000).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrclinonc2011116_CR61", "doi-asserted-by": "publisher", "first-page": "2105", "DOI": "10.1200/JCO.1999.17.7.2105", "volume": "17", "author": "MB Atkins", "year": "1999", "unstructured": "Atkins, M. B.  et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105\u20132116 (1999).", "journal-title": "J. Clin. Oncol."}], "container-title": ["Nature Reviews Clinical Oncology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrclinonc.2011.116", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrclinonc.2011.116.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrclinonc.2011.116.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 27]], "date-time": "2019-04-27T19:33:45Z", "timestamp": 1556393625000}, "score": 32.121666, "issued": {"date-parts": [[2011, 8, 2]]}, "references-count": 61, "journal-issue": {"published-print": {"date-parts": [[2011, 10]]}, "issue": "10"}, "alternative-id": ["BFnrclinonc2011116"], "URL": "http://dx.doi.org/10.1038/nrclinonc.2011.116", "relation": {"cites": []}, "ISSN": ["1759-4774", "1759-4782"], "issn-type": [{"value": "1759-4774", "type": "print"}, {"value": "1759-4782", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T15:02:03Z", "timestamp": 1574866923944}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2018, 1]]}, "DOI": "10.1158/1535-7163.targ-17-kn03", "type": "proceedings-article", "created": {"date-parts": [[2018, 8, 17]], "date-time": "2018-08-17T19:23:09Z", "timestamp": 1534533789000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract KN03: Keynote Lecture: Cell transfer immunotherapy targeting unique somatic mutations in cancer"], "prefix": "10.1158", "author": [{"given": "Steven A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2018, 1, 1]]}, "event": {"name": "Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA"}, "container-title": ["Tumor Immunology Targets"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.TARG-17-KN03", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 17]], "date-time": "2018-08-17T19:26:10Z", "timestamp": 1534533970000}, "score": 31.960009, "issued": {"date-parts": [[2018, 1]]}, "references-count": 0, "alternative-id": ["10.1158/1535-7163.TARG-17-KN03"], "URL": "http://dx.doi.org/10.1158/1535-7163.targ-17-kn03"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T05:20:51Z", "timestamp": 1574400051493}, "publisher-location": "Boston, MA", "reference-count": 85, "publisher": "Springer US", "isbn-type": [{"value": "9781461288831", "type": "print"}, {"value": "9781461315957", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1989]]}, "DOI": "10.1007/978-1-4613-1595-7_12", "type": "book-chapter", "created": {"date-parts": [[2011, 9, 19]], "date-time": "2011-09-19T07:27:33Z", "timestamp": 1316417253000}, "page": "213-233", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Adoptive immunotherapy of urologic tumors"], "prefix": "10.1007", "author": [{"given": "Arie", "family": "Belldegrun", "sequence": "first", "affiliation": []}, {"given": "Steven A.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "12_CR1", "doi-asserted-by": "publisher", "first-page": "1007", "DOI": "10.1126/science.181845", "volume": "193", "author": "DA Morgan", "year": "1976", "unstructured": "Morgan DA, Ruscetti FW, Gallo, RG: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007, 1976.", "journal-title": "Science"}, {"key": "12_CR2", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1038/302305a0", "volume": "302", "author": "T Taniguchi", "year": "1983", "unstructured": "Taniguchi T, Matsui H, Fujita T, et al.: Structure and expression of a cloned cDNA for human interleukin-2. Nature 302: 305, 1983.", "journal-title": "Nature"}, {"key": "12_CR3", "doi-asserted-by": "publisher", "first-page": "1412", "DOI": "10.1126/science.6367046", "volume": "223", "author": "SA Rosenberg", "year": "1984", "unstructured": "Rosenberg SA, Grimm EA, McGrogen M, Doyle M, Kawasaki E, Koths K, Mark DE: Biological activity of recombinant human interleukin-2 produced in E. coli. Science 223: 1412, 1984.", "journal-title": "Science"}, {"key": "12_CR4", "doi-asserted-by": "publisher", "first-page": "727", "DOI": "10.1126/science.3008337", "volume": "232", "author": "TA Waldmann", "year": "1986", "unstructured": "Waldmann TA: The structure, function and expression of interleukin-2 receptor on normal and malignant lymphocytes. Science 232: 727, 1986.", "journal-title": "Science"}, {"key": "12_CR5", "author": "SA Rosenberg", "first-page": "55", "year": "1986", "unstructured": "Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: Important Advances in Oncology, De Vita VT, Hellman S, Rosenberg SA (eds). JB Lippincott, New York, 1986, pp. 55\u201391.", "volume-title": "Important Advances in Oncology"}, {"key": "12_CR6", "first-page": "2865", "volume": "135", "author": "MT Lotze", "year": "1985", "unstructured": "Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA: In vivo administration of purified human interleukin-2. II. Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. Immunol 135: 2865, 1985.", "journal-title": "Immunol"}, {"key": "12_CR7", "first-page": "157", "volume": "134", "author": "MT Lotze", "year": "1985", "unstructured": "Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA: In vivo administration of purified human interleukin-2. I. Half life and immunologic effects of the Jurkat cell line derived IL-2. J Immuno 134: 157, 1985.", "journal-title": "J Immuno"}, {"key": "12_CR8", "first-page": "238", "volume": "125", "author": "I Yron", "year": "1980", "unstructured": "Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA: In vivo growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125: 238, 1980.", "journal-title": "J Immunol"}, {"key": "12_CR9", "first-page": "4420", "volume": "41", "author": "MT Lotze", "year": "1981", "unstructured": "Lotze MT, Grimm E, Mazumder A, Strausser JL, Rosenberg SA: In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res 41: 4420, 1981.", "journal-title": "Cancer Res"}, {"key": "12_CR10", "doi-asserted-by": "publisher", "first-page": "1823", "DOI": "10.1084/jem.155.6.1823", "volume": "155", "author": "EA Grimm", "year": "1982", "unstructured": "Grimm EA, Ramsey KM, Mazumder A, Wilson DJK, Djeu JY, Rosenberg SA: Lymphokine-activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823, 1982.", "journal-title": "J Exp Med"}, {"key": "12_CR11", "author": "SA Rosenberg", "first-page": "213", "year": "1982", "unstructured": "Rosenberg SA, Grimm EA, Lotze MT: The growth of human lymphocytes in T cell growth factor: Potential applications for tumor immunotherapy. In: Lymphokines, Vol. 7, Mizel SB (ed). Academic Press, New York, 1982, pp. 213\u2013247.", "volume-title": "Lymphokines"}, {"key": "12_CR12", "doi-asserted-by": "publisher", "first-page": "1327", "DOI": "10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O", "volume": "55", "author": "AA Rayner", "year": "1985", "unstructured": "Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA: Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to immunotherapy of human cancer. Cancer 55: 1327, 1985.", "journal-title": "Cancer"}, {"key": "12_CR13", "doi-asserted-by": "publisher", "first-page": "1327", "DOI": "10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O", "volume": "55", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg SA: Lymphokine-activated killer cells: A new approach to the immunotherapy of human cancer. Cancer 55: 1327, 1985.", "journal-title": "Cancer"}, {"key": "12_CR14", "doi-asserted-by": "publisher", "first-page": "1450", "DOI": "10.1084/jem.160.5.1450", "volume": "160", "author": "TA Waldmann", "year": "1984", "unstructured": "Waldmann TA, Goldman CK, Robb RJ, et al.: Expression of interleukin-2 receptors on activated human B cells. J Exp Med 160: 1450, 1984.", "journal-title": "J Exp Med"}, {"key": "12_CR15", "doi-asserted-by": "publisher", "first-page": "1597", "DOI": "10.1084/jem.160.5.1597", "volume": "160", "author": "LKL Jung", "year": "1984", "unstructured": "Jung LKL, Toshiro H, Fu SM: Detection and functional studies of p60\u201355 (Tac antigeni) on activated human B cells. J Exp Med 160: 1597, 1984.", "journal-title": "J Exp Med"}, {"key": "12_CR16", "doi-asserted-by": "publisher", "first-page": "262", "DOI": "10.1038/325262a0", "volume": "325", "author": "M Malkovsky", "year": "1987", "unstructured": "Malkovsky M, Loveland B, North M, et al.: Recombinant interleukin-2 directly augments the cytotoxicity of human moncytes. Nature 325: 262, 1987.", "journal-title": "Nature"}, {"key": "12_CR17", "first-page": "185", "volume": "138", "author": "WW Hancock", "year": "1987", "unstructured": "Hancock WW, Muller WA, Cotran RS: Interleukin-2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and moncyte cell lines. J Immunol 138: 185, 1987.", "journal-title": "J Immunol"}, {"key": "12_CR18", "first-page": "948", "volume": "44", "author": "ME Horwitz", "year": "1985", "unstructured": "Horwitz ME, Hofman F, Gray D, Gillis S, Horwitz DA: Interleukin-2 can bind to human monocytes. Fed Proc 44: 948, 1985.", "journal-title": "Fed Proc"}, {"key": "12_CR19", "doi-asserted-by": "publisher", "first-page": "1318", "DOI": "10.1126/science.3489291", "volume": "223", "author": "SA Rosenberg", "year": "1986", "unstructured": "Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 223: 1318, 1986.", "journal-title": "Science"}, {"key": "12_CR20", "doi-asserted-by": "publisher", "first-page": "1327", "DOI": "10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O", "volume": "55", "author": "AA Rayner", "year": "1985", "unstructured": "Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA: Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55: 1327, 1985.", "journal-title": "Cancer"}, {"key": "12_CR21", "doi-asserted-by": "crossref", "first-page": "150", "DOI": "10.1016/S0022-5347(17)42342-1", "volume": "139", "author": "A Belldegrun", "year": "1988", "unstructured": "Belldegrun A, Uppenkamp I, Rosenberg SA: Antitumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer. J Urol 139: 150, 1988.", "journal-title": "J Urol"}, {"key": "12_CR22", "author": "EA Grimm", "year": "1983", "unstructured": "Grimm EA, Rosenberg SA: The human lymphokine activated killer cell phenomenon. In: Lymphokines, Vol. 9, Pick E, Candy M (eds). Academic Press, New York, 1983.", "volume-title": "Lymphokines"}, {"key": "12_CR23", "unstructured": "Skibber J, Lotze M, Muul L, Uppenkamp I, Ross W, Rosenberg SA: Human lymphokine activated killer cells: Isolation and characterization of the precursor and effector cell. Submitted."}, {"key": "12_CR24", "doi-asserted-by": "publisher", "first-page": "814", "DOI": "10.1084/jem.164.3.814", "volume": "164", "author": "J Philips", "year": "1986", "unstructured": "Philips J, Lanier L: Dissection of the lymphokine activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814, 1986.", "journal-title": "J Exp Med"}, {"key": "12_CR25", "unstructured": "Lotze MT, Custer MC, Rosenberg SA: Interleukin-2 (IL-2) administration to humans results in the rapid emigration of a specific lymphokine subset (CD2+, 3\u2212, 11+, 16+) from the peripheral blood. Submitted, 1987."}, {"key": "12_CR26", "first-page": "3899", "volume": "136", "author": "JJ Mule", "year": "1986", "unstructured": "Mule JJ, Yang J, Shu S, Rosenberg SA: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136: 3899, 1986.", "journal-title": "J Immunol"}, {"key": "12_CR27", "first-page": "408", "volume": "36", "author": "JC Yang", "year": "1985", "unstructured": "Yang JC, Mule JJ, Rosenberg SA: Characterization of the murine lymphokine-activated killer precursor and effector cell. Surg Forum 36: 408, 1985.", "journal-title": "Surg Forum"}, {"key": "12_CR28", "first-page": "285", "volume": "139", "author": "JJ Mule", "year": "1987", "unstructured": "Mule JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol 139: 285, 1987.", "journal-title": "J Immunol"}, {"key": "12_CR29", "first-page": "595", "volume": "75", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg SA: Lymphokine-activated killer cells: A new approach to the immunotherapy of cancer, [guest editorial] J Natl Cancer Inst 75: 595, 1985.", "journal-title": "J Natl Cancer Inst"}, {"key": "12_CR30", "doi-asserted-by": "publisher", "first-page": "1487", "DOI": "10.1126/science.6332379", "volume": "225", "author": "JJ Mule", "year": "1984", "unstructured": "Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487, 1984.", "journal-title": "Science"}, {"key": "12_CR31", "first-page": "646", "volume": "135", "author": "JJ Mule", "year": "1985", "unstructured": "Mule JJ, Shu S, Rosenberg SA: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135: 646, 1985.", "journal-title": "J Immunol"}, {"key": "12_CR32", "doi-asserted-by": "publisher", "first-page": "1169", "DOI": "10.1084/jem.161.5.1169", "volume": "161", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz S: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant IL-2. J Exp Med 161: 1169, 1985.", "journal-title": "J Exp Med"}, {"key": "12_CR33", "first-page": "3735", "volume": "45", "author": "R Lafreniere", "year": "1985", "unstructured": "Lafreniere R, Rosenberg SA: Successful immunotherapy of murine hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735, 1985.", "journal-title": "Cancer Res"}, {"key": "12_CR34", "first-page": "4273", "volume": "135", "author": "R Lafreniere", "year": "1985", "unstructured": "Lafreniere R, Rosenberg SA: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J Immunol 135: 4273, 1985.", "journal-title": "J Immunol"}, {"key": "12_CR35", "first-page": "676", "volume": "46", "author": "JJ Mule", "year": "1986", "unstructured": "Mule JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: An analysis of survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 46: 676, 1986.", "journal-title": "Cancer Res"}, {"key": "12_CR36", "first-page": "3623", "volume": "135", "author": "S Ettinghausen", "year": "1985", "unstructured": "Ettinghausen S, Lipford E, Mule J, Rosenberg SA: Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 135: 3623, 1985.", "journal-title": "J Immunol"}, {"key": "12_CR37", "first-page": "285", "volume": "139", "author": "JJ Mule", "year": "1987", "unstructured": "Mule JJ, Yang JC, Lafreniere R, et al.: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol 139: 285, 1987.", "journal-title": "J Immunol"}, {"key": "12_CR38", "author": "SA Rosenberg", "first-page": "217", "year": "1988", "unstructured": "Rosenberg SA: Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: Important Advances in Oncology, De Vita VT, Hellman S, Rosenberg SA (ed). JB Lippincott, New York, 1988, pp. 217\u2013257.", "volume-title": "Important Advances in Oncology"}, {"key": "12_CR39", "first-page": "238", "volume": "125", "author": "I Yron", "year": "1980", "unstructured": "Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA: In vivo growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125: 238, 1980.", "journal-title": "J Immunol"}, {"key": "12_CR40", "doi-asserted-by": "publisher", "first-page": "895", "DOI": "10.1002/ijc.2910200612", "volume": "20", "author": "BM Vose", "year": "1977", "unstructured": "Vose BM, Vanky F, Klein E: Human tumor-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumor infiltrating blood and lymph node lymphocytes with autologous tumor cells. Int J Cancer 20: 895, 1977.", "journal-title": "Int J Cancer"}, {"key": "12_CR41", "doi-asserted-by": "publisher", "first-page": "872", "DOI": "10.1002/eji.1830081209", "volume": "8", "author": "TH Totterman", "year": "1978", "unstructured": "Totterman TH, Hayry P, Saksela E, Timonen T, Eklund B: Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. Eur J Immunol 8: 872, 1978.", "journal-title": "Eur J Immunol"}, {"key": "12_CR42", "doi-asserted-by": "publisher", "first-page": "579", "DOI": "10.1002/ijc.2910240510", "volume": "24", "author": "BM Vose", "year": "1979", "unstructured": "Vose BM, Moore M: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer 24: 579, 1979.", "journal-title": "Int J Cancer"}, {"key": "12_CR43", "doi-asserted-by": "publisher", "first-page": "166", "DOI": "10.1038/bjc.1981.167", "volume": "44", "author": "O Eremin", "year": "1981", "unstructured": "Eremin O, Coombs RRA, Ashby J: Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer 44: 166, 1981.", "journal-title": "Br J Cancer"}, {"key": "12_CR44", "first-page": "57", "volume": "45", "author": "PM Moy", "year": "1985", "unstructured": "Moy PM, Holmes EC, Golub, SH: Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 45: 57, 1985.", "journal-title": "Cancer Res"}, {"key": "12_CR45", "first-page": "173", "volume": "47", "author": "H Rabinowich", "year": "1987", "unstructured": "Rabinowich H, Cohen R, Buderman I, et al.: Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173, 1987.", "journal-title": "Cancer Res"}, {"key": "12_CR46", "author": "E Klein", "first-page": "79", "year": "1980", "unstructured": "Klein E, Vanky F, Galili U, Vose BM, Fopp M: Separation and characteristics of tumor infiltrating lymphocytes in man. In: Contemporary Topics in Immunobiology, Vol. 10, Witz IP, Hanna MG Jr (eds). New York, Plenum Press, 1980, pp. 79\u2013107.", "volume-title": "Contemporary Topics in Immunobiology"}, {"key": "12_CR47", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.1002/ijc.2910300202", "volume": "30", "author": "BM Vose", "year": "1982", "unstructured": "Vose BM: Quantitation of proliferative and cytotoxic precursor cells directed against human tumors: Limiting dilution analysis in peripheral blood and at the tumor site. Int J Cancer 30: 135, 1982.", "journal-title": "Int J Cancer"}, {"key": "12_CR48", "first-page": "178", "volume": "15", "author": "A Keong", "year": "1983", "unstructured": "Keong A, Rabson AR: Supernatants derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells. Cancer Immunol Immunother 15: 178, 1983.", "journal-title": "Cancer Immunol Immunother"}, {"key": "12_CR49", "first-page": "1899", "volume": "136", "author": "S Miescher", "year": "1986", "unstructured": "Miescher S, Witheside TL, Carrel S, Fliedner V: Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136: 1899, 1986.", "journal-title": "J Immunol"}, {"key": "12_CR50", "doi-asserted-by": "publisher", "first-page": "105", "DOI": "10.1007/BF00205309", "volume": "13", "author": "BM Vose", "year": "1982", "unstructured": "Vose BM, Ferguson R, Moore M: Mitogen responsiveness and inhibitory activity of mesenteric lymph node cells. Cancer Immunol Immunother 13: 105, 1982.", "journal-title": "Cancer Immunol Immunother"}, {"key": "12_CR51", "first-page": "390", "volume": "37", "author": "SL Topalian", "year": "1987", "unstructured": "Topalian SL, Muul LM, Rosenberg SA: Growth and immunologic characteristics of lymphocytes infiltrating human tumor. Surg Forum 37: 390, 1987.", "journal-title": "Surg Forum"}, {"key": "12_CR52", "doi-asserted-by": "publisher", "first-page": "127", "DOI": "10.1016/S0022-1759(87)80018-2", "volume": "102", "author": "SL Topalian", "year": "1987", "unstructured": "Topalian SL, Muul LM, Dolomon D, Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Meth 102: 127, 1987.", "journal-title": "J Immunol Meth"}, {"key": "12_CR53", "first-page": "671", "volume": "37", "author": "A Belldegrun", "year": "1986", "unstructured": "Belldegrun A, Linehan MW, Robertson CN, Rosenberg SA: Isolation and characterization of lymphocytes infiltrating human renal cell cancer: Possible application for therapeutic adoptive immunotherapy. Surg Forum 37: 671, 1986.", "journal-title": "Surg Forum"}, {"key": "12_CR54", "first-page": "206", "volume": "48", "author": "A Belldegrun", "year": "1988", "unstructured": "Belldegrun A, Muul LM, Rosenberg SA: Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: Isolation, characterization and antitumor activity. Cancer Res 48: 206, 1988.", "journal-title": "Cancer Res"}, {"key": "12_CR55", "first-page": "989", "volume": "138", "author": "LM Muul", "year": "1987", "unstructured": "Muul LM, Spiess PJ, Director EP, Rosenberg SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989, 1987.", "journal-title": "J Immunol"}, {"key": "12_CR56", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1200/JCO.1988.6.5.839", "volume": "6", "author": "SL Topalian", "year": "1988", "unstructured": "Topalian SL, Solomon D, Avis FP, Change AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6: 839, 1988.", "journal-title": "J Clin Oncol"}, {"key": "12_CR57", "first-page": "3011", "volume": "46", "author": "K Itoh", "year": "1986", "unstructured": "Itoh K, Tilden AB, Balch CM: Interleukin-2 activation of cytotoxic T lymphocytes into human metastatic melanomas. Cancer Res 46: 3011, 1986.", "journal-title": "Cancer Res"}, {"key": "12_CR58", "first-page": "688", "volume": "38", "author": "A Belldegrun", "year": "1987", "unstructured": "Belldegrun A, Topalian SL, Linehan WM, Robertson CN, Rosenberg SA: Growth and antitumor activity of tumor-involved draining lymph node cells versus tumor-infiltrating lymphocytes from patients with renal cell cancer. Surg Forum 38: 688, 1987.", "journal-title": "Surg Forum"}, {"key": "12_CR59", "doi-asserted-by": "publisher", "first-page": "149", "DOI": "10.1016/0008-8749(86)90015-8", "volume": "100", "author": "T Nishimura", "year": "1986", "unstructured": "Nishimura T, Yagi H, Uchiyama Y, Hashimoto Y: Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes. Cell Immunol 100: 149, 1986.", "journal-title": "Cell Immunol"}, {"key": "12_CR60", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1007/BF00199303", "volume": "25", "author": "TM Anderson", "year": "1987", "unstructured": "Anderson TM, Ibayashi Y, Holmes EC, Golub SH: Modification of natural killer activity of lymphocytes infiltrating human lung cancers. Cancer Immunol Immunother 25: 65, 1987.", "journal-title": "Cancer Immunol Immunother"}, {"key": "12_CR61", "first-page": "173", "volume": "47", "author": "H Rabinowich", "year": "1987", "unstructured": "Rabinowich H, Cohen R, Burderman I, Steiner Z, Klajman A: Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173, 1987.", "journal-title": "Cancer Res"}, {"key": "12_CR62", "doi-asserted-by": "publisher", "first-page": "367", "DOI": "10.1016/0090-1229(86)90247-3", "volume": "38", "author": "JT Kurnick", "year": "1986", "unstructured": "Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA: Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 38: 367, 1986.", "journal-title": "Clin Immunol Immunopathol"}, {"key": "12_CR63", "first-page": "1006", "volume": "75", "author": "H Kimura", "year": "1984", "unstructured": "Kimura H, Yamaguchi Y, Fujisawa T: Cytotoxicity of autologous and allogeneic lymphocytes against cultured human lung cancer cells: Optimal conditions for the production of cytotoxic lymphocytes. Gann 75: 1006, 1984.", "journal-title": "Gann"}, {"key": "12_CR64", "first-page": "6353", "volume": "47", "author": "DS Heo", "year": "1987", "unstructured": "Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB: Long-term interleukin-2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 47: 6353, 1987.", "journal-title": "Cancer Res"}, {"key": "12_CR65", "first-page": "4004", "volume": "138", "author": "S Miescher", "year": "1987", "unstructured": "Miescher S, Whiteside TL, Moretta L, Von Fliedner V: Clonal and frequency analyses of tumor infiltrating T lymphocytes from human solid tumors. J Immunol 138: 4004, 1987.", "journal-title": "J Immunol"}, {"key": "12_CR66", "first-page": "1067", "volume": "79", "author": "PJ Spiess", "year": "1987", "unstructured": "Spiess PJ, Yang JC, Rosenberg SA: In vivo activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Nat Cancer Inst 79: 1067, 1987.", "journal-title": "J Nat Cancer Inst"}, {"key": "12_CR67", "doi-asserted-by": "publisher", "first-page": "1485", "DOI": "10.1056/NEJM198512053132327", "volume": "313", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485, 1985.", "journal-title": "N Engl J Med"}, {"key": "12_CR68", "doi-asserted-by": "publisher", "first-page": "889", "DOI": "10.1056/NEJM198704093161501", "volume": "316", "author": "SA Rosenberg", "year": "1987", "unstructured": "Rosenberg SA, Lotze MT, Muul LM, Change AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889, 1987.", "journal-title": "N Engl J Med"}, {"key": "12_CR69", "doi-asserted-by": "publisher", "first-page": "58", "DOI": "10.1016/0167-5699(88)91261-3", "volume": "9", "author": "SA Rosenberg", "year": "1988", "unstructured": "Rosenberg SA: Immunotherapy of cancer using interleukin-2: Current status and future prospects. Immunol Today 9: 58, 1988.", "journal-title": "Immunol Today"}, {"key": "12_CR70", "doi-asserted-by": "crossref", "first-page": "403", "DOI": "10.1200/JCO.1988.6.3.403", "volume": "6", "author": "SA Rosenberg", "year": "1988", "unstructured": "Rosenberg SA: Cancer therapy with interleukin-2: Immunologic manipulations can mediate the regression of cancer in man. J Clin Oncol 6: 403, 1988.", "journal-title": "J Clin Oncol"}, {"key": "12_CR71", "first-page": "501", "volume": "3", "author": "SA Rosenberg", "year": "1984", "unstructured": "Rosenberg SA: Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. J Biol Res Mod 3: 501, 1984.", "journal-title": "J Biol Res Mod"}, {"key": "12_CR72", "first-page": "35", "volume": "17", "author": "M Rosenstein", "year": "1986", "unstructured": "Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 17: 35, 1986.", "journal-title": "J Immunol"}, {"key": "12_CR73", "doi-asserted-by": "crossref", "first-page": "817", "DOI": "10.7326/0003-4819-106-6-817", "volume": "106", "author": "A Belldegrun", "year": "1987", "unstructured": "Belldegrun A, Webb DE, Austin HA, et al.: Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Int Med 106: 817, 1987.", "journal-title": "Ann Int Med"}, {"key": "12_CR74", "unstructured": "Webb DE, Austin HA, Belldegrun A, et al.: Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol, in press."}, {"key": "12_CR75", "doi-asserted-by": "crossref", "first-page": "499", "DOI": "10.1016/S0022-5347(17)40872-X", "volume": "141", "author": "DE Webb", "year": "1989", "unstructured": "Belldegrun A, Webb DE, Austin HA, et al.: Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: Effect of pretherapy nephrectomy. J Urol 141: 499, 1989.", "journal-title": "J Urol"}, {"key": "12_CR76", "first-page": "1654", "volume": "69", "author": "SE Ettignhausen", "year": "1987", "unstructured": "Ettignhausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA: Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654, 1987.", "journal-title": "Blood"}, {"key": "12_CR77", "unstructured": "Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA: Cardiorespiratory effects of immunotherapy with interleukin-2. Ann Int Med, in press."}, {"key": "12_CR78", "doi-asserted-by": "publisher", "first-page": "898", "DOI": "10.1056/NEJM198704093161502", "volume": "316", "author": "K Tauer", "year": "1987", "unstructured": "West W, Tauer K, Yannelli J, Marshall G, Orr D, Thurman G, Oldham R: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898, 1987.", "journal-title": "N Engl J Med"}, {"key": "12_CR79", "doi-asserted-by": "publisher", "first-page": "1016", "DOI": "10.1016/0002-9343(87)90936-3", "volume": "83", "author": "J Wang", "year": "1987", "unstructured": "Wang J, Walle A, Gorden B, et al.: Adoptive immunotherapy for Stage IV renal cell carcinoma: A novel protocol using periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. Am J Med 83: 1016, 1987.", "journal-title": "Am J Med"}, {"key": "12_CR80", "unstructured": "Papa MZ, Yang J, Vetto JT, Shiloni E, Eisenthal A, Eisenthal A, Rosenberg SA: Synergistic effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res, in press."}, {"key": "12_CR81", "unstructured": "Mitchell MS, Kempf AR, Harel W, et al.: Effectiveness and tolerability of low dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409.", "DOI": "10.1200/JCO.1988.6.3.409", "doi-asserted-by": "crossref"}, {"key": "12_CR82", "first-page": "3358", "volume": "46", "author": "PR Salup", "year": "1986", "unstructured": "Salup PR, Wiltrout RH: Adjuvant immunotherapy of established murine renal cancer by interleukin-2-stimulated cytotoxic lymphocytes. Cancer Res 46: 3358, 1986.", "journal-title": "Cancer Res"}, {"key": "12_CR83", "first-page": "3948", "volume": "47", "author": "JL Winkelhake", "year": "1987", "unstructured": "Winkelhake JL, Stampfl S, Zimmerman RJ: Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res 47: 3948, 1987.", "journal-title": "Cancer Res"}, {"key": "12_CR84", "doi-asserted-by": "publisher", "first-page": "763", "DOI": "10.1002/ijc.2910380521", "volume": "38", "author": "PGG Brouckaert", "year": "1986", "unstructured": "Brouckaert PGG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W: In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with murine IFN-, on a syngeneic murine melanoma. Int J Cancer 38: 763, 1986.", "journal-title": "Int J Cancer"}, {"key": "12_CR85", "doi-asserted-by": "publisher", "first-page": "365", "DOI": "10.1002/ijc.2910400314", "volume": "40", "author": "MJ Brunda", "year": "1987", "unstructured": "Brunda MJ, Bellantoni D, Sulich V: In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine mode. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40: 365, 1987.", "journal-title": "Int J Cancer"}], "container-title": ["Urologic Oncology", "Cancer Treatment and Research"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4613-1595-7_12", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 7]], "date-time": "2019-04-07T01:03:53Z", "timestamp": 1554599033000}, "score": 31.646618, "issued": {"date-parts": [[1989]]}, "ISBN": ["9781461288831", "9781461315957"], "references-count": 85, "URL": "http://dx.doi.org/10.1007/978-1-4613-1595-7_12", "relation": {"cites": []}, "ISSN": ["0927-3042"], "issn-type": [{"value": "0927-3042", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T13:56:51Z", "timestamp": 1574171811633}, "reference-count": 97, "publisher": "Springer Science and Business Media LLC", "issue": "9", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2003, 9, 1]], "date-time": "2003-09-01T00:00:00Z", "timestamp": 1062374400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Cancer"], "published-print": {"date-parts": [[2003, 9]]}, "DOI": "10.1038/nrc1167", "type": "journal-article", "created": {"date-parts": [[2003, 9, 1]], "date-time": "2003-09-01T16:40:41Z", "timestamp": 1062434441000}, "page": "666-675", "source": "Crossref", "is-referenced-by-count": 385, "title": ["Adoptive-cell-transfer therapy for the treatment of patients with cancer"], "prefix": "10.1038", "volume": "3", "author": [{"given": "Mark E.", "family": "Dudley", "sequence": "first", "affiliation": []}, {"given": "Steven A.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "BFnrc1167_CR1", "doi-asserted-by": "crossref", "first-page": "463", "DOI": "10.1146/annurev.immunol.20.100301.064819", "volume": "20", "author": "N Shastri", "year": "2002", "unstructured": "Shastri, N., Schwab, S. & Serwold, T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20, 463\u2013493 (2002).", "journal-title": "Annu. Rev. Immunol."}, {"key": "BFnrc1167_CR2", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1007/s002620000169", "volume": "50", "author": "N Renkvist", "year": "2001", "unstructured": "Renkvist, N., Castelli, C., Robbins, P. F. & Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50, 3\u201315 (2001).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnrc1167_CR3", "doi-asserted-by": "crossref", "first-page": "1185", "DOI": "10.1084/jem.183.3.1185", "volume": "183", "author": "PF Robbins", "year": "1996", "unstructured": "Robbins, P. F. et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185\u20131192 (1996).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR4", "doi-asserted-by": "publisher", "first-page": "265", "DOI": "10.1084/jem.187.2.265", "volume": "187", "author": "E Jager", "year": "1998", "unstructured": "Jager, E. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265\u2013270 (1998).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR5", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1084/jem.180.1.347", "volume": "180", "author": "Y Kawakami", "year": "1994", "unstructured": "Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347\u2013352 (1994).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR6", "first-page": "3961", "volume": "154", "author": "Y Kawakami", "year": "1995", "unstructured": "Kawakami, Y. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961\u20133968 (1995).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR7", "doi-asserted-by": "crossref", "first-page": "65", "DOI": "10.1146/annurev.immunol.19.1.65", "volume": "19", "author": "LG Guidotti", "year": "2001", "unstructured": "Guidotti, L. G. & Chisari, F. V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65\u201391 (2001).", "journal-title": "Annu. Rev. Immunol."}, {"key": "BFnrc1167_CR8", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.1146/annurev.immunol.18.1.275", "volume": "18", "author": "JT Harty", "year": "2000", "unstructured": "Harty, J. T., Tvinnereim, A. R. & White, D. W. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18, 275\u2013308 (2000).", "journal-title": "Annu. Rev. Immunol."}, {"key": "BFnrc1167_CR9", "doi-asserted-by": "crossref", "first-page": "321", "DOI": "10.1038/nm0398-321", "volume": "4", "author": "SA Rosenberg", "year": "1998", "unstructured": "Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321\u2013327 (1998).", "journal-title": "Nature Med."}, {"key": "BFnrc1167_CR10", "doi-asserted-by": "crossref", "first-page": "186", "DOI": "10.1002/cncr.11045", "volume": "97", "author": "J Weber", "year": "2003", "unstructured": "Weber, J. et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97, 186\u2013200 (2003).", "journal-title": "Cancer"}, {"key": "BFnrc1167_CR11", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1084/jem.186.2.229", "volume": "186", "author": "M Wick", "year": "1997", "unstructured": "Wick, M. et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229\u2013238 (1997).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR12", "first-page": "2187", "volume": "161", "author": "A Prevost-Blondel", "year": "1998", "unstructured": "Prevost-Blondel, A. et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161, 2187\u20132194 (1998).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR13", "doi-asserted-by": "crossref", "first-page": "1058", "DOI": "10.1038/35082583", "volume": "411", "author": "AF Ochsenbein", "year": "2001", "unstructured": "Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058\u20131064 (2001).", "journal-title": "Nature"}, {"key": "BFnrc1167_CR14", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1126/science.1071059", "volume": "296", "author": "P Matzinger", "year": "2002", "unstructured": "Matzinger, P. The danger model: a renewed sense of self. Science 296, 301\u2013305 (2002).", "journal-title": "Science"}, {"key": "BFnrc1167_CR15", "doi-asserted-by": "crossref", "first-page": "389", "DOI": "10.1038/nri821", "volume": "2", "author": "EM Shevach", "year": "2002", "unstructured": "Shevach, E. M. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Rev. Immunol. 2, 389\u2013400 (2002).", "journal-title": "Nature Rev. Immunol."}, {"key": "BFnrc1167_CR16", "first-page": "5211", "volume": "163", "author": "J Shimizu", "year": "1999", "unstructured": "Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211\u20135218 (1999).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR17", "doi-asserted-by": "crossref", "first-page": "999", "DOI": "10.1038/ni1102-999", "volume": "3", "author": "HT Khong", "year": "2002", "unstructured": "Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol. 3, 999\u20131005 (2002).", "journal-title": "Nature Immunol."}, {"key": "BFnrc1167_CR18", "doi-asserted-by": "crossref", "first-page": "850", "DOI": "10.1126/science.1076514", "volume": "298", "author": "ME Dudley", "year": "2002", "unstructured": "Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850\u2013854 (2002). This report describes adoptive cell transfer with TILs following non-myeloablative chemotherapy for treatment of patients with melanoma, and represents the first successful use of this combination therapy for the treatment of solid malignancy in patients.", "journal-title": "Science"}, {"key": "BFnrc1167_CR19", "first-page": "1549", "volume": "92", "author": "CM Rooney", "year": "1998", "unstructured": "Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein\u2013Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549\u20131555 (1998). This paper describes the generation and clinical use of lymphocyte cultures for ACT therapy of patients with metastatic cancer.", "journal-title": "Blood"}, {"key": "BFnrc1167_CR20", "doi-asserted-by": "crossref", "first-page": "277", "DOI": "10.1084/jem.188.2.277", "volume": "188", "author": "WW Overwijk", "year": "1998", "unstructured": "Overwijk, W. W. et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277\u2013286 (1998). Demonstration in an animal model that immune manipulation can result in efficacious tumour treatments mediated through unmutated melanocyte-differentiation antigens.", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR21", "first-page": "4371", "volume": "50", "author": "K Sakai", "year": "1990", "unstructured": "Sakai, K., Chang, A. E. & Shu, S. Y. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma. Cancer Res. 50, 4371\u20134376 (1990).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR22", "doi-asserted-by": "crossref", "first-page": "562", "DOI": "10.4049/jimmunol.164.2.562", "volume": "164", "author": "DR Surman", "year": "2000", "unstructured": "Surman, D. R., Dudley, M. E., Overwijk, W. W. & Restifo, N. P. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 164, 562\u2013565 (2000).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR23", "first-page": "1043", "volume": "53", "author": "AE Chang", "year": "1993", "unstructured": "Chang, A. E. et al. Clinical observations on adoptive immunotherapy with vaccine-primed T- lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53, 1043\u20131050 (1993).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR24", "doi-asserted-by": "crossref", "first-page": "24", "DOI": "10.1006/cimm.1997.1124", "volume": "178", "author": "L Peng", "year": "1997", "unstructured": "Peng, L., Shu, S. & Krauss, J. C. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol. 178, 24\u201332 (1997).", "journal-title": "Cell Immunol."}, {"key": "BFnrc1167_CR25", "first-page": "989", "volume": "162", "author": "HJ Zeh 3rd", "year": "1999", "unstructured": "Zeh, H. J. 3rd, Perry\u2013Lalley, D., Dudley, M. E., Rosenberg, S. A., & Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989\u2013994 (1999).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR26", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.1007/BF01517220", "volume": "41", "author": "A Aruga", "year": "1995", "unstructured": "Aruga, A., Shu, S. & Chang, A. E. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother. 41, 317\u2013324 (1995).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnrc1167_CR27", "doi-asserted-by": "crossref", "first-page": "647", "DOI": "10.1084/jem.173.3.647", "volume": "173", "author": "RJ Barth Jr", "year": "1991", "unstructured": "Barth, R. J. Jr, Mule, J. J., Spiess, P. J. & Rosenberg, S. A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173, 647\u2013658 (1991).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR28", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.1084/jem.171.1.249", "volume": "171", "author": "RB Cameron", "year": "1990", "unstructured": "Cameron, R. B., Spiess, P. J. & Rosenberg, S. A. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J. Exp. Med. 171, 249\u2013263 (1990).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR29", "doi-asserted-by": "crossref", "first-page": "968", "DOI": "10.1084/jem.155.4.968", "volume": "155", "author": "MA Cheever", "year": "1982", "unstructured": "Cheever, M. A., Greenberg, P. D., Fefer, A. & Gillis, S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J. Exp. Med. 155, 968\u2013980 (1982).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR30", "first-page": "1775", "volume": "141", "author": "T Chou", "year": "1988", "unstructured": "Chou, T., Bertera, S., Chang, A. E. & Shu, S. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol. 141, 1775\u20131781 (1988).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR31", "doi-asserted-by": "crossref", "first-page": "1318", "DOI": "10.1126/science.3489291", "volume": "233", "author": "SA Rosenberg", "year": "1986", "unstructured": "Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986). This seminal paper describes the use of TILs, together with cyclophosphamide conditioning, to treat advanced tumours in mice.", "journal-title": "Science"}, {"key": "BFnrc1167_CR32", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.1006/cimm.1999.1489", "volume": "194", "author": "JA Bristol", "year": "1999", "unstructured": "Bristol, J. A., Schlom, J. & Abrams, S. I. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. Cell Immunol. 194, 78\u201389 (1999).", "journal-title": "Cell Immunol."}, {"key": "BFnrc1167_CR33", "unstructured": "Overwijk, W. W. et al. Tumor regression and autoimmunity following reversal of a functionally tolerant state of self-reactive CD8+ cells. J. Exp. Med. (in the press)."}, {"key": "BFnrc1167_CR34", "first-page": "1649", "volume": "49", "author": "M Awwad", "year": "1989", "unstructured": "Awwad, M. & North, R. J. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 49, 1649\u20131654 (1989).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR35", "first-page": "234", "volume": "115", "author": "JR Berenson", "year": "1975", "unstructured": "Berenson, J. R., Einstein, A. B. Jr & Fefer, A. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J. Immunol. 115, 234\u2013238 (1975).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR36", "first-page": "711", "volume": "125", "author": "MA Cheever", "year": "1980", "unstructured": "Cheever, M. A., Greenberg, P. D. & Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 125, 711\u2013714 (1980).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR37", "doi-asserted-by": "crossref", "first-page": "1063", "DOI": "10.1084/jem.155.4.1063", "volume": "155", "author": "RJ North", "year": "1982", "unstructured": "North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063\u20131074 (1982).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR38", "doi-asserted-by": "crossref", "first-page": "2592", "DOI": "10.1182/blood.V99.7.2592", "volume": "99", "author": "P Comoli", "year": "2002", "unstructured": "Comoli, P. et al. Infusion of autologous Epstein\u2013Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99, 2592\u20132598 (2002).", "journal-title": "Blood"}, {"key": "BFnrc1167_CR39", "doi-asserted-by": "crossref", "first-page": "436", "DOI": "10.1016/S0140-6736(02)09672-1", "volume": "360", "author": "T Haque", "year": "2002", "unstructured": "Haque, T. et al. Treatment of Epstein\u2013Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436\u2013442 (2002).", "journal-title": "Lancet"}, {"key": "BFnrc1167_CR40", "doi-asserted-by": "crossref", "first-page": "195", "DOI": "10.1111/j.1600-065X.1997.tb00983.x", "volume": "157", "author": "RJ O'Reilly", "year": "1997", "unstructured": "O'Reilly, R. J. et al. Biology and adoptive cell therapy of Epstein\u2013Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol. Rev. 157, 195\u2013216 (1997).", "journal-title": "Immunol. Rev."}, {"key": "BFnrc1167_CR41", "first-page": "2594", "volume": "87", "author": "KG Lucas", "year": "1996", "unstructured": "Lucas, K. G., Small, T. N., Heller, G., Dupont, B. & O'Reilly, R. J. The development of cellular immunity to Epstein\u2013Barr virus after allogeneic bone marrow transplantation. Blood 87, 2594\u20132603 (1996).", "journal-title": "Blood"}, {"key": "BFnrc1167_CR42", "doi-asserted-by": "crossref", "first-page": "1823", "DOI": "10.1084/jem.155.6.1823", "volume": "155", "author": "EA Grimm", "year": "1982", "unstructured": "Grimm, E. A., Mazumder, A., Zhang, H. Z. & Rosenberg, S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2- activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823\u20131841 (1982).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR43", "doi-asserted-by": "crossref", "first-page": "1487", "DOI": "10.1126/science.6332379", "volume": "225", "author": "JJ Mule", "year": "1984", "unstructured": "Mule, J. J., Shu, S., Schwarz, S. L. & Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487\u20131489 (1984).", "journal-title": "Science"}, {"key": "BFnrc1167_CR44", "doi-asserted-by": "crossref", "first-page": "1485", "DOI": "10.1056/NEJM198512053132327", "volume": "313", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485\u20131492 (1985).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc1167_CR45", "doi-asserted-by": "crossref", "first-page": "408", "DOI": "10.1097/00002371-200109000-00003", "volume": "24", "author": "LG Lum", "year": "2001", "unstructured": "Lum, L. G., LeFever, A. V., Treisman, J. S., Garlie, N. K. & Hanson J. P. Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J. Immunother. 24, 408\u2013419 (2001).", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR46", "doi-asserted-by": "crossref", "first-page": "2752", "DOI": "10.1200/JCO.1998.16.8.2752", "volume": "16", "author": "BD Curti", "year": "1998", "unstructured": "Curti, B. D. et al. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 16, 2752\u20132760 (1998).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc1167_CR47", "doi-asserted-by": "crossref", "first-page": "22", "DOI": "10.1002/(SICI)1097-0142(19990701)86:1<22::AID-CNCR5>3.0.CO;2-T", "volume": "86", "author": "JA Kim", "year": "1999", "unstructured": "Kim, J. A. et al. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer 86, 22\u201330 (1999).", "journal-title": "Cancer"}, {"key": "BFnrc1167_CR48", "doi-asserted-by": "crossref", "first-page": "622", "DOI": "10.1093/jnci/85.8.622", "volume": "85", "author": "SA Rosenberg", "year": "1993", "unstructured": "Rosenberg, S. A. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85, 622\u2013632 (1993).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnrc1167_CR49", "doi-asserted-by": "crossref", "first-page": "884", "DOI": "10.1200/JCO.2003.08.023", "volume": "21", "author": "AE Chang", "year": "2003", "unstructured": "Chang, A. E. et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884\u2013890 (2003).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc1167_CR50", "doi-asserted-by": "crossref", "first-page": "1225", "DOI": "10.1001/archotol.126.10.1225", "volume": "126", "author": "WC To", "year": "2000", "unstructured": "To, W. C. et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch. Otolaryngol. Head Neck Surg. 126, 1225\u20131231 (2000).", "journal-title": "Arch. Otolaryngol. Head Neck Surg."}, {"key": "BFnrc1167_CR51", "doi-asserted-by": "crossref", "first-page": "617", "DOI": "10.1016/S0090-4295(99)00303-9", "volume": "54", "author": "GE Plautz", "year": "1999", "unstructured": "Plautz, G. E. et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 54, 617\u2013623 (1999).", "journal-title": "Urology"}, {"key": "BFnrc1167_CR52", "doi-asserted-by": "crossref", "first-page": "359", "DOI": "10.1097/00002371-200207000-00008", "volume": "25", "author": "SL Meijer", "year": "2002", "unstructured": "Meijer, S. L. et al. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J. Immunother. 25, 359\u2013372 (2002).", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR53", "doi-asserted-by": "crossref", "first-page": "2161", "DOI": "10.4049/jimmunol.170.4.2161", "volume": "170", "author": "N Meidenbauer", "year": "2003", "unstructured": "Meidenbauer, N. et al. Survival and tumor localization of adoptively transferred melan-a-specific T cells in melanoma patients. J. Immunol. 170, 2161\u20132169 (2003).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR54", "doi-asserted-by": "crossref", "first-page": "143", "DOI": "10.1038/nbt0202-143", "volume": "20", "author": "MV Maus", "year": "2002", "unstructured": "Maus, M. V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nature Biotechnol. 20, 143\u2013148 (2002).", "journal-title": "Nature Biotechnol."}, {"key": "BFnrc1167_CR55", "doi-asserted-by": "crossref", "first-page": "259", "DOI": "10.1006/clim.2002.5277", "volume": "105", "author": "AK Thomas", "year": "2002", "unstructured": "Thomas, A. K., Maus, M. V., Shalaby, W. S., June, C. H. & Riley, J. L. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin. Immunol. 105, 259\u2013272 (2002).", "journal-title": "Clin. Immunol."}, {"key": "BFnrc1167_CR56", "doi-asserted-by": "crossref", "first-page": "619", "DOI": "10.1038/nm869", "volume": "9", "author": "M Oelke", "year": "2003", "unstructured": "Oelke, M. et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nature Med. 9, 619\u2013624 (2003).", "journal-title": "Nature Med."}, {"key": "BFnrc1167_CR57", "doi-asserted-by": "crossref", "first-page": "241", "DOI": "10.1097/00002371-200305000-00008", "volume": "26", "author": "U Sili", "year": "2003", "unstructured": "Sili, U. et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J. Immunother. 26, 241\u2013256 (2003).", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR58", "doi-asserted-by": "crossref", "first-page": "1038", "DOI": "10.1056/NEJM199510193331603", "volume": "333", "author": "EA Walter", "year": "1995", "unstructured": "Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038\u20131044 (1995). This influential paper describes the use of CMV-specific cloned lymphocytes for the treatment of bone-marrow-transplant recipients, and their efficacy in prevention of CMV-induced disease.", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc1167_CR59", "doi-asserted-by": "crossref", "first-page": "363", "DOI": "10.1097/00002371-200107000-00012", "volume": "24", "author": "ME Dudley", "year": "2001", "unstructured": "Dudley, M. E. et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363\u2013373 (2001).", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR60", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1097/00002371-200205000-00007", "volume": "25", "author": "ME Dudley", "year": "2002", "unstructured": "Dudley, M. E. et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243\u2013251 (2002). The failure of non-myeloablative chemotherapy followed by administration of highly avid T-cell clones for treatment of patients with melanoma is documented.", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR61", "doi-asserted-by": "crossref", "first-page": "16168", "DOI": "10.1073/pnas.242600099", "volume": "99", "author": "C Yee", "year": "2002", "unstructured": "Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168\u201316173 (2002). An excellent example of the failure of highly avid T-cell clones to induce objective clinical responses in patients with metastatic solid tumours. T-cell function, transport and persistence were monitored.", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1167_CR62", "first-page": "1506", "volume": "93", "author": "R Tan", "year": "1999", "unstructured": "Tan, R. et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 93, 1506\u20131510 (1999).", "journal-title": "Blood"}, {"key": "BFnrc1167_CR63", "doi-asserted-by": "crossref", "first-page": "34", "DOI": "10.1038/4716", "volume": "5", "author": "SJ Brodie", "year": "1999", "unstructured": "Brodie, S. J. et al. in vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. 5, 34\u201341 (1999).", "journal-title": "Nature Med."}, {"key": "BFnrc1167_CR64", "doi-asserted-by": "crossref", "first-page": "6047", "DOI": "10.4049/jimmunol.165.11.6047", "volume": "165", "author": "AL Marzo", "year": "2000", "unstructured": "Marzo, A. L. et al. Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J. Immunol. 165, 6047\u20136055 (2000).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR65", "first-page": "215", "volume": "61", "author": "CK Donawho", "year": "2001", "unstructured": "Donawho, C. K., Pride, M. W. & Kripke, M. L. Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity. Cancer Res. 61, 215\u2013221 (2001).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR66", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1200/JCO.1988.6.5.839", "volume": "6", "author": "SL Topalian", "year": "1988", "unstructured": "Topalian, S. L. et al. Immunotherapy of patients with advanced cancer using tumor- infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6, 839\u2013853 (1988).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc1167_CR67", "doi-asserted-by": "crossref", "first-page": "577", "DOI": "10.1016/S0140-6736(89)91609-7", "volume": "1", "author": "RL Kradin", "year": "1989", "unstructured": "Kradin, R. L. et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1, 577\u2013580 (1989).", "journal-title": "Lancet"}, {"key": "BFnrc1167_CR68", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1002/1097-0142(19910701)68:1<1::AID-CNCR2820680102>3.0.CO;2-K", "volume": "68", "author": "RO Dillman", "year": "1991", "unstructured": "Dillman, R. O. et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68, 1\u20138 (1991).", "journal-title": "Cancer"}, {"key": "BFnrc1167_CR69", "doi-asserted-by": "crossref", "first-page": "315", "DOI": "10.1007/BF01741170", "volume": "36", "author": "F Arienti", "year": "1993", "unstructured": "Arienti, F. et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol. Immunother. 36, 315\u2013322 (1993).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnrc1167_CR70", "doi-asserted-by": "crossref", "first-page": "740", "DOI": "10.1016/S0022-5347(01)64304-0", "volume": "158", "author": "RA Figlin", "year": "1997", "unstructured": "Figlin, R. A. et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 158, 740\u2013745 (1997).", "journal-title": "J. Urol."}, {"key": "BFnrc1167_CR71", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1023/A:1006293606710", "volume": "45", "author": "KB Quattrocchi", "year": "1999", "unstructured": "Quattrocchi, K. B. et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45, 141\u2013157 (1999).", "journal-title": "J. Neurooncol."}, {"key": "BFnrc1167_CR72", "first-page": "1743", "volume": "62", "author": "D Valmori", "year": "2002", "unstructured": "Valmori, D. et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(\u2212) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62, 1743\u20131750 (2002).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR73", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1097/00002371-199402000-00002", "volume": "15", "author": "JH Finke", "year": "1994", "unstructured": "Finke, J. H. et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J. Immunother. Emphasis. Tumor Immunol. 15, 91\u2013104 (1994).", "journal-title": "J. Immunother. Emphasis. Tumor Immunol."}, {"key": "BFnrc1167_CR74", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1007/BF01789124", "volume": "36", "author": "SS Hom", "year": "1993", "unstructured": "Hom, S. S., Rosenberg, S. A. & Topalian, S. L. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol. Immunother. 36, 1\u20138 (1993).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnrc1167_CR75", "doi-asserted-by": "crossref", "first-page": "631", "DOI": "10.1002/(SICI)1097-0215(19970317)70:6<631::AID-IJC1>3.0.CO;2-W", "volume": "70", "author": "T Hoshino", "year": "1997", "unstructured": "Hoshino, T. et al. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int. J. Cancer 70, 631\u2013638 (1997).", "journal-title": "Int. J. Cancer"}, {"key": "BFnrc1167_CR76", "doi-asserted-by": "crossref", "first-page": "2489", "DOI": "10.1002/1097-0142(19881215)62:12<2489::AID-CNCR2820621207>3.0.CO;2-J", "volume": "62", "author": "H Nakamura", "year": "1988", "unstructured": "Nakamura, H., Ishiguro, K., & Mori, T. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer 62, 2489\u20132497 (1988).", "journal-title": "Cancer"}, {"key": "BFnrc1167_CR77", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1097/00002371-199207000-00001", "volume": "12", "author": "DJ Schwartzentruber", "year": "1992", "unstructured": "Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A. & Topalian, S. L. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12, 1\u201312 (1992).", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR78", "first-page": "3011", "volume": "46", "author": "K Itoh", "year": "1986", "unstructured": "Itoh, K., Tilden, A. B., & Balch, C. M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res. 46, 3011\u20133017 (1986).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR79", "first-page": "3714", "volume": "142", "author": "SL Topalian", "year": "1989", "unstructured": "Topalian, S. L., Solomon, D., & Rosenberg, S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714\u20133725 (1989).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR80", "doi-asserted-by": "crossref", "first-page": "413", "DOI": "10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#", "volume": "65", "author": "JR Yannelli", "year": "1996", "unstructured": "Yannelli, J. R. et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65, 413\u2013421 (1996).", "journal-title": "Int. J. Cancer"}, {"key": "BFnrc1167_CR81", "doi-asserted-by": "crossref", "first-page": "332", "DOI": "10.1097/00002371-200307000-00005", "volume": "26", "author": "ME Dudley", "year": "2003", "unstructured": "Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332\u2013342 (2003).", "journal-title": "J. Immunother."}, {"key": "BFnrc1167_CR82", "doi-asserted-by": "crossref", "first-page": "1159", "DOI": "10.1093/jnci/86.15.1159", "volume": "86", "author": "SA Rosenberg", "year": "1994", "unstructured": "Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159\u20131166 (1994). A comprehensive summary of the clinical experience with TIL for the treatment of patients with melanoma in the absence of non-myeloablative conditioning.", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnrc1167_CR83", "doi-asserted-by": "crossref", "first-page": "570", "DOI": "10.1056/NEJM199008303230904", "volume": "323", "author": "SA Rosenberg", "year": "1990", "unstructured": "Rosenberg, S. A. et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570\u2013578 (1990).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc1167_CR84", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1172/JCI0216166", "volume": "110", "author": "GN Maine", "year": "2002", "unstructured": "Maine, G. N. & Mule, J. J. Making room for T cells. J. Clin. Invest. 110, 157\u2013159 (2002).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrc1167_CR85", "doi-asserted-by": "crossref", "first-page": "564", "DOI": "10.1016/S1471-4906(01)02028-2", "volume": "22", "author": "TJ Fry", "year": "2001", "unstructured": "Fry, T. J. & Mackall, C. L. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends. Immunol. 22, 564\u2013571 (2001).", "journal-title": "Trends. Immunol."}, {"key": "BFnrc1167_CR86", "doi-asserted-by": "crossref", "first-page": "3477", "DOI": "10.1200/JCO.2001.19.15.3477", "volume": "19", "author": "GQ Phan", "year": "2001", "unstructured": "Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E. & Rosenberg, S. A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19, 3477\u20133482 (2001).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc1167_CR87", "doi-asserted-by": "crossref", "first-page": "1637", "DOI": "10.1084/jem.192.11.1637", "volume": "192", "author": "C Yee", "year": "2000", "unstructured": "Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637\u20131644 (2000).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR88", "doi-asserted-by": "crossref", "first-page": "355", "DOI": "10.1084/jem.190.3.355", "volume": "190", "author": "A van Elsas", "year": "1999", "unstructured": "van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355\u2013366 (1999).", "journal-title": "J. Exp. Med."}, {"key": "BFnrc1167_CR89", "doi-asserted-by": "crossref", "first-page": "2982", "DOI": "10.1073/pnas.96.6.2982", "volume": "96", "author": "WW Overwijk", "year": "1999", "unstructured": "Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982\u20132987 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1167_CR90", "doi-asserted-by": "crossref", "first-page": "8372", "DOI": "10.1073/pnas.1533209100", "volume": "100", "author": "GQ Phan", "year": "2003", "unstructured": "Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372\u20138377 (2003).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1167_CR91", "first-page": "507", "volume": "163", "author": "TM Clay", "year": "1999", "unstructured": "Clay, T. M. et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163, 507\u2013513 (1999).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR92", "first-page": "3369", "volume": "55", "author": "P Hwu", "year": "1995", "unstructured": "Hwu, P. et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55, 3369\u20133373 (1995).", "journal-title": "Cancer Res."}, {"key": "BFnrc1167_CR93", "doi-asserted-by": "crossref", "first-page": "225", "DOI": "10.1038/ni889", "volume": "4", "author": "EJ Wherry", "year": "2003", "unstructured": "Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 4, 225\u2013234 (2003).", "journal-title": "Nature Immunol."}, {"key": "BFnrc1167_CR94", "doi-asserted-by": "crossref", "first-page": "4260", "DOI": "10.1182/blood-2002-11-3577", "volume": "101", "author": "J Geginat", "year": "2003", "unstructured": "Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260\u20134266 (2003).", "journal-title": "Blood"}, {"key": "BFnrc1167_CR95", "doi-asserted-by": "crossref", "first-page": "6356", "DOI": "10.4049/jimmunol.167.11.6356", "volume": "167", "author": "K Liu", "year": "2001", "unstructured": "Liu, K. & Rosenberg, S. A. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356\u20136365 (2001).", "journal-title": "J. Immunol."}, {"key": "BFnrc1167_CR96", "doi-asserted-by": "crossref", "first-page": "339", "DOI": "10.1126/science.1083317", "volume": "300", "author": "JC Sun", "year": "2003", "unstructured": "Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339\u2013342 (2003).", "journal-title": "Science"}, {"key": "BFnrc1167_CR97", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1126/science.1082305", "volume": "300", "author": "DJ Shedlock", "year": "2003", "unstructured": "Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337\u2013339 (2003).", "journal-title": "Science"}], "container-title": ["Nature Reviews Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrc1167.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrc1167", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrc1167.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T22:44:29Z", "timestamp": 1552862669000}, "score": 31.443983, "issued": {"date-parts": [[2003, 9]]}, "references-count": 97, "journal-issue": {"published-print": {"date-parts": [[2003, 9]]}, "issue": "9"}, "alternative-id": ["BFnrc1167"], "URL": "http://dx.doi.org/10.1038/nrc1167", "relation": {"cites": []}, "ISSN": ["1474-175X", "1474-1768"], "issn-type": [{"value": "1474-175X", "type": "print"}, {"value": "1474-1768", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T01:24:06Z", "timestamp": 1574558646370}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "S3", "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["j. immunotherapy cancer"], "published-print": {"date-parts": [[2014, 12]]}, "DOI": "10.1186/2051-1426-2-s3-p28", "type": "journal-article", "created": {"date-parts": [[2014, 11, 6]], "date-time": "2014-11-06T14:14:30Z", "timestamp": 1415283270000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Specific increase in T cell potency via structure-based design of a T cell receptor for adoptive immunotherapy"], "prefix": "10.1186", "volume": "2", "author": [{"given": "Karolina", "family": "Malecek", "sequence": "first", "affiliation": []}, {"given": "Arsen", "family": "Grigoryan", "sequence": "additional", "affiliation": []}, {"given": "Shi", "family": "Zhong", "sequence": "additional", "affiliation": []}, {"given": "Wei Jun", "family": "Gu", "sequence": "additional", "affiliation": []}, {"given": "Laura A", "family": "Johnson", "sequence": "additional", "affiliation": []}, {"given": "Steven A", "family": "Rosenberg", "sequence": "additional", "affiliation": []}, {"given": "Timothy", "family": "Cardozo", "sequence": "additional", "affiliation": []}, {"given": "Michelle", "family": "Krogsgaard", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 11, 6]]}, "container-title": ["Journal for ImmunoTherapy of Cancer"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/2051-1426-2-S3-P28.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T07:13:51Z", "timestamp": 1548141231000}, "score": 30.401543, "issued": {"date-parts": [[2014, 11, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2014, 12]]}, "issue": "S3"}, "alternative-id": ["481"], "URL": "http://dx.doi.org/10.1186/2051-1426-2-s3-p28", "ISSN": ["2051-1426"], "issn-type": [{"value": "2051-1426", "type": "electronic"}], "assertion": [{"value": "6 November 2014", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}], "article-number": "P28"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T22:43:58Z", "timestamp": 1574462638962}, "reference-count": 166, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 3, 22]], "date-time": "2012-03-22T00:00:00Z", "timestamp": 1332374400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Immunol"], "published-print": {"date-parts": [[2012, 4]]}, "DOI": "10.1038/nri3191", "type": "journal-article", "created": {"date-parts": [[2012, 3, 23]], "date-time": "2012-03-23T09:22:24Z", "timestamp": 1332494544000}, "page": "269-281", "source": "Crossref", "is-referenced-by-count": 797, "title": ["Adoptive immunotherapy for cancer: harnessing the T cell response"], "prefix": "10.1038", "volume": "12", "author": [{"given": "Nicholas P.", "family": "Restifo", "sequence": "first", "affiliation": []}, {"given": "Mark E.", "family": "Dudley", "sequence": "additional", "affiliation": []}, {"given": "Steven A.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 3, 22]]}, "reference": [{"key": "BFnri3191_CR1", "doi-asserted-by": "publisher", "first-page": "632", "DOI": "10.1016/j.immuni.2010.09.016", "volume": "33", "author": "J Deguine", "year": "2010", "unstructured": "Deguine, J., Breart, B., Lemaitre, F., Di Santo, J. P. & Bousso, P. Intravital imaging reveals distinct dynamics for natural killer and CD8+ T cells during tumor regression. Immunity 33, 632\u2013644 (2010).", "journal-title": "Immunity"}, {"key": "BFnri3191_CR2", "doi-asserted-by": "publisher", "first-page": "4099", "DOI": "10.1182/blood-2010-04-281931", "volume": "116", "author": "JN Kochenderfer", "year": "2010", "unstructured": "Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).", "journal-title": "Blood"}, {"key": "BFnri3191_CR3", "doi-asserted-by": "publisher", "first-page": "4817", "DOI": "10.1182/blood-2011-04-348540", "volume": "118", "author": "RJ Brentjens", "year": "2011", "unstructured": "Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).", "journal-title": "Blood"}, {"key": "BFnri3191_CR4", "doi-asserted-by": "publisher", "first-page": "4550", "DOI": "10.1158/1078-0432.CCR-11-0116", "volume": "17", "author": "SA Rosenberg", "year": "2011", "unstructured": "Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnri3191_CR5", "doi-asserted-by": "publisher", "first-page": "725", "DOI": "10.1056/NEJMoa1103849", "volume": "365", "author": "DL Porter", "year": "2011", "unstructured": "Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnri3191_CR6", "doi-asserted-by": "publisher", "first-page": "917", "DOI": "10.1200/JCO.2010.32.2537", "volume": "29", "author": "PF Robbins", "year": "2011", "unstructured": "Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011). This study provides evidence that gene-engineered T cells can treat other solid tumour histologies (in this case, metastatic synovial cell sarcoma), in addition to melanoma.", "journal-title": "J. Clin. Oncol."}, {"issue": "12", "key": "BFnri3191_CR7", "doi-asserted-by": "publisher", "first-page": "2709", "DOI": "10.1182/blood-2011-10-384388", "volume": "119", "author": "J. N. Kochenderfer", "year": "2011", "unstructured": "Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 8 Dec 2011 (doi:10.1182/blood-2011-10-384388). References 2, 3, 5 and 7 demonstrate the therapeutic power of genetically engineered T cells in the treatment of CD19+ lymphoma.", "journal-title": "Blood"}, {"key": "BFnri3191_CR8", "doi-asserted-by": "publisher", "first-page": "2350", "DOI": "10.1172/JCI46102", "volume": "121", "author": "L Baitsch", "year": "2011", "unstructured": "Baitsch, L. et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350\u20132360 (2011).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR9", "doi-asserted-by": "publisher", "first-page": "1537", "DOI": "10.1182/blood-2008-12-195792", "volume": "114", "author": "M Ahmadzadeh", "year": "2009", "unstructured": "Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537\u20131544 (2009).", "journal-title": "Blood"}, {"key": "BFnri3191_CR10", "doi-asserted-by": "publisher", "first-page": "190", "DOI": "10.1016/j.coi.2009.02.006", "volume": "21", "author": "R Offringa", "year": "2009", "unstructured": "Offringa, R. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21, 190\u2013199 (2009).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnri3191_CR11", "doi-asserted-by": "publisher", "first-page": "265", "DOI": "10.1084/jem.177.2.265", "volume": "177", "author": "NP Restifo", "year": "1993", "unstructured": "Restifo, N. P. et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265\u2013272 (1993).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR12", "doi-asserted-by": "publisher", "first-page": "100", "DOI": "10.1093/jnci/88.2.100", "volume": "88", "author": "NP Restifo", "year": "1996", "unstructured": "Restifo, N. P. et al. Loss of functional \u03b22-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100\u2013108 (1996).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnri3191_CR13", "doi-asserted-by": "publisher", "first-page": "1565", "DOI": "10.1126/science.1203486", "volume": "331", "author": "RD Schreiber", "year": "2011", "unstructured": "Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).", "journal-title": "Science"}, {"key": "BFnri3191_CR14", "doi-asserted-by": "publisher", "first-page": "400", "DOI": "10.1038/nature10755", "volume": "482", "author": "H Matsushita", "year": "2012", "unstructured": "Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).", "journal-title": "Nature"}, {"key": "BFnri3191_CR15", "doi-asserted-by": "publisher", "first-page": "1643", "DOI": "10.1126/science.1840703", "volume": "254", "author": "P van der Bruggen", "year": "1991", "unstructured": "van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643\u20131647 (1991).", "journal-title": "Science"}, {"key": "BFnri3191_CR16", "doi-asserted-by": "publisher", "first-page": "620", "DOI": "10.1038/mt.2010.272", "volume": "19", "author": "MR Parkhurst", "year": "2011", "unstructured": "Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).", "journal-title": "Mol. Ther."}, {"key": "BFnri3191_CR17", "doi-asserted-by": "publisher", "first-page": "8446", "DOI": "10.1158/0008-5472.CAN-08-1864", "volume": "68", "author": "R Bos", "year": "2008", "unstructured": "Bos, R. et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 68, 8446\u20138455 (2008).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR18", "doi-asserted-by": "publisher", "first-page": "433", "DOI": "10.1615/CritRevImmunol.v20.i6.10", "volume": "20", "author": "WW Overwijk", "year": "2000", "unstructured": "Overwijk, W. W. & Restifo, N. P. Autoimmunity and the immunotherapy of cancer: targeting the \u201cself\u201d to destroy the \u201cother\u201d. Crit. Rev. Immunol. 20, 433\u2013450 (2000).", "journal-title": "Crit. Rev. Immunol."}, {"key": "BFnri3191_CR19", "doi-asserted-by": "publisher", "first-page": "277", "DOI": "10.1084/jem.188.2.277", "volume": "188", "author": "WW Overwijk", "year": "1998", "unstructured": "Overwijk, W. W. et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of \u201cself\u201d-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277\u2013286 (1998).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR20", "doi-asserted-by": "publisher", "first-page": "3515", "DOI": "10.1073/pnas.91.9.3515", "volume": "91", "author": "Y Kawakami", "year": "1994", "unstructured": "Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91, 3515\u20133519 (1994).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR21", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1182/blood-2009-03-211714", "volume": "114", "author": "LA Johnson", "year": "2009", "unstructured": "Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).", "journal-title": "Blood"}, {"key": "BFnri3191_CR22", "doi-asserted-by": "publisher", "first-page": "8061", "DOI": "10.1073/pnas.0710929105", "volume": "105", "author": "DC Palmer", "year": "2008", "unstructured": "Palmer, D. C. et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl Acad. Sci. USA 105, 8061\u20138066 (2008).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR23", "doi-asserted-by": "publisher", "first-page": "981", "DOI": "10.1016/j.ophtha.2008.12.004", "volume": "116", "author": "S Yeh", "year": "2009", "unstructured": "Yeh, S. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116, 981\u2013989 (2009).", "journal-title": "Ophthalmology"}, {"key": "BFnri3191_CR24", "doi-asserted-by": "publisher", "first-page": "5545", "DOI": "10.1038/onc.2010.323", "volume": "29", "author": "MA Davies", "year": "2010", "unstructured": "Davies, M. A. & Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 29, 5545\u20135555 (2010).", "journal-title": "Oncogene"}, {"key": "BFnri3191_CR25", "doi-asserted-by": "publisher", "first-page": "155", "DOI": "10.1111/j.1755-148X.2012.00976.x", "volume": "25", "author": "V Walia", "year": "2012", "unstructured": "Walia, V., Mu, E. W., Lin, J. C. & Samuels, Y. Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res. 25, 155\u2013170 (2012).", "journal-title": "Pigment Cell Melanoma Res."}, {"key": "BFnri3191_CR26", "doi-asserted-by": "publisher", "first-page": "e14", "DOI": "10.1038/skinbio.2011.6", "volume": "131", "author": "BA Gilchrest", "year": "2011", "unstructured": "Gilchrest, B. A. Molecular aspects of tanning. J. Invest. Dermatol. 131, e14\u2013e17 (2011).", "journal-title": "J. Invest. Dermatol."}, {"key": "BFnri3191_CR27", "doi-asserted-by": "publisher", "first-page": "1185", "DOI": "10.1084/jem.183.3.1185", "volume": "183", "author": "PF Robbins", "year": "1996", "unstructured": "Robbins, P. F. et al. A mutated \u03b2-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185\u20131192 (1996).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR28", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1016/j.coi.2010.01.020", "volume": "22", "author": "MK Brenner", "year": "2010", "unstructured": "Brenner, M. K. & Heslop, H. E. Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 22, 251\u2013257 (2010).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnri3191_CR29", "doi-asserted-by": "publisher", "first-page": "1838", "DOI": "10.1056/NEJMoa0810097", "volume": "361", "author": "GG Kenter", "year": "2009", "unstructured": "Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838\u20131847 (2009).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnri3191_CR30", "doi-asserted-by": "publisher", "first-page": "755", "DOI": "10.1016/j.ccr.2011.10.019", "volume": "20", "author": "K Anders", "year": "2011", "unstructured": "Anders, K. et al. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 20, 755\u2013767 (2011).", "journal-title": "Cancer Cell"}, {"key": "BFnri3191_CR31", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1038/nature10733", "volume": "481", "author": "J Zhang", "year": "2012", "unstructured": "Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329\u2013334 (2012).", "journal-title": "Nature"}, {"key": "BFnri3191_CR32", "doi-asserted-by": "publisher", "first-page": "20422", "DOI": "10.1073/pnas.0810777105", "volume": "105", "author": "O Hofmann", "year": "2008", "unstructured": "Hofmann, O. et al. Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA 105, 20422\u201320427 (2008).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR33", "doi-asserted-by": "publisher", "first-page": "D816", "DOI": "10.1093/nar/gkn673", "volume": "37", "author": "LG Almeida", "year": "2009", "unstructured": "Almeida, L. G. et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 37, D816\u2013D819 (2009).", "journal-title": "Nucleic Acids Res."}, {"key": "BFnri3191_CR34", "doi-asserted-by": "publisher", "first-page": "726", "DOI": "10.1038/nrc3130", "volume": "11", "author": "SB Baylin", "year": "2011", "unstructured": "Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome \u2014 biological and translational implications. Nature Rev. Cancer 11, 726\u2013734 (2011).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnri3191_CR35", "doi-asserted-by": "publisher", "first-page": "1105", "DOI": "10.1158/0008-5472.CAN-05-3020", "volume": "66", "author": "ZS Guo", "year": "2006", "unstructured": "Guo, Z. S. et al. De novo induction of a cancer/testis antigen by 5-aza-2\u2032-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 66, 1105\u20131113 (2006).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR36", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1007/s00262-008-0562-x", "volume": "58", "author": "JA Wargo", "year": "2009", "unstructured": "Wargo, J. A. et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58, 383\u2013394 (2009).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnri3191_CR37", "doi-asserted-by": "publisher", "first-page": "615", "DOI": "10.1038/nrc1669", "volume": "5", "author": "AJ Simpson", "year": "2005", "unstructured": "Simpson, A. J., Caballero, O. L., Jungbluth, A., Chen, Y. T. & Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nature Rev. Cancer 5, 615\u2013625 (2005).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnri3191_CR38", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.4049/jimmunol.1001775", "volume": "186", "author": "N Chinnasamy", "year": "2011", "unstructured": "Chinnasamy, N. et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186, 685\u2013696 (2011).", "journal-title": "J. Immunol."}, {"issue": "8", "key": "BFnri3191_CR39", "doi-asserted-by": "publisher", "first-page": "2796", "DOI": "10.1073/pnas.1104303108", "volume": "109", "author": "B. Ruffell", "year": "2011", "unstructured": "Ruffell, B. et al. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. USA 8 Aug 2011 (doi:10.1073/pnas.1104303108).", "journal-title": "Proceedings of the National Academy of Sciences"}, {"key": "BFnri3191_CR40", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1016/j.semcancer.2011.12.008", "volume": "22", "author": "B Engels", "year": "2012", "unstructured": "Engels, B., Rowley, D. A. & Schreiber, H. Targeting stroma to treat cancers. Semin. Cancer Biol. 22, 41\u201349 (2012).", "journal-title": "Semin. Cancer Biol."}, {"key": "BFnri3191_CR41", "doi-asserted-by": "publisher", "first-page": "827", "DOI": "10.1126/science.1195300", "volume": "330", "author": "M Kraman", "year": "2010", "unstructured": "Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-\u03b1. Science 330, 827\u2013830 (2010).", "journal-title": "Science"}, {"key": "BFnri3191_CR42", "doi-asserted-by": "publisher", "first-page": "3953", "DOI": "10.1172/JCI43490", "volume": "120", "author": "D Chinnasamy", "year": "2010", "unstructured": "Chinnasamy, D. et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953\u20133968 (2010).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR43", "doi-asserted-by": "publisher", "first-page": "6171", "DOI": "10.1158/0008-5472.CAN-10-0153", "volume": "70", "author": "RK Shrimali", "year": "2010", "unstructured": "Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171\u20136180 (2010).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR44", "doi-asserted-by": "publisher", "first-page": "505", "DOI": "10.1038/nrc2868", "volume": "10", "author": "AS Chung", "year": "2010", "unstructured": "Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nature Rev. Cancer 10, 505\u2013514 (2010).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnri3191_CR45", "first-page": "2177", "volume": "29", "author": "A Fefer", "year": "1969", "unstructured": "Fefer, A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 29, 2177\u20132183 (1969).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR46", "doi-asserted-by": "publisher", "first-page": "952", "DOI": "10.1084/jem.154.3.952", "volume": "154", "author": "PD Greenberg", "year": "1981", "unstructured": "Greenberg, P. D., Cheever, M. A. & Fefer, A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2\u2212 lymphocytes. J. Exp. Med. 154, 952\u2013963 (1981). An important and remarkable landmark paper that describes in significant detail the scientific foundations of lymphodepletion prior to adoptive immunotherapy using what are now known as CD4+ T cells.", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR47", "doi-asserted-by": "publisher", "first-page": "323", "DOI": "10.1016/S0065-230X(08)60637-5", "volume": "25", "author": "SA Rosenberg", "year": "1977", "unstructured": "Rosenberg, S. A. & Terry, W. D. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25, 323\u2013388 (1977).", "journal-title": "Adv. Cancer Res."}, {"key": "BFnri3191_CR48", "first-page": "4685", "volume": "154", "author": "M Wang", "year": "1995", "unstructured": "Wang, M. et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154, 4685\u20134692 (1995).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR49", "doi-asserted-by": "publisher", "first-page": "7209", "DOI": "10.4049/jimmunol.173.12.7209", "volume": "173", "author": "DC Palmer", "year": "2004", "unstructured": "Palmer, D. C. et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173, 7209\u20137216 (2004).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR50", "first-page": "224", "volume": "156", "author": "PW Chen", "year": "1996", "unstructured": "Chen, P. W. et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156, 224\u2013231 (1996).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR51", "first-page": "5282", "volume": "154", "author": "V Bronte", "year": "1995", "unstructured": "Bronte, V. et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154, 5282\u20135292 (1995).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR52", "first-page": "37", "volume": "3", "author": "JN Cormier", "year": "1997", "unstructured": "Cormier, J. N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37\u201344 (1997).", "journal-title": "Cancer J. Sci. Am."}, {"key": "BFnri3191_CR53", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1038/nm813", "volume": "9", "author": "WW Leitner", "year": "2003", "unstructured": "Leitner, W. W. et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature Med. 9, 33\u201339 (2003).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR54", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1038/10548", "volume": "5", "author": "H Ying", "year": "1999", "unstructured": "Ying, H. et al. Cancer therapy using a self-replicating RNA vaccine. Nature Med. 5, 823\u2013827 (1999).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR55", "doi-asserted-by": "publisher", "first-page": "2982", "DOI": "10.1073/pnas.96.6.2982", "volume": "96", "author": "WW Overwijk", "year": "1999", "unstructured": "Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a \u201cself\u201d antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982\u20132987 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR56", "doi-asserted-by": "publisher", "first-page": "6169", "DOI": "10.4049/jimmunol.175.9.6169", "volume": "175", "author": "SA Rosenberg", "year": "2005", "unstructured": "Rosenberg, S. A. et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169\u20136176 (2005).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR57", "doi-asserted-by": "publisher", "first-page": "1595", "DOI": "10.1093/jnci/89.21.1595", "volume": "89", "author": "KR Irvine", "year": "1997", "unstructured": "Irvine, K. R. et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl Cancer Inst. 89, 1595\u20131601 (1997).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnri3191_CR58", "first-page": "3357", "volume": "156", "author": "JB Rao", "year": "1996", "unstructured": "Rao, J. B. et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7\u20131 expression. J. Immunol. 156, 3357\u20133365 (1996).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR59", "first-page": "2536", "volume": "59", "author": "KR Irvine", "year": "1999", "unstructured": "Irvine, K. R. et al. Recombinant virus vaccination against \u201cself\u201d antigens using anchor-fixed immunogens. Cancer Res. 59, 2536\u20132540 (1999).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR60", "first-page": "238", "volume": "156", "author": "KR Irvine", "year": "1996", "unstructured": "Irvine, K. R., Rao, J. B., Rosenberg, S. A. & Restifo, N. P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156, 238\u2013245 (1996).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR61", "doi-asserted-by": "publisher", "first-page": "1881", "DOI": "10.1093/jnci/90.24.1881", "volume": "90", "author": "MW Carroll", "year": "1998", "unstructured": "Carroll, M. W. et al. Construction and characterization of a triple-recombinant vaccinia virus encoding B7\u20131, interleukin 12, and a model tumor antigen. J. Natl Cancer Inst. 90, 1881\u20131887 (1998).", "journal-title": "J. Natl Cancer Inst."}, {"key": "BFnri3191_CR62", "doi-asserted-by": "publisher", "first-page": "2", "DOI": "10.1089/cbr.2012.1200", "volume": "27", "author": "J Schlom", "year": "2012", "unstructured": "Schlom, J. Recent advances in therapeutic cancer vaccines. Cancer Biother. Radiopharm. 27, 2\u20135 (2012).", "journal-title": "Cancer Biother. Radiopharm."}, {"key": "BFnri3191_CR63", "doi-asserted-by": "publisher", "first-page": "909", "DOI": "10.1038/nm1100", "volume": "10", "author": "SA Rosenberg", "year": "2004", "unstructured": "Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909\u2013915 (2004).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR64", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1111/j.1600-065X.2010.00979.x", "volume": "239", "author": "CA Klebanoff", "year": "2011", "unstructured": "Klebanoff, C. A., Acquavella, N., Yu, Z. & Restifo, N. P. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239, 27\u201344 (2011). An update on recent vaccine trials showing that although current therapeutic cancer vaccines can extend survival in some studies (by months, not years), they are rarely if ever curative.", "journal-title": "Immunol. Rev."}, {"key": "BFnri3191_CR65", "doi-asserted-by": "publisher", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "volume": "363", "author": "PW Kantoff", "year": "2010", "unstructured": "Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010). Although criticized by some for the trial design, this study nevertheless served as a key basis for the FDA licensing of sipuleucel-T (Provenge; Dendreon).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnri3191_CR66", "doi-asserted-by": "publisher", "first-page": "212", "DOI": "10.1097/CJI.0b013e318209c94c", "volume": "34", "author": "O Itzhaki", "year": "2011", "unstructured": "Itzhaki, O. et al. Establishment and large-scale expansion of minimally cultured \u201cyoung\u201d tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 34, 212\u2013220 (2011).", "journal-title": "J. Immunother."}, {"key": "BFnri3191_CR67", "doi-asserted-by": "publisher", "first-page": "2646", "DOI": "10.1158/1078-0432.CCR-10-0041", "volume": "16", "author": "MJ Besser", "year": "2010", "unstructured": "Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646\u20132655 (2010).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnri3191_CR68", "doi-asserted-by": "publisher", "first-page": "5343", "DOI": "10.1158/1078-0432.CCR-11-0503", "volume": "17", "author": "CA Klebanoff", "year": "2011", "unstructured": "Klebanoff, C. A. et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343\u20135352 (2011).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnri3191_CR69", "doi-asserted-by": "publisher", "first-page": "999", "DOI": "10.1038/ni1102-999", "volume": "3", "author": "HT Khong", "year": "2002", "unstructured": "Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nature Immunol. 3, 999\u20131005 (2002).", "journal-title": "Nature Immunol."}, {"key": "BFnri3191_CR70", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1038/nrclinonc.2011.122", "volume": "8", "author": "S Ogino", "year": "2011", "unstructured": "Ogino, S., Galon, J., Fuchs, C. S. & Dranoff, G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nature Rev. Clin. Oncol. 8, 711\u2013719 (2011).", "journal-title": "Nature Rev. Clin. Oncol."}, {"key": "BFnri3191_CR71", "doi-asserted-by": "publisher", "first-page": "1553", "DOI": "10.1126/science.1204040", "volume": "331", "author": "MR Stratton", "year": "2011", "unstructured": "Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553\u20131558 (2011).", "journal-title": "Science"}, {"key": "BFnri3191_CR72", "doi-asserted-by": "publisher", "first-page": "6050", "DOI": "10.1182/blood-2011-05-354449", "volume": "118", "author": "CU Louis", "year": "2011", "unstructured": "Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).", "journal-title": "Blood"}, {"key": "BFnri3191_CR73", "doi-asserted-by": "publisher", "first-page": "3875", "DOI": "10.1182/blood-2010-01-265041", "volume": "116", "author": "JN Kochenderfer", "year": "2010", "unstructured": "Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875\u20133886 (2010).", "journal-title": "Blood"}, {"key": "BFnri3191_CR74", "doi-asserted-by": "publisher", "first-page": "343", "DOI": "10.1097/CJI.0b013e3182187600", "volume": "34", "author": "SP Kerkar", "year": "2011", "unstructured": "Kerkar, S. P. et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. 34, 343\u2013352 (2011).", "journal-title": "J. Immunother."}, {"key": "BFnri3191_CR75", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1097/CJI.0b013e31815c193f", "volume": "31", "author": "JD Abad", "year": "2008", "unstructured": "Abad, J. D. et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31, 1\u20136 (2008).", "journal-title": "J. Immunother."}, {"key": "BFnri3191_CR76", "doi-asserted-by": "publisher", "first-page": "126", "DOI": "10.1126/science.1129003", "volume": "314", "author": "RA Morgan", "year": "2006", "unstructured": "Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).", "journal-title": "Science"}, {"key": "BFnri3191_CR77", "doi-asserted-by": "publisher", "first-page": "1264", "DOI": "10.1038/nm.1882", "volume": "14", "author": "MA Pule", "year": "2008", "unstructured": "Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Med. 14, 1264\u20131270 (2008).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR78", "unstructured": "Recombinant DNA Advisory Committee. Human gene transfer protocols. National Institutes of Health \n                    [online]\n                    \n                  , (2011)."}, {"key": "BFnri3191_CR79", "doi-asserted-by": "publisher", "first-page": "1390", "DOI": "10.1038/nm.1779", "volume": "14", "author": "A Varela-Rohena", "year": "2008", "unstructured": "Varela-Rohena, A. et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Med. 14, 1390\u20131395 (2008).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR80", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1016/j.coi.2009.02.009", "volume": "21", "author": "M Sadelain", "year": "2009", "unstructured": "Sadelain, M., Brentjens, R. & Riviere, I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215\u2013223 (2009).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnri3191_CR81", "doi-asserted-by": "publisher", "first-page": "843", "DOI": "10.1038/mt.2010.24", "volume": "18", "author": "RA Morgan", "year": "2010", "unstructured": "Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).", "journal-title": "Mol. Ther."}, {"key": "BFnri3191_CR82", "unstructured": "Baeuerle, P. A. & Itin, C. Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. Curr. Pharm. Biotechnol. 14 Feb 2012 [epub ahead of print]."}, {"key": "BFnri3191_CR83", "doi-asserted-by": "publisher", "first-page": "843", "DOI": "10.1517/14712598.2011.572874", "volume": "11", "author": "BD Choi", "year": "2011", "unstructured": "Choi, B. D. et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin. Biol. Ther. 11, 843\u2013853 (2011).", "journal-title": "Expert Opin. Biol. Ther."}, {"key": "BFnri3191_CR84", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1016/j.semcancer.2011.12.006", "volume": "22", "author": "E Merhavi-Shoham", "year": "2011", "unstructured": "Merhavi-Shoham, E., Haga-Friedman, A. & Cohen, C. J. Genetically modulating T-cell function to target cancer. Semin. Cancer Biol. 22, 14\u201322 (2011).", "journal-title": "Semin. Cancer Biol."}, {"key": "BFnri3191_CR85", "doi-asserted-by": "publisher", "first-page": "1290", "DOI": "10.1038/nm.2446", "volume": "17", "author": "L Gattinoni", "year": "2011", "unstructured": "Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nature Med. 17, 1290\u20131297 (2011).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR86", "doi-asserted-by": "publisher", "first-page": "1440", "DOI": "10.1038/nm1676", "volume": "13", "author": "MT Stephan", "year": "2007", "unstructured": "Stephan, M. T. et al. T cell-encoded CD80 and 4\u20131BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Med. 13, 1440\u20131449 (2007).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR87", "doi-asserted-by": "publisher", "first-page": "2001", "DOI": "10.1158/0008-5472.CAN-04-2006", "volume": "65", "author": "J Charo", "year": "2005", "unstructured": "Charo, J. et al. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65, 2001\u20132008 (2005).", "journal-title": "Cancer Res."}, {"issue": "18", "key": "BFnri3191_CR88", "doi-asserted-by": "publisher", "first-page": "4133", "DOI": "10.1182/blood-2011-12-400044", "volume": "119", "author": "H. J. Pegram", "year": "2012", "unstructured": "Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 21 Feb 2012 (doi:10.1182/blood-2011-12-400044).", "journal-title": "Blood"}, {"key": "BFnri3191_CR89", "doi-asserted-by": "publisher", "first-page": "4746", "DOI": "10.1172/JCI58814", "volume": "121", "author": "SP Kerkar", "year": "2011", "unstructured": "Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746\u20134757 (2011).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR90", "doi-asserted-by": "publisher", "first-page": "6725", "DOI": "10.1158/0008-5472.CAN-10-0735", "volume": "70", "author": "SP Kerkar", "year": "2010", "unstructured": "Kerkar, S. P. et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70, 6725\u20136734 (2010).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR91", "doi-asserted-by": "publisher", "first-page": "5458", "DOI": "10.1158/1078-0432.CCR-10-0712", "volume": "16", "author": "W Peng", "year": "2010", "unstructured": "Peng, W. et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16, 5458\u20135468 (2010).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnri3191_CR92", "doi-asserted-by": "publisher", "first-page": "565", "DOI": "10.1038/nm.2128", "volume": "16", "author": "GM Bendle", "year": "2010", "unstructured": "Bendle, G. M. et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Med. 16, 565\u2013570 (2010). An important paper that explores in significant detail the consequences of 'mispairing' of transduced TCR \u03b1- and \u03b2-chains.", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR93", "doi-asserted-by": "publisher", "first-page": "1744", "DOI": "10.1038/mt.2010.195", "volume": "18", "author": "SA Rosenberg", "year": "2010", "unstructured": "Rosenberg, S. A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 18, 1744\u20131745 (2010).", "journal-title": "Mol. Ther."}, {"key": "BFnri3191_CR94", "doi-asserted-by": "publisher", "first-page": "e1408", "DOI": "10.1073/pnas.1115050108", "volume": "108", "author": "DN Vatakis", "year": "2011", "unstructured": "Vatakis, D. N. et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl Acad. Sci. USA 108, e1408\u2013e1416 (2011).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR95", "doi-asserted-by": "publisher", "first-page": "4273", "DOI": "10.1172/JCI43274", "volume": "120", "author": "SP Ha", "year": "2010", "unstructured": "Ha, S. P. et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J. Clin. Invest. 120, 4273\u20134288 (2010).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR96", "doi-asserted-by": "publisher", "first-page": "276", "DOI": "10.2174/156652311796150390", "volume": "11", "author": "A Jorritsma", "year": "2011", "unstructured": "Jorritsma, A., Schotte, R., Coccoris, M., de Witte, M. A. & Schumacher, T. N. Prospects and limitations of T cell receptor gene therapy. Curr. Gene Ther. 11, 276\u2013287 (2011).", "journal-title": "Curr. Gene Ther."}, {"key": "BFnri3191_CR97", "doi-asserted-by": "publisher", "first-page": "666", "DOI": "10.1038/mt.2010.31", "volume": "18", "author": "R Brentjens", "year": "2010", "unstructured": "Brentjens, R., Yeh, R., Bernal, Y., Riviere, I. & Sadelain, M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666\u2013668 (2010).", "journal-title": "Mol. Ther."}, {"key": "BFnri3191_CR98", "doi-asserted-by": "publisher", "first-page": "1673", "DOI": "10.1056/NEJMoa1106152", "volume": "365", "author": "A Di Stasi", "year": "2011", "unstructured": "Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011). This paper describes a highly effective means of rapidly deleting gene-engineered T cells in the event of toxicity.", "journal-title": "N. Engl. J. Med."}, {"key": "BFnri3191_CR99", "doi-asserted-by": "publisher", "first-page": "1063", "DOI": "10.1084/jem.155.4.1063", "volume": "155", "author": "RJ North", "year": "1982", "unstructured": "North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063\u20131074 (1982).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR100", "first-page": "711", "volume": "125", "author": "MA Cheever", "year": "1980", "unstructured": "Cheever, M. A., Greenberg, P. D. & Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 125, 711\u2013714 (1980).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR101", "first-page": "3838", "volume": "96", "author": "V Bronte", "year": "2000", "unstructured": "Bronte, V. et al. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood 96, 3838\u20133846 (2000).", "journal-title": "Blood"}, {"key": "BFnri3191_CR102", "doi-asserted-by": "publisher", "first-page": "492", "DOI": "10.1172/JCI30414", "volume": "117", "author": "C Wrzesinski", "year": "2007", "unstructured": "Wrzesinski, C. et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117, 492\u2013501 (2007).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR103", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1097/CJI.0b013e3181b88ffc", "volume": "33", "author": "C Wrzesinski", "year": "2010", "unstructured": "Wrzesinski, C. et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33, 1\u20137 (2010).", "journal-title": "J. Immunother."}, {"key": "BFnri3191_CR104", "doi-asserted-by": "publisher", "first-page": "850", "DOI": "10.1126/science.1076514", "volume": "298", "author": "ME Dudley", "year": "2002", "unstructured": "Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850\u2013854 (2002).", "journal-title": "Science"}, {"key": "BFnri3191_CR105", "doi-asserted-by": "publisher", "first-page": "5233", "DOI": "10.1200/JCO.2008.16.5449", "volume": "26", "author": "ME Dudley", "year": "2008", "unstructured": "Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233\u20135239 (2008).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnri3191_CR106", "doi-asserted-by": "publisher", "first-page": "253", "DOI": "10.1038/nri3175", "volume": "12", "author": "DI Gabrilovich", "year": "2012", "unstructured": "Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nature Rev. Immunol. 12, 253\u2013268 (2012).", "journal-title": "Nature Rev. Immunol."}, {"key": "BFnri3191_CR107", "first-page": "5313", "volume": "161", "author": "V Bronte", "year": "1998", "unstructured": "Bronte, V. et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161, 5313\u20135320 (1998). One of the first descriptions of the suppressive myeloid subset later known as MDSCs.", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR108", "doi-asserted-by": "publisher", "first-page": "6254", "DOI": "10.1073/pnas.92.14.6254", "volume": "92", "author": "LP Seung", "year": "1995", "unstructured": "Seung, L. P., Rowley, D. A., Dubey, P. & Schreiber, H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl Acad. Sci. USA 92, 6254\u20136258 (1995). This paper describes a classic experiment demonstrating that depletion of GR1+ cells can enhance tumour immunotherapy.", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR109", "doi-asserted-by": "publisher", "first-page": "907", "DOI": "10.1084/jem.20050732", "volume": "202", "author": "L Gattinoni", "year": "2005", "unstructured": "Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR110", "doi-asserted-by": "publisher", "first-page": "2197", "DOI": "10.1172/JCI32205", "volume": "117", "author": "CM Paulos", "year": "2007", "unstructured": "Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197\u20132204 (2007).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR111", "doi-asserted-by": "publisher", "first-page": "2591", "DOI": "10.4049/jimmunol.174.5.2591", "volume": "174", "author": "PA Antony", "year": "2005", "unstructured": "Antony, P. A. et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591\u20132601 (2005).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR112", "doi-asserted-by": "publisher", "first-page": "3186", "DOI": "10.4049/jimmunol.1101649", "volume": "187", "author": "W Kastenmuller", "year": "2011", "unstructured": "Kastenmuller, W. et al. Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction. J. Immunol. 187, 3186\u20133197 (2011).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR113", "doi-asserted-by": "publisher", "first-page": "120", "DOI": "10.1097/01.cji.0000155049.26787.45", "volume": "28", "author": "PA Antony", "year": "2005", "unstructured": "Antony, P. A. & Restifo, N. P. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28, 120\u2013128 (2005).", "journal-title": "J. Immunother."}, {"key": "BFnri3191_CR114", "doi-asserted-by": "publisher", "first-page": "2129", "DOI": "10.1056/NEJMe1110900", "volume": "365", "author": "JA Bluestone", "year": "2011", "unstructured": "Bluestone, J. A. The yin and yang of interleukin-2-mediated immunotherapy. N. Engl. J. Med. 365, 2129\u20132131 (2011).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnri3191_CR115", "doi-asserted-by": "publisher", "first-page": "1616", "DOI": "10.1172/JCI24480", "volume": "115", "author": "L Gattinoni", "year": "2005", "unstructured": "Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005).", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR116", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1038/nri1842", "volume": "6", "author": "L Gattinoni", "year": "2006", "unstructured": "Gattinoni, L., Powell, D. J. Jr, Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nature Rev. Immunol. 6, 383\u2013393 (2006).", "journal-title": "Nature Rev. Immunol."}, {"key": "BFnri3191_CR117", "doi-asserted-by": "publisher", "first-page": "1182", "DOI": "10.1038/nm.2502", "volume": "17", "author": "F Sallusto", "year": "2011", "unstructured": "Sallusto, F. & Lanzavecchia, A. Memory in disguise. Nature Med. 17, 1182\u20131183 (2011).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR118", "doi-asserted-by": "publisher", "first-page": "214", "DOI": "10.1111/j.0105-2896.2006.00391.x", "volume": "211", "author": "CA Klebanoff", "year": "2006", "unstructured": "Klebanoff, C. A., Gattinoni, L. & Restifo, N. P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214\u2013224 (2006).", "journal-title": "Immunol. Rev."}, {"key": "BFnri3191_CR119", "doi-asserted-by": "publisher", "first-page": "592", "DOI": "10.1016/j.it.2009.09.009", "volume": "30", "author": "DC Palmer", "year": "2009", "unstructured": "Palmer, D. C. & Restifo, N. P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 30, 592\u2013602 (2009).", "journal-title": "Trends Immunol."}, {"key": "BFnri3191_CR120", "doi-asserted-by": "publisher", "first-page": "17469", "DOI": "10.1073/pnas.0907448106", "volume": "106", "author": "CS Hinrichs", "year": "2009", "unstructured": "Hinrichs, C. S. et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl Acad. Sci. USA 106, 17469\u201317474 (2009).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR121", "doi-asserted-by": "publisher", "first-page": "808", "DOI": "10.1182/blood-2010-05-286286", "volume": "117", "author": "CS Hinrichs", "year": "2011", "unstructured": "Hinrichs, C. S. et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808\u2013814 (2011).", "journal-title": "Blood"}, {"key": "BFnri3191_CR122", "doi-asserted-by": "publisher", "first-page": "9571", "DOI": "10.1073/pnas.0503726102", "volume": "102", "author": "CA Klebanoff", "year": "2005", "unstructured": "Klebanoff, C. A. et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571\u20139576 (2005).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR123", "doi-asserted-by": "publisher", "first-page": "1969", "DOI": "10.1073/pnas.0307298101", "volume": "101", "author": "CA Klebanoff", "year": "2004", "unstructured": "Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA 101, 1969\u20131974 (2004).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR124", "doi-asserted-by": "publisher", "first-page": "294", "DOI": "10.1172/JCI32103", "volume": "118", "author": "C Berger", "year": "2008", "unstructured": "Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294\u2013305 (2008). An important study in non-human primates showing that cells derived from central memory T cells are more persistentthan those derived from effector memory T cells.", "journal-title": "J. Clin. Invest."}, {"key": "BFnri3191_CR125", "doi-asserted-by": "publisher", "first-page": "1888", "DOI": "10.1182/blood-2010-10-310599", "volume": "117", "author": "X Wang", "year": "2011", "unstructured": "Wang, X. et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117, 1888\u20131898 (2011).", "journal-title": "Blood"}, {"issue": "12", "key": "BFnri3191_CR126", "doi-asserted-by": "publisher", "first-page": "4592", "DOI": "10.1073/pnas.1113748109", "volume": "109", "author": "A. G. Chapuis", "year": "2012", "unstructured": "Chapuis, A. et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. 5 Mar 2012 (doi:10.1073/pnas.1113748109). References 122 and 126 show that central memory T cells mediate superior antitumour immunity compared with effector memory T cells in murine systems.", "journal-title": "Proceedings of the National Academy of Sciences"}, {"key": "BFnri3191_CR127", "doi-asserted-by": "publisher", "first-page": "1299", "DOI": "10.1038/nm1326", "volume": "11", "author": "Y Zhang", "year": "2005", "unstructured": "Zhang, Y., Joe, G., Hexner, E., Zhu, J. & Emerson, S. G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nature Med. 11, 1299\u20131305 (2005).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR128", "doi-asserted-by": "publisher", "first-page": "808", "DOI": "10.1038/nm.1982", "volume": "15", "author": "L Gattinoni", "year": "2009", "unstructured": "Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Med. 15, 808\u2013813 (2009).", "journal-title": "Nature Med."}, {"key": "BFnri3191_CR129", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1038/nri2970", "volume": "11", "author": "CL Mackall", "year": "2011", "unstructured": "Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nature Rev. Immunol. 11, 330\u2013342 (2011).", "journal-title": "Nature Rev. Immunol."}, {"key": "BFnri3191_CR130", "doi-asserted-by": "publisher", "first-page": "321", "DOI": "10.1016/0167-5699(94)90080-9", "volume": "15", "author": "CH June", "year": "1994", "unstructured": "June, C. H., Bluestone, J. A., Nadler, L. M. & Thompson, C. B. The B7 and CD28 receptor families. Immunol. Today 15, 321\u2013331 (1994).", "journal-title": "Immunol. Today"}, {"key": "BFnri3191_CR131", "doi-asserted-by": "publisher", "first-page": "1230", "DOI": "10.1038/ni.2153", "volume": "12", "author": "Y Ji", "year": "2011", "unstructured": "Ji, Y. et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunol. 12, 1230\u20131237 (2011).", "journal-title": "Nature Immunol."}, {"key": "BFnri3191_CR132", "doi-asserted-by": "publisher", "first-page": "5326", "DOI": "10.1182/blood-2007-09-113050", "volume": "111", "author": "CS Hinrichs", "year": "2008", "unstructured": "Hinrichs, C. S. et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111, 5326\u20135333 (2008).", "journal-title": "Blood"}, {"key": "BFnri3191_CR133", "doi-asserted-by": "publisher", "first-page": "3516", "DOI": "10.1158/0008-5472.CAN-10-3843", "volume": "71", "author": "H Singh", "year": "2011", "unstructured": "Singh, H. et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 71, 3516\u20133527 (2011).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR134", "doi-asserted-by": "publisher", "first-page": "4695", "DOI": "10.1158/1078-0432.CCR-10-0356", "volume": "16", "author": "L Gattinoni", "year": "2010", "unstructured": "Gattinoni, L., Ji, Y. & Restifo, N. P. Wnt/\u03b2-catenin signaling in T-cell immunity and cancer immunotherapy. Clin. Cancer Res. 16, 4695\u20134701 (2010).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnri3191_CR135", "doi-asserted-by": "publisher", "first-page": "11ps12", "DOI": "10.1126/scitranslmed.3000302", "volume": "1", "author": "L Gattinoni", "year": "2009", "unstructured": "Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci. Transl. Med. 1, 11ps12 (2009).", "journal-title": "Sci. Transl. Med."}, {"key": "BFnri3191_CR136", "doi-asserted-by": "publisher", "first-page": "588", "DOI": "10.1016/S0952-7915(98)80228-8", "volume": "10", "author": "DM Pardoll", "year": "1998", "unstructured": "Pardoll, D. M. & Topalian, S. L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588\u2013594 (1998).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnri3191_CR137", "doi-asserted-by": "publisher", "first-page": "651", "DOI": "10.1084/jem.20091921", "volume": "207", "author": "Y Xie", "year": "2010", "unstructured": "Xie, Y. et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651\u2013667 (2010).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR138", "doi-asserted-by": "publisher", "first-page": "637", "DOI": "10.1084/jem.20091918", "volume": "207", "author": "SA Quezada", "year": "2010", "unstructured": "Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637\u2013650 (2010).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR139", "doi-asserted-by": "publisher", "first-page": "8633", "DOI": "10.1073/pnas.96.15.8633", "volume": "96", "author": "D Mumberg", "year": "1999", "unstructured": "Mumberg, D. et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-\u03b3. Proc. Natl Acad. Sci. USA 96, 8633\u20138638 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR140", "doi-asserted-by": "publisher", "first-page": "371", "DOI": "10.1016/j.immuni.2005.02.003", "volume": "22", "author": "A Corthay", "year": "2005", "unstructured": "Corthay, A. et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22, 371\u2013383 (2005).", "journal-title": "Immunity"}, {"key": "BFnri3191_CR141", "doi-asserted-by": "publisher", "first-page": "787", "DOI": "10.1016/j.immuni.2009.09.014", "volume": "31", "author": "N Martin-Orozco", "year": "2009", "unstructured": "Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787\u2013798 (2009).", "journal-title": "Immunity"}, {"key": "BFnri3191_CR142", "doi-asserted-by": "publisher", "first-page": "362", "DOI": "10.1182/blood-2007-11-120998", "volume": "112", "author": "P Muranski", "year": "2008", "unstructured": "Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362\u2013373 (2008).", "journal-title": "Blood"}, {"key": "BFnri3191_CR143", "doi-asserted-by": "publisher", "first-page": "972", "DOI": "10.1016/j.immuni.2011.09.019", "volume": "35", "author": "P Muranski", "year": "2011", "unstructured": "Muranski, P. et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35, 972\u2013985 (2011).", "journal-title": "Immunity"}, {"key": "BFnri3191_CR144", "doi-asserted-by": "publisher", "first-page": "5988", "DOI": "10.4049/jimmunol.1000189", "volume": "184", "author": "TL Frankel", "year": "2010", "unstructured": "Frankel, T. L. et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 184, 5988\u20135998 (2010).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR145", "doi-asserted-by": "publisher", "first-page": "367", "DOI": "10.1097/PPO.0b013e3181eacba8", "volume": "16", "author": "C Yee", "year": "2010", "unstructured": "Yee, C. Adoptive therapy using antigen-specific T-cell clones. Cancer J. 16, 367\u2013373 (2010).", "journal-title": "Cancer J."}, {"key": "BFnri3191_CR146", "doi-asserted-by": "publisher", "first-page": "2698", "DOI": "10.1056/NEJMoa0800251", "volume": "358", "author": "NN Hunder", "year": "2008", "unstructured": "Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698\u20132703 (2008).", "journal-title": "N. Engl. J. Med."}, {"issue": "3", "key": "BFnri3191_CR147", "doi-asserted-by": "publisher", "first-page": "297", "DOI": "10.1016/j.coi.2012.01.014", "volume": "24", "author": "Shingo Nakayamada", "year": "2012", "unstructured": "Nakayamada, S., Takahashi, H., Kanno, Y. & O'Shea, J. J. Helper T cell diversity and plasticity. Curr. Opin. Immunol. 15 Feb 2012 (doi:10.1016/j.coi.2012.01.014).", "journal-title": "Current Opinion in Immunology"}, {"key": "BFnri3191_CR148", "doi-asserted-by": "publisher", "first-page": "S52", "DOI": "10.1007/PL00014051", "volume": "46", "author": "T Nishimura", "year": "2000", "unstructured": "Nishimura, T. et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46, S52\u2013S61 (2000).", "journal-title": "Cancer Chemother. Pharmacol."}, {"key": "BFnri3191_CR149", "doi-asserted-by": "publisher", "first-page": "200", "DOI": "10.1016/j.coi.2009.02.004", "volume": "21", "author": "P Muranski", "year": "2009", "unstructured": "Muranski, P. & Restifo, N. P. Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21, 200\u2013208 (2009).", "journal-title": "Curr. Opin. Immunol."}, {"key": "BFnri3191_CR150", "doi-asserted-by": "publisher", "first-page": "248", "DOI": "10.1038/nri2742", "volume": "10", "author": "W Zou", "year": "2010", "unstructured": "Zou, W. & Restifo, N. P. TH17 cells in tumour immunity and immunotherapy. Nature Rev. Immunol. 10, 248\u2013256 (2010).", "journal-title": "Nature Rev. Immunol."}, {"key": "BFnri3191_CR151", "doi-asserted-by": "publisher", "first-page": "231", "DOI": "10.1182/blood-2009-04-215541", "volume": "114", "author": "P Muranski", "year": "2009", "unstructured": "Muranski, P. & Restifo, N. P. Does IL-17 promote tumor growth? Blood 114, 231\u2013232 (2009).", "journal-title": "Blood"}, {"key": "BFnri3191_CR152", "doi-asserted-by": "publisher", "first-page": "596", "DOI": "10.1182/blood-2009-02-203935", "volume": "114", "author": "CS Hinrichs", "year": "2009", "unstructured": "Hinrichs, C. S. et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114, 596\u2013599 (2009).", "journal-title": "Blood"}, {"key": "BFnri3191_CR153", "doi-asserted-by": "publisher", "first-page": "7161", "DOI": "10.4049/jimmunol.0900368", "volume": "183", "author": "HR Yen", "year": "2009", "unstructured": "Yen, H. R. et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183, 7161\u20137168 (2009).", "journal-title": "J. Immunol."}, {"key": "BFnri3191_CR154", "doi-asserted-by": "publisher", "first-page": "4746", "DOI": "10.1182/blood-2008-07-169797", "volume": "112", "author": "A Boni", "year": "2008", "unstructured": "Boni, A. et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 112, 4746\u20134754 (2008).", "journal-title": "Blood"}, {"key": "BFnri3191_CR155", "unstructured": "Restifo, N. P. & Bachinski, M. Imagining a cure: for cancer patients, close is not good enough. The Scientist April 2011, 28\u201329 (2011)."}, {"key": "BFnri3191_CR156", "doi-asserted-by": "publisher", "first-page": "1359", "DOI": "10.1007/s00262-011-1079-2", "volume": "60", "author": "CU Blank", "year": "2011", "unstructured": "Blank, C. U., Hooijkaas, A. I., Haanen, J. B. & Schumacher, T. N. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol. Immunother. 60, 1359\u20131371 (2011).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnri3191_CR157", "doi-asserted-by": "publisher", "first-page": "1776", "DOI": "10.1182/blood-2008-12-192419", "volume": "114", "author": "CA Klebanoff", "year": "2009", "unstructured": "Klebanoff, C. A. et al. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood 114, 1776\u20131783 (2009).", "journal-title": "Blood"}, {"key": "BFnri3191_CR158", "doi-asserted-by": "publisher", "first-page": "569", "DOI": "10.1084/jem.20030590", "volume": "198", "author": "WW Overwijk", "year": "2003", "unstructured": "Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR159", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.1016/j.ccr.2010.11.002", "volume": "18", "author": "NP Restifo", "year": "2010", "unstructured": "Restifo, N. P. Can antitumor immunity help to explain \u201concogene addiction\u201d? Cancer Cell 18, 403\u2013405 (2010).", "journal-title": "Cancer Cell"}, {"key": "BFnri3191_CR160", "doi-asserted-by": "publisher", "first-page": "485", "DOI": "10.1016/j.ccr.2010.10.002", "volume": "18", "author": "K Rakhra", "year": "2010", "unstructured": "Rakhra, K. et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485\u2013498 (2010). A paper that explores the immunological consequences of oncogene withdrawal.", "journal-title": "Cancer Cell"}, {"key": "BFnri3191_CR161", "doi-asserted-by": "publisher", "first-page": "1651", "DOI": "10.1084/jem.20051848", "volume": "203", "author": "H Sumimoto", "year": "2006", "unstructured": "Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF\u2013MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651\u20131656 (2006).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR162", "doi-asserted-by": "publisher", "first-page": "5213", "DOI": "10.1158/0008-5472.CAN-10-0118", "volume": "70", "author": "A Boni", "year": "2010", "unstructured": "Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213\u20135219 (2010).", "journal-title": "Cancer Res."}, {"key": "BFnri3191_CR163", "doi-asserted-by": "publisher", "first-page": "405", "DOI": "10.1038/nature10803", "volume": "482", "author": "M DuPage", "year": "2012", "unstructured": "DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405\u2013409 (2012).", "journal-title": "Nature"}, {"key": "BFnri3191_CR164", "doi-asserted-by": "publisher", "first-page": "1178", "DOI": "10.1073/pnas.95.3.1178", "volume": "95", "author": "K Staveley-O'Carroll", "year": "1998", "unstructured": "Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178\u20131183 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnri3191_CR165", "doi-asserted-by": "publisher", "first-page": "2357", "DOI": "10.1084/jem.188.12.2357", "volume": "188", "author": "K Hung", "year": "1998", "unstructured": "Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357\u20132368 (1998).", "journal-title": "J. Exp. Med."}, {"key": "BFnri3191_CR166", "doi-asserted-by": "publisher", "first-page": "104ra100", "DOI": "10.1126/scitranslmed.3002949", "volume": "3", "author": "I Kryczek", "year": "2011", "unstructured": "Kryczek, I. et al. Human TH17 cells are long-lived effector memory cells. Sci. Transl. Med. 3, 104ra100 (2011).", "journal-title": "Sci. Transl. Med."}], "container-title": ["Nature Reviews Immunology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nri3191.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nri3191", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nri3191.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 27]], "date-time": "2019-04-27T02:18:59Z", "timestamp": 1556331539000}, "score": 29.987116, "issued": {"date-parts": [[2012, 3, 22]]}, "references-count": 166, "journal-issue": {"published-print": {"date-parts": [[2012, 4]]}, "issue": "4"}, "alternative-id": ["BFnri3191"], "URL": "http://dx.doi.org/10.1038/nri3191", "relation": {"cites": []}, "ISSN": ["1474-1733", "1474-1741"], "issn-type": [{"value": "1474-1733", "type": "print"}, {"value": "1474-1741", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T04:08:20Z", "timestamp": 1574741300816}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "S2", "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["j. immunotherapy cancer"], "published-print": {"date-parts": [[2015, 12]]}, "DOI": "10.1186/2051-1426-3-s2-p20", "type": "journal-article", "created": {"date-parts": [[2015, 11, 5]], "date-time": "2015-11-05T05:03:55Z", "timestamp": 1446699835000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens"], "prefix": "10.1186", "volume": "3", "author": [{"given": "Ken-ichi", "family": "Hanada", "sequence": "first", "affiliation": []}, {"given": "Christopher", "family": "Chow", "sequence": "additional", "affiliation": []}, {"given": "Raul Gil", "family": "Hoyos", "sequence": "additional", "affiliation": []}, {"given": "Jared J", "family": "Gartner", "sequence": "additional", "affiliation": []}, {"given": "Todd D", "family": "Prickett", "sequence": "additional", "affiliation": []}, {"given": "Robert", "family": "Somerville", "sequence": "additional", "affiliation": []}, {"given": "Katherine", "family": "Hogan", "sequence": "additional", "affiliation": []}, {"given": "Paul F", "family": "Robbins", "sequence": "additional", "affiliation": []}, {"given": "Steven A", "family": "Rosenberg", "sequence": "additional", "affiliation": []}, {"given": "James C", "family": "Yang", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2015, 11, 4]]}, "container-title": ["Journal for ImmunoTherapy of Cancer"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/2051-1426-3-S2-P20.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T14:40:19Z", "timestamp": 1548168019000}, "score": 29.199188, "issued": {"date-parts": [[2015, 11, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 12]]}, "issue": "S2"}, "alternative-id": ["786"], "URL": "http://dx.doi.org/10.1186/2051-1426-3-s2-p20", "ISSN": ["2051-1426"], "issn-type": [{"value": "2051-1426", "type": "electronic"}], "assertion": [{"value": "4 November 2015", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}], "article-number": "P20"}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T04:00:03Z", "timestamp": 1574136003167}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1986, 5, 1]], "date-time": "1986-05-01T00:00:00Z", "timestamp": 515289600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Springer Semin Immunopathol"], "published-print": {"date-parts": [[1986, 5]]}, "DOI": "10.1007/bf00201905", "type": "journal-article", "created": {"date-parts": [[2004, 8, 30]], "date-time": "2004-08-30T22:39:28Z", "timestamp": 1093905568000}, "source": "Crossref", "is-referenced-by-count": 19, "title": ["The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2"], "prefix": "10.1007", "volume": "9", "author": [{"given": "StephenE.", "family": "Ettinghausen", "sequence": "first", "affiliation": []}, {"given": "StevenA.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Springer Seminars in Immunopathology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/BF00201905.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/BF00201905/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/BF00201905", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 3]], "date-time": "2019-04-03T10:27:54Z", "timestamp": 1554287274000}, "score": 29.093328, "issued": {"date-parts": [[1986, 5]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1986, 5]]}, "issue": "1"}, "alternative-id": ["BF00201905"], "URL": "http://dx.doi.org/10.1007/bf00201905", "ISSN": ["0344-4325", "1432-2196"], "issn-type": [{"value": "0344-4325", "type": "print"}, {"value": "1432-2196", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T08:22:08Z", "timestamp": 1574410928129}, "publisher-location": "Boston, MA", "reference-count": 24, "publisher": "Springer US", "isbn-type": [{"value": "9781461294160", "type": "print"}, {"value": "9781461322993", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1986]]}, "DOI": "10.1007/978-1-4613-2299-3_24", "type": "book-chapter", "created": {"date-parts": [[2011, 10, 20]], "date-time": "2011-10-20T11:14:17Z", "timestamp": 1319109257000}, "page": "307-319", "source": "Crossref", "is-referenced-by-count": 3, "title": ["New Approaches to the Adoptive Immunotherapy of Established Metastatic Cancer using Lymphokine-Activated Killer Cells and Recombinant Interleukin-2"], "prefix": "10.1007", "author": [{"given": "S. A.", "family": "Rosenberg", "sequence": "first", "affiliation": []}, {"given": "J. J.", "family": "Mul\u00e9", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "24_CR1", "doi-asserted-by": "publisher", "first-page": "323", "DOI": "10.1016/S0065-230X(08)60637-5", "volume": "25", "author": "SA Rosenberg", "year": "1977", "unstructured": "Rosenberg, S.A., and Terry, W. Adv. Cancer Res. 25:323, 1977.", "journal-title": "Adv. Cancer Res."}, {"key": "24_CR2", "first-page": "233", "volume": "68", "author": "SA Rosenberg", "year": "1984", "unstructured": "Rosenberg, S.A. Cancer Treat. Reports 68:233, 1984.", "journal-title": "Cancer Treat. Reports"}, {"key": "24_CR3", "first-page": "310", "volume": "2", "author": "I Hellstrom", "year": "1983", "unstructured": "Hellstrom, I., and Hellstrom, K.E. J. Biol. Response Mod. 2: 310, 1983.", "journal-title": "J. Biol. Response Mod."}, {"key": "24_CR4", "doi-asserted-by": "crossref", "first-page": "83", "DOI": "10.1007/BF00200041", "volume": "17", "author": "EA Grimm", "year": "1984", "unstructured": "Grimm, E.A., Vose, B.M., Chu, E.W., Wilson, D.J., Lotze, M.T., Rayner, A.A., and Rosenberg, S.A. Cancer Immunol. and Immunother. 17:83, 1984.", "journal-title": "Cancer Immunol. and Immunother."}, {"key": "24_CR5", "first-page": "238", "volume": "125", "author": "I Yron", "year": "1980", "unstructured": "Yron, I., Wood, T.A., Spiess, P., and Rosenberg, S.A. J. Immunol. 125:238, 1980.", "journal-title": "J. Immunol."}, {"key": "24_CR6", "first-page": "4420", "volume": "41", "author": "MT Lotze", "year": "1981", "unstructured": "Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L., and Rosenberg, S.A. Cancer Res. 41:4420, 1981.", "journal-title": "Cancer Res."}, {"key": "24_CR7", "first-page": "1946", "volume": "44", "author": "M Rosenstein", "year": "1984", "unstructured": "Rosenstein, M., Yron, I., Kaufmann, Y., and Rosenberg, S.A. Cancer Res. 44:1946, 1984.", "journal-title": "Cancer Res."}, {"key": "24_CR8", "doi-asserted-by": "publisher", "first-page": "1356", "DOI": "10.1084/jem.158.4.1356", "volume": "158", "author": "EA Grimm", "year": "1983", "unstructured": "Grimm, E.A., Robb, R.J., Roth, J.A., Neckers, L.M., Lachman, L.B., Wilson, D.J., and Rosenberg, S.A. J. Exp. Med. 158:1356, 1983.", "journal-title": "J. Exp. Med."}, {"key": "24_CR9", "doi-asserted-by": "publisher", "first-page": "1412", "DOI": "10.1126/science.6367046", "volume": "223", "author": "SA Rosenberg", "year": "1984", "unstructured": "Rosenberg, S.A., Grimm, E.A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., and Mark, D.F. Science 223:1412, 1984.", "journal-title": "Science"}, {"key": "24_CR10", "author": "EA Grimm", "first-page": "279", "year": "1984", "unstructured": "Grimm, E.A., and Rosenberg, S.A. In:Lymphokines, Vol. 9, p. 279, 1984.", "volume-title": "Lymphokines"}, {"key": "24_CR11", "doi-asserted-by": "publisher", "first-page": "1487", "DOI": "10.1126/science.6332379", "volume": "225", "author": "JJ Mul\u00e9", "year": "1984", "unstructured": "Mul\u00e9, J.J., Shu, S., Schwarz, S.L., and Rosenberg, S.A. Science 225:1487, 1984.", "journal-title": "Science"}, {"key": "24_CR12", "first-page": "646", "volume": "135", "author": "JJ Mul\u00e9", "year": "1985", "unstructured": "Mul\u00e9, J.J., Shu, S., and Rosenberg, S.A. J. Immunol. 135:646, 1985", "journal-title": "J. Immunol."}, {"key": "24_CR13", "unstructured": "Rosenberg, S.A., and Mul\u00e9, J.J. Surgery (in press)."}, {"key": "24_CR14", "doi-asserted-by": "publisher", "first-page": "495", "DOI": "10.1084/jem.159.2.495", "volume": "159", "author": "A Mazumder", "year": "1985", "unstructured": "Mazumder, A., and Rosenberg, S.A. J. Exp. Med. 159:495, 1985.", "journal-title": "J. Exp. Med."}, {"key": "24_CR15", "unstructured": "Lafreniere, R., and Rosenberg, S.A. Cancer Res. (in press)."}, {"key": "24_CR16", "unstructured": "Lafreniere, R., and Rosenberg, S.A. J. Immunol. (in press)."}, {"key": "24_CR17", "unstructured": "Rosenberg, S.A. J. Natl. Cancer Inst. (in press)."}, {"key": "24_CR18", "unstructured": "Mul\u00e9, J.J., Ettinghause, S.E., Spiess, P.J., Shu, S., and Rosenberg, S.A. Cancer Res. (in press)."}, {"key": "24_CR19", "first-page": "2203", "volume": "130", "author": "JH Donohue", "year": "1983", "unstructured": "Donohue, J.H., and Rosenberg, S.A. J. Immunol. 130: 2203, 1983.", "journal-title": "J. Immunol."}, {"key": "24_CR20", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1038/302305a0", "volume": "302", "author": "T Taniguchi", "year": "1983", "unstructured": "Taniguchi, T., Matsui, H., Fajita, T., Takaoki, C., Kashina, N., Yoshimoto, R., and Hamuro, J. Nature (Lond.) 302: 305, 1983.", "journal-title": "Nature (Lond.)"}, {"key": "24_CR21", "unstructured": "Mul\u00e9, J.J., Yang, J., Shu, S., and Rosenberg, S.A. J. Exp. Med. (submitted)."}, {"key": "24_CR22", "unstructured": "Papa, M., Mul\u00e9, J.J., and Rosenberg, S.A. J. Exp. Med. (submitted)."}, {"key": "24_CR23", "doi-asserted-by": "publisher", "first-page": "1169", "DOI": "10.1084/jem.161.5.1169", "volume": "161", "author": "SA Rosenberg", "year": "1985", "unstructured": "Rosenberg, S.A., Mul\u00e9, J.J., Spiess, P.J., Reichert, C.M., and Schwarz, S.L. J. Exp. Med. 161:1169, 1985.", "journal-title": "J. Exp. Med."}, {"key": "24_CR24", "unstructured": "Ettinghausen, S.E., Lipford, E.H., Mul\u00e9, J.J., and Rosenberg, S.A. J. Immunol. (in press)."}], "container-title": ["Biochemistry and Molecular Genetics of Cancer Metastasis"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4613-2299-3_24", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T11:45:38Z", "timestamp": 1555155938000}, "score": 29.042326, "issued": {"date-parts": [[1986]]}, "ISBN": ["9781461294160", "9781461322993"], "references-count": 24, "URL": "http://dx.doi.org/10.1007/978-1-4613-2299-3_24", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T08:38:48Z", "timestamp": 1575275928296}, "publisher-location": "Boston, MA", "reference-count": 28, "publisher": "Springer US", "isbn-type": [{"value": "9781489950390", "type": "print"}, {"value": "9781489950376", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1988]]}, "DOI": "10.1007/978-1-4899-5037-6_50", "type": "book-chapter", "created": {"date-parts": [[2013, 9, 13]], "date-time": "2013-09-13T15:20:33Z", "timestamp": 1379085633000}, "page": "459-467", "source": "Crossref", "is-referenced-by-count": 15, "title": ["Current Approaches to the Adoptive Immunotherapy of Cancer"], "prefix": "10.1007", "author": [{"given": "James C.", "family": "Yang", "sequence": "first", "affiliation": []}, {"given": "Steven A.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "50_CR1", "doi-asserted-by": "publisher", "first-page": "323", "DOI": "10.1016/S0065-230X(08)60637-5", "volume": "25", "author": "SA Rosenberg", "year": "1977", "unstructured": "S.A. Rosenberg, W. Terry, Passive immunotherapy of cancer in animals and man, Adv Cancer Res 25:323\u2013388 (1977).", "journal-title": "Adv Cancer Res"}, {"key": "50_CR2", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1016/S0065-230X(08)60190-6", "volume": "38", "author": "E Kedar", "year": "1983", "unstructured": "E. Kedar, D.W. Weiss, The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy, Adv Cancer Res 38: 171\u2013287 (1983).", "journal-title": "Adv Cancer Res"}, {"key": "50_CR3", "doi-asserted-by": "publisher", "first-page": "1412", "DOI": "10.1126/science.6367046", "volume": "223", "author": "SA Rosenberg", "year": "1984", "unstructured": "S.A. Rosenberg, E.A. Grimm, M. McGrogan et al., Biological activity of recombinant human interleukin-2 produced in E. Coli, Science 223:1412\u20131415 (1984).", "journal-title": "Science"}, {"key": "50_CR4", "doi-asserted-by": "publisher", "first-page": "1485", "DOI": "10.1056/NEJM198512053132327", "volume": "313", "author": "SA Rosenberg", "year": "1985", "unstructured": "S.A. Rosenberg, M.T. Lotze, L.M. Muul et al., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med 313:1485\u20131492 (1985).", "journal-title": "N Engl J Med"}, {"key": "50_CR5", "doi-asserted-by": "publisher", "first-page": "889", "DOI": "10.1056/NEJM198704093161501", "volume": "316", "author": "SA Rosenberg", "year": "1987", "unstructured": "S.A. Rosenberg, M.T. Lotze, L.M. Muul et al., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med 316:889\u2013897 (1987).", "journal-title": "N Engl J Med"}, {"key": "50_CR6", "doi-asserted-by": "publisher", "first-page": "898", "DOI": "10.1056/NEJM198704093161502", "volume": "313", "author": "WH West", "year": "1987", "unstructured": "W.H. West, K.W. Tauer, J.R. Yannelli et al., Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, N Engl J Med 313:898\u2013905 (1987).", "journal-title": "N Engl J Med"}, {"key": "50_CR7", "doi-asserted-by": "publisher", "first-page": "1007", "DOI": "10.1126/science.181845", "volume": "193", "author": "DA Morgan", "year": "1976", "unstructured": "D.A. Morgan, F.W. Ruscetti, R. Gallo, Selective in vitro growth of lymphocytes from normal human bone marrows, Science 193: 1007 (1976).", "journal-title": "Science"}, {"key": "50_CR8", "doi-asserted-by": "publisher", "first-page": "1823", "DOI": "10.1084/jem.155.6.1823", "volume": "155", "author": "EA Grimm", "year": "1982", "unstructured": "E.A. Grimm, A. Mazumder, H.Z. Zhang, S.A. Rosenberg, Lymphokineactivated killer cell phenomenon: Lysis of natural killer cell resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes, J Ex Med 155: 1823\u20131841 (1982).", "journal-title": "J Ex Med"}, {"key": "50_CR9", "doi-asserted-by": "publisher", "first-page": "884", "DOI": "10.1084/jem.157.3.884", "volume": "157", "author": "EA Grimm", "year": "1983", "unstructured": "E.A. Grimm, K.M. Ramsey, A. Mazumder et al., Lymphokine-activated killer cell phenomenon: II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymusderived lymphocytes and natural killer cells, J Ex Med 157:884\u2013897 (1983).", "journal-title": "J Ex Med"}, {"key": "50_CR10", "first-page": "1946", "volume": "44", "author": "M Rosenstein", "year": "1984", "unstructured": "M. Rosenstein, I. Yron, Y. Kaufmann, S.A. Rosenberg, Lymphocyteactivated killer cells: Lysis of fresh syngeneic natural killerresistant murine tumor cells by lymphocytes cultured in interleukin 2, Cancer Res 44:1946\u20131953 (1984).", "journal-title": "Cancer Res"}, {"key": "50_CR11", "author": "EA Grimm", "year": "1984", "unstructured": "E.A. Grimm, S.A. Rosenberg, The lymphokine-activated killer cell phenomenon, in: \u201cLymphokines Vol.9,\u201d E. Pick ed., Academic Press, New York, N.Y. (1984).", "volume-title": "Lymphokines"}, {"key": "50_CR12", "doi-asserted-by": "publisher", "first-page": "1356", "DOI": "10.1084/jem.158.4.1356", "volume": "158", "author": "EA Grimm", "year": "1983", "unstructured": "E.A. Grimm, R.J. Robb, J.A. Roth et al., Lymphokine-activated killer cell phenomenon: III. Evidence that IL2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells, J Ex Med 158:1356\u20131361 (1983).", "journal-title": "J Ex Med"}, {"key": "50_CR13", "unstructured": "A.T. Lefor, S.A. Rosenberg, The specificity of lymphokine activated killer (LAK) cells in vitro: Fresh normal murine tissues are resistant to LAK mediated lysis, (submitted for publication)."}, {"key": "50_CR14", "doi-asserted-by": "publisher", "first-page": "1327", "DOI": "10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O", "volume": "55", "author": "AA Rayner", "year": "1985", "unstructured": "A.A. Rayner, E.A. Grimm, M.T. Lotze et al., Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer, Cancer 55:1327\u20131333 (1985).", "journal-title": "Cancer"}, {"key": "50_CR15", "first-page": "715", "volume": "137", "author": "JC Yang", "year": "1986", "unstructured": "J.C. Yang, J.J. Mule, S.A. Rosenberg, Murine lymphokine-activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells, J Immunol 137:715\u2013722 (1986).", "journal-title": "J Immunol"}, {"key": "50_CR16", "unstructured": "J.M. Skibber, M.T. Lotze, L.M. Muul et al., Isolation of the human lymphokine activated killer cell: Further characterization of the precursor and effector cell, (submitted)."}, {"key": "50_CR17", "first-page": "309", "volume": "76", "author": "R Lafreniere", "year": "1986", "unstructured": "R. Lafreniere, S.A. Rosenberg, A novel approach to the generation and identification of experimental hepatic metastases in a murine model, J Nat Cancer Inst 76:309\u2013322 (1986).", "journal-title": "J Nat Cancer Inst"}, {"key": "50_CR18", "first-page": "3623", "volume": "135", "author": "SE Ettinghausen", "year": "1985", "unstructured": "S.E. Ettinghausen, E.H. Lipford, J.J. Mule, S.A. Rosenberg, Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells, J Immunol, 135:3623\u20133635 (1985).", "journal-title": "J Immunol"}, {"key": "50_CR19", "first-page": "646", "volume": "135", "author": "JJ Mule", "year": "1985", "unstructured": "J.J. Mule, S. Shu, S.A. Rosenberg, The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo, J Immunol 135:646\u2013652 (1985).", "journal-title": "J Immunol"}, {"key": "50_CR20", "first-page": "3735", "volume": "45", "author": "R Lafreniere", "year": "1985", "unstructured": "R. Lafreniere, S.A. Rosenberg, Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2, Cancer Res 45:3735\u20133741 (1985).", "journal-title": "Cancer Res"}, {"key": "50_CR21", "doi-asserted-by": "publisher", "first-page": "1487", "DOI": "10.1126/science.6332379", "volume": "225", "author": "JJ Mule", "year": "1984", "unstructured": "J.J. Mule, S. Shu, S.L. Schwarz, S.A. Rosenberg, Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2, Science 225:1487\u20131489 (1984).", "journal-title": "Science"}, {"key": "50_CR22", "first-page": "4973", "volume": "46", "author": "MZ Papa", "year": "1986", "unstructured": "M.Z. Papa, J.J. Mule, S.A. Rosenberg, Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types, Cancer Res 46:4973\u20134978 (1986).", "journal-title": "Cancer Res"}, {"key": "50_CR23", "first-page": "2865", "volume": "135", "author": "MT Lotze", "year": "1985", "unstructured": "M.T. Lotze, Y.L. Matory, S.E. Ettinghausen, et al., In vivo administration of purified human interleukin 2: II. Half life, immunological effects, and expansion of peripheral lymphoid cells in vivo with recombinant interleukin 2, J Immunol 135:2865\u20132875 (1985).", "journal-title": "J Immunol"}, {"key": "50_CR24", "doi-asserted-by": "publisher", "first-page": "896", "DOI": "10.1002/1097-0142(19840215)53:4<896::AID-CNCR2820530414>3.0.CO;2-E", "volume": "53", "author": "A Mazumder", "year": "1984", "unstructured": "A. Mazumder, T.J. Eberlein, E.A. Grimm, et al., Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells, Cancer 53:896\u2013905 (1984).", "journal-title": "Cancer"}, {"key": "50_CR25", "first-page": "238", "volume": "125", "author": "I Yron", "year": "1980", "unstructured": "I. Yron, T.A. Wood, P.J. Spiess, S.A. Rosenberg, In Vitro growth of murine T cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors, J Immunol 125:238\u2013245 (1980).", "journal-title": "J Immunol"}, {"key": "50_CR26", "unstructured": "P.J. Spiess, J.C. Yang, S.A. Rosenberg, The in vivo anti-tumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2 (submitted)."}, {"key": "50_CR27", "unstructured": "S.L. Topalian, L.M. Muul, D. Solomon, S.A. Rosenberg, Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials, J of Immunol Methods (in press)."}, {"key": "50_CR28", "first-page": "989", "volume": "138", "author": "LM Muul", "year": "1987", "unstructured": "L.M. Muul, P.J. Spiess, E.P. Director, S.A. Rosenberg, Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma, J of Immunol 138:989\u2013995 (1987).", "journal-title": "J of Immunol"}], "container-title": ["Advances in Experimental Medicine and Biology", "Cancer Metastasis"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-1-4899-5037-6_50", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 17]], "date-time": "2019-05-17T07:49:57Z", "timestamp": 1558079397000}, "score": 29.042326, "issued": {"date-parts": [[1988]]}, "ISBN": ["9781489950390", "9781489950376"], "references-count": 28, "URL": "http://dx.doi.org/10.1007/978-1-4899-5037-6_50", "relation": {"cites": []}, "ISSN": ["0065-2598", "2214-8019"], "issn-type": [{"value": "0065-2598", "type": "print"}, {"value": "2214-8019", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T10:07:48Z", "timestamp": 1574158068877}, "reference-count": 23, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Immunotherapy"], "published-print": {"date-parts": [[2005, 1]]}, "DOI": "10.1097/00002371-200501000-00007", "type": "journal-article", "created": {"date-parts": [[2004, 12, 21]], "date-time": "2004-12-21T09:02:36Z", "timestamp": 1103619756000}, "page": "53-62", "source": "Crossref", "is-referenced-by-count": 92, "title": ["Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy"], "prefix": "10.1097", "volume": "28", "author": [{"given": "Juhua", "family": "Zhou", "sequence": "first", "affiliation": []}, {"given": "Mark E.", "family": "Dudley", "sequence": "additional", "affiliation": []}, {"given": "Steven A.", "family": "Rosenberg", "sequence": "additional", "affiliation": []}, {"given": "Paul F.", "family": "Robbins", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Journal of Immunotherapy"], "language": "en", "deposited": {"date-parts": [[2018, 2, 8]], "date-time": "2018-02-08T23:10:46Z", "timestamp": 1518131446000}, "score": 28.855782, "subtitle": [""], "issued": {"date-parts": [[2005, 1]]}, "references-count": 23, "journal-issue": {"issue": "1"}, "URL": "http://dx.doi.org/10.1097/00002371-200501000-00007", "ISSN": ["1524-9557"], "issn-type": [{"value": "1524-9557", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}